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ANALISIS PENJUJUKAN EKSOM MENYELURUH KE ATAS 
PESAKIT “CEREBRAL PALSY” DENGAN FAKTOR GENETIK 
ABSTRAK 
 “Cerebral palsy” (CP) adalah gangguan disebabkan disfungsi neurologi yang 
tidaklah bertambah buruk seiring bertambahnya usia namun akan tertampil sebagai 
kerosakan otot sehingga dewasa. Beberapa faktor risiko CP adalah jangkitan kuman 
semasa kehamilan, malformasi otak, kelahiran secara instrumental dan lain-lain yang 
berlaku pada tiga kejadian berbeza (antenatal, intrapartum dan postpartum). Sementara 
itu, CP idiopatik adalah merujuk kes-kes CP tanpa faktor-faktor risiko yang jelas. 
Kajian berbentuk penerokaan tanpa cadangan hipotesis bagi lokus spesifik ini 
dilakukan untuk meneroka genetik CP pada pesakit Kelantan dengan faktor genetik 
tersembunyi, menggunakan Penjujukan Eksom Menyeluruh (WES). Berbeza dengan 
sindrom-sindrom gangguan saraf lain, pengaruh ketidaknormalan genomik terhadap 
kejadian CP belum banyak dikaji walaupun ia menyumbang 70- 80% bagi kes dengan 
faktor pranatal. Tambahan pula, Malaysia belum membangunkan pangkalan data 
kelaziman dan genetik CP. Justeru, pengenalpastian punca genomik akan 
meningkatkan pemahaman punca CP dalam keluarga-keluarga terlibat. 
Keseluruhannya, terdapat 20 subjek iaitu 10 individu CP dan 10 ibu bapa normal. 
Sampel DNA yang dijujuk kemudiannya dianalisis menggunakan protokol 
bioinformatik Genome Analysis Toolkit (GATK) untuk mendapatkan semua varian 
berkemungkinan. Kami menemui 37 varian unik iaitu varian de novo (n = 29) dan 
varian perwarisan (n = 8) daripada sejumlah 29 gen dan mengklasifikannya mengikut 
garis panduan piawai American College Medical Genetic (ACMG). Terdapat sembilan 
gen berkait sistem saraf (CDKL2 CEP164, FAM10B, FAM163A, FXR2, KCNK18, 
xxi 
KCNQ3, MAPRE3 dan RBMX) dan mutasi mereka disyaki menyumbang kepada 
kerosakan sistem saraf pusat (CNS), di mana CP adalah gangguan yang berasal 
daripada kerosakan “CNS”. Sembilan gen berkait imuniti bermutasi (COL6A6, 
COL7A1, CYHR1, DLL1, GPR97, HLA-DRB1, HLA-DRB5, LYST dan MUC16 pula 
hanya terdapat pada subjek CP, ini menunjukkan individu CP berpotensi menghidapi 
masalah imuniti. Justeru, CP berpotensi dikategorikan sebagai gangguan neurologi 
yang terkait dengan disregulasi imuniti. Seterusnya adalah tiga gen yang berpotensi 
sebagai gen berkait imuniti (ANKRD36, DNAH17 dan TTC13) di mana fungsi molekul 
mereka tidak diketahui, namun terlibat dalam sistem imuniti. Terdapat juga lapan gen 
lain-lain kategori (ANO5, ASTE1, BEST3, CTBP2, CTDSP2, DCHS2, GLYR1 dan 
KRTAP19-6). Berdasarkan data varian, adalah dihipotesis bahawa genetik CP 
kekeluargaan adalah gangguan genetik secara heterogen yang mana kedua-dua varian 
perwarisan dan varian de novo yang terlibat berkemungkinan mengandungi maklumat 
ramalan genetik penting bagi CP. Ini menggalakkan berbagai kajian di masa hadapan 
dengan menggunakan sampel yang lebih besar, analisis pengesahan yang lebih banyak 
dan kajian pengkelasan fungsi untuk memahami lebih lanjut sumbangan gen-gen 
terlibat ini terhadap CP. Hal ini berkemungkinan membantu pembangunan molekul 




WHOLE EXOME SEQUENCING ANALYSIS OF CEREBRAL PALSY 
PATIENTS WITH UNDERLYING GENETIC FACTORS 
ABSTRACT 
 Cerebral palsy (CP) is a result of neurological dysfunctions that do not worsen 
with age but will be manifested as muscle impairments till adulthood. Some CP risk 
factors are intrauterine infection, brain malformation, instrumental delivery, etc. that 
occur at three different events (antenatal, intrapartum and postpartum). Meanwhile, 
idiopathic CP refers to CP cases with unknown risk factors. This exploratory study 
with no proposed hypothesis of specific loci was carried out to explore CP genetic in 
Kelantan patients with underlying genetic factors using Whole Exome Sequencing 
(WES). As opposed to other neurodevelopmental disabilities, contribution of genomic 
abnormalities to CP occurrence has not been extensively researched despite probably 
accounting for 70–80% of cases with prenatal causes. Plus, Malaysia has yet to 
establish CP prevalence and genetic database. Therefore, identification of genomic 
causes would improve CP causal insight in selected families. In total, 20 subjects 
consisting of 10 CP individuals and 10 unaffected parents were analysed in the current 
study. The sequenced DNA samples were analysed using bioinformatics Genome 
Analysis Toolkit (GATK) to generate all possible variants. We found 37 rare de novo 
(n=29) and inherited variants (n=8) from a total of 29 genes and classified them 
according to American College Medical Genetic (ACMG) standard guidelines. There 
are nine central nervous system (CNS) related genes (CDKL2, CEP164, FAM104B, 
FAM163A, FXR2, KCNK18, KCNQ3, MAPRE3 and RBMX, CP is a disorder of CNS 
origin and these genetic mutations are anticipated to contribute to CNS defect. Nine 
mutated immune-related genes (COL6A6, COL7A1, CYHR1, DLL1, GPR97, HLA-
xxiii 
DRB1, HLA-DRB5, LYST and MUC16) are present in CP subjects only, which possibly 
indicates that CP individuals may have potential of developing immune-related 
problems. Thus, CP may be categorized as immune dysregulation-related neurological 
disorder. Next are three potentially immune-related mutated genes (ANKRD36, 
DNAH17 and TTC13) with unknown molecular function, but are associated with the 
immune system. There are also eight mutated genes of other categories (ANO5, ASTE1 
BEST3, CTBP2 CTDSP2, DCHS2, GLYR1 and KRTAP19-6). Based on the variant data 
we hypothesize that familial genetic CP is genetically heterogenous, consisting of 
discovered de novo and inherited variants that may contain important predictive 
information on CP. This encourages future studies with bigger sample size, more 
validation analysis and functional characterization to further understand the 
contribution of the related genes to CP. This could help in the future development of 






1.1 Cerebral Palsy Definition 
By terminology “Cerebral” refers to the brain, while “Palsy” refers to the weakness or 
paralysis or lack of muscle control. Therefore, cerebral palsy (CP) is a condition of 
any brain part anomalies that occur during brain development resulting in muscle 
control disorders (Parveen et. al., 2018). In 2004, the International Working Groupon 
the Definition and Classification of Cerebral Palsy defined CP as a group of permanent 
disorders of movement and posture development resulting in activity limitation of non- 
progressive disturbances that occurs in the developing foetal or an infant brain. The 
motor disorders of CP are accompanied by epilepsy, secondary musculoskeletal 
problem and disturbances of sensation, perception, cognition, communication, and 
behaviour (Rosenbaum et al., 2007). 
Basically, CP is a result of any neurological dysfunctions that do not get worse with 
age but will be manifested in movement and coordination impairments till adulthood. 
As a chronic disability of Central Nervous System (CNS) origin (Grether et. al., 1992) 
this “cerebral palsy” term in a clinical descriptive is also applied to the heterogeneous 
group of neurodevelopmental disorders in which motor impairments usually co-occur 
with a range of medical disorders or comorbidities (Moreno-de-Luca et al. 2012). 
Recently, it is suggested for CP to be defined as a spectrum disorder due to CP itself 
as a condition of heterogeneous nature in all its aspects of aetiology, severity, treatment 
options, individual’s trajectories and outcomes (Shevell, 2019).  
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1.2 Epidemiology of Cerebral Palsy 
CP is the most common cause of physical disability in childhood (Kirby et al., 2011). 
To date, the CP prevalence in Malaysia is not available, this might be due to lack of 
CP studies locally. However, based on direct communication (via e-mail) with the 
Department of Social Welfare Malaysia, up until February 2018 a record of 12908 CP 
cases (two years old to 19 years old) have been registered from all around Malaysia 
(Malaysia Social Welfare, 2018). Several studies from Asian countries showed 
different CP prevalence. In Bangladesh, the CP prevalence for a time-frame of 1998 
to 2016 was 3.4 per 1000 live-births which was considered high due to lack of early 
intervention as a result of substantially delayed diagnosis (Khandaker et. al., 2019). 
 
A study by Liu and team (1999) showed CP prevalence of 1.6 per 1000 live-births in 
China for 1990 to 1997 time period, which was considered low. This was in accordance 
with low survival rate of low-birth weight (LBW) children in China (Liu et. al., 1999), 
whereby LBW is one of the CP risk factors. Multiple studies in Japan reported different 
CP prevalences, ranging from 1.4 to 2.9 per 1000 CP children (Takeshita et. al., 1989; 
Touyama et. al., 2008; Koterazawa et. al., 2016; Toyokawa et. al., 2017). These 
different CP prevalence values vary by study variables or parameters such as children's 
age, specified period of time, and location-based surveillance. Another study involving 
the Asian population who were residing in California, United States of America (USA) 
showed CP prevalence in those Asian Americans was lower than in whites, which was 
1.09 in 1000 live-births compared to 1.36 per 1000 live-births (Lang et. al., 2012). The 
studied Asian American ethnicities were East Asian (Chinese, Japanese, Koreans), 
Filipino, Indian, Pacific Islander (Guamanians, Hawaiians, and Pacific Islanders), 
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Samoan or Southeast Asian (Cambodian, Laotian, Thai, Vietnamese) (Lang et. al., 
2012). On top of all, a study showed a worldwide prevalence of 2–3 per 1000 live- 
births that has remained stable for more than four decades, despite substantial 
improvements in obstetric and neonatal care (Clark et. al., 2003). Besides that, CP is 
shown to be common in males compared to females through multiples studies of 
different populations and races across the world (Izuora et. al., 1981; Nelson et. al., 
1985; Blair et. al., 1988; Laisram et. al., 1992; Jarvis et. al., 2005; OʼCallaghan et. al., 
2011). This possibly happens due to recessive X-linked chromosome variants in males 
in which they are more vulnerable to genetic mutation since male has one X 
chromosome only (Jacquemont et. al., 2014). Indirectly, this finding tells us that 
genetic factor may also play a role in CP incidence. 
 
 
1.3 General Causes of Cerebral Palsy 
There are three different timings of CP causal events which are antenatal, intrapartum 
and postpartum. In addition to that, there is also idiopathic causal category sincemore 
than 30% of reported CP cases are due to unknown risk factors (Rosenbaum et. al., 
2003). Antenatal (from inception of pregnancy to the onset of labour) risk factors are 
abdominal trauma, birth defect, chorioamnionitis, foetal brain malformation, hypoxia, 
intrauterine growth restriction, intrauterine infection, low birth-weight, maternal fever, 
multiple gestation, thrombophilia and viral infection (Murphy et. al., 1995; Stanley et. 
al., 2000; Gibson et al., 2003; Jones et. al., 2007; McIntyre et. al., 2013;). Examples of 
intrapartum risk factors are abnormal foetal presentation, birth asphyxia, meconium 
aspiration, prematurity, vaginal breech delivery, prolonged and difficult labour, 
delivery, instruments, placental abruption and uterine rupture (Murphy et. al., 1995;  
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Gibson et al., 2003; Jacobsson et. al., 2004; McIntyre et. al., 2013). Risk factors for 
postpartum are asphyxia, hypoglycaemia, neonatal seizures, cerebral infarction, 
respiratory distress, neonatal infection (sepsis and meningitis), jaundice and head 
injury (Stanley et. al., 2000; Han et. al., 2005; Jones et. al., 2007; McIntyre et. al., 
2013). Aforementioned risk factors prove that, CP disorder is actually a result of 
multiple aetiologies. A recent systematic review study had shown ten risk factors that 
were consistently reported as statistically significant to be causing CP in term born 
infants. These are birth asphyxia, hypoglycaemia, instrumental ⁄ emergency caesarean 
delivery, LBW, major and minor birth defects, meconium aspiration, neonatal 
infections, neonatal seizures, placental abnormalities and respiratory distress 
syndrome (McIntyre et. al., 2013). 
 
1.3.1 Antenatal Risk Factors 
According to above mentioned systematic review study by McIntyre et. al., 2013, 
analyses showed that birth defect risk factor is the highest relative risk for CP with a 
wide range of central estimates between studies which are 2.6 — 20.7 for all CP types 
and 2.2 — 27.4 for term CP infant (> 2500 g) category (McIntyre et. al., 2013). Other 
studies showed a higher incidence of birth defect that is associated with maternal age 
(≥ 35 years old) and maternal age is also one of CP risk factors (Salem et. al., 2011; 
Johnson et. al., 2012). The congenital abnormalities include chromosomal 
abnormalities and other organ anomalies (Johnson et. al., 2012). The congenital 
anomalies that are highly reported in CP children involve cerebral defects of 
microcephaly and hydrocephaly, cardiac defect, musculoskeletal defect and urogenital 
defect (Odding et. al., 2006; Andersen et. al., 2008; Rankin et. al., 2010; Moreno-de-
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luca et. al., 2012). Besides that, CP risk increases by 50% in newborns with low birth- 
weight (< 2500g) compared to newborns with normal weight (Odding et. al., 2006). 
The risk of having LBW newborn is significantly higher in a pregnant mother with 
older age (≥ 35 years old) (Johnson et. al., 2012). A case control study was done 
between the LBW survivors at young adulthood age and control group of young 
adulthood of normal weight-born that showed the LBW individuals have higher 
neurosensory impairment (P < 0.001) compared to the control group. This 
neurodevelopmental condition is persistent until their adulthood (Hack et. al., 2002). 
LBW is also reported to be occurring due to intrauterine growth restriction (IUGR), 
one of the CP risk factors (Williams et. al., 1997). The IUGR describes a condition of 
foetus that does not grow at expected rate during pregnancy, which later resulting in 
the infant with LBW.  
 
The IUGR is also influenced by placental abnormalities risk factor when a foetus does 
not receive adequate oxygen and nutrient (McIntyre et. al., 2013). Based on the reports, 
maternal age, IUGR and LBW may together contribute to the development of CP. 
Normal placenta is essential for a healthy pregnancy by transporting the nutrient and 
oxygen, removing waste products, protecting from infection and modulating maternal 
immune system and hormone production to maintain the pregnancy (Heazell A., 
2012). However, placenta with abnormal structures of area, thickness, size and volume 
causes placenta insufficiency (Ohgiya et. al., 2016). This indicates that placenta 
abnormalities do affect its functions which later disturb the foetus’ growth. Small 
placenta or low weight placenta increases the CP risk in term infants (Strand et. al., 
2016)  
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1.3.2 Intrapartum Risk Factors 
Birth asphyxia which is also known as birth trauma describes the difficult vagina 
delivery event. Over the past three decades, a consistent trend shows that 17% to 24% 
of CP cases are related to birth asphyxia (Volpe, 2008). Theoretically, birth asphyxia 
is a clinical situation of foetal distress when a foetus is deprived of oxygen during 
labour. This contributes to irreversible brain damage effect in CP (Blair et. al., 1988; 
Stanley et. al., 2000). The criteria for birth asphyxia diagnosis are low Apgar score (≤ 
3) for over 5 min, abnormal umbilical artery (pH < 7) and newborn cerebral 
dysfunction (seizure) (Gilstrap et. al., 1989). However, one in every six to nine CP 
cases is estimated to reduce brain injury risk by 10% if the asphyxiated newborn 
receives hypothermia intervention within six hours of the birth asphyxia event (Jacobs 
et. al., 2013; McIntyre et. al., 2013). 
 
Instrumental deliveries occur secondary to a prolonged second stage of labour, 
meanwhile the emergency caesarean sections occur due to failure to progress or as a 
result of foetal stress and possible hypoxia (Philpot et. al., 2018). These show that 
instrumental and emergency caesarean deliveries are common alternatives taken 
during a difficult vagina delivery. Multiple association studies had shown that these 
two risk factors are significantly associated with the increased risk of CP in term 
infants (Walstab et al. 2004; Stelmach et al. 2005; Thorngren-jerneck et. al., 2006; 
O’Callaghan et. al., 2013). Meconium aspiration during intrapartum is another 
statistically significant reported risk factor of CP (Beligere et. al., 2008; McIntyre et. 
al., 2013). This is considered as presence of foetal distress during the labour. 
Meconium consists of a mixture of blood, cellular debris, gastrointestinal, hepatic 
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secretion, lanugo, pancreatic secretions, swallowed amniotic fluid and vernix caseosa. 
Meconium that presents in the foetus’ tracheobronchial can cause airways blocking, 
interference with alveolar gas exchange, chemical pneumonitis and surfactant 
dysfunction. 
 
1.3.3 Postpartum Risk Factors 
Glucose is important for brain development. An infant with low blood glucose within 
few days after birth is considered hypoglycaemic. Koh et. al., (1988) had shown that 
full-term infants with blood glucose level < 2.6 mmol/L resulted reversible injury to 
the nervous system. This threshold is also proposed for pre-term infant cases (Lucas 
et. al., 1988). Regardless of different gestational ages and infant birth-weights, blood 
glucose level below 2.6 mmol/L (< 2.6 mmol/L) has been used as a hypoglycaemia 
intervention threshold value for infants. Persistent or recurrent hypoglycaemia can 
cause permanent brain injury called neonatal hypoglycaemia encephalopathy which 
later results in many impaired conditions such as long-term vision impairment, hearing 
impairment, cognitive abnormalities, epilepsy (Su et. al., 2012) and central nervous 
system disorders including CP (Lou et. al., 2010) as available at 
http://en.cnki.com.cn/Article_en/CJFDTotal-YXZS201013031.htm. In fact, these 
impairments are all CP comorbidities. Hypoglycaemia also contributes to neonatal 
seizure (Montassir et. al., 2009). The positive correlation between these two CP risk 
factors of hypoglycaemia and neonatal seizure has made neonatal seizure as a 
prognostic factor for neonatal hypoglycaemia condition in which both lead to 
neurological outcome (Koivisto et. al., 1972; Pildes et. al., 1974; Yager et. al., 2002). 
Neonatal seizure occurrence is estimated at 1 in 4000 term births (Nelson et. al., 2004). 
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Neonatal infection is developed in infants with cerebral abnormalities (Blair et. al., 
1993; Walstab et. al., 2004) that is verified during the Neonatal Intensive Care Unit 
(NICU) stay. 
 
The example of neonatal infection are pneumonia, septicaemia, meningitis, 
encephalitis, neonatal urinary tract infection (UTI) or ventriculitis (Kimberlin D, 2004; 
Ganatra et. al., 2010; Emamghorashi et. al., 2012; Shimol et. al., 2012; Camacho- 
Gonzalez et. al., 2013). Respiratory distress syndrome in infant is caused by lack of 
surfactants in the lung, which leads to atelectasis, decreased gas exchange and hypoxia 
(Thygesen et. al., 2016). This infant respiratory syndrome causes intracerebral 
haemorrhage/ intraventricular haemorrhage (ICH/IVH) and also periventricular 
leucomalacia (PVL), which are also risk factors of CP (Kinney et. al., 2006; Sun et. 
al., 2013). Based on these explanations, it is clear that some risk factors are influencing 
each other impact, which later contributes to CP pathway. 
 
1.3.4 Genetic Factors As Possible Causal of Cerebral Palsy 
Many CP cases with unknown causes are found to be associated with genetic 
alterations which either directly cause CP or contribute to CP susceptibility (Moreno-
-de-luca et. al., 2012; McMichael et. al., 2015). As opposed to other 
neurodevelopmental disabilities, the genomic abnormalities contribution to CP 
occurrence has not been researched extensively, despite probably accounting for a 
proportion of 70–80% of cases with prenatal causes. (Moreno-De-Luca et al., 2012). 
Several lines of evidence support the theory that multiple genetic factors contribute to 
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the cause of CP. First, mutations in multiple genes result in mendelian disorders that 
are present with CP-like features (Moreno-De-Luca et al., 2012), and several single- 
gene mutations have been identified in idiopathic (ie, non-syndromic) CP pedigrees 
(Lynex et al., 2004; Lerer et al., 2005; Verkerk et al., 2009; Abou Jamra et al., 2011; 
Moreno-De-Luca et al., 2011). These mutations, however, represent too limited cases 
to assure generalization. There is a great clinical heterogeneity between cases. This 
may be due to genetic heterogeneity, whereby different genetic abnormalities as a 
result of mutations at two or more genetic loci contribute to the same outcome 
phenotype in different individuals (McGinniss, et. al., 2013). 
 
Second, the prevalence of congenital anomalies in individuals with CP (11–32%) is 
significantly higher than in the general population (2–3%) (Blair et al., 2007; Garne et 
al., 2008). Third, register-based studies have reported a significantly higher 
concordance rate for CP in monozygotic twins than in dizygotic twin pairs (p = 0.0026) 
(Petterson et al., 1990). Fourth, the risk of CP in consanguineous families is about 2.5 
times higher than the risk in outbred families (Al-Rajeh et al., 1991; Erkin et al., 2008). 
Fifth, several studies have reported familial aggregation of CP, including identical CP 
syndromes in the same family (Gustavson et. al., 1969; Palmer et al., 1994; Amor et 
al., 2001; Hemminki et al., 2007). Sixth, a paternal age effect has been described in 






1.4 Early Signs of Cerebral Palsy 
As a neurological condition that affect movement and coordination, CP is usually 
apparent within the first few years of life (Illingworth et. al., 1966). CP diagnosis is 
made before the age of 2 years for infants or toddlers with CP symptoms (Ashwal et. 
al., 2004). The major signs for CP diagnosis are delayed motor milestones, abnormal 
neurological, primitive reflexes persistence and abnormal postural reactions (Jones et. 
al., 2007). The child is considered delayed in motor milestones if he/she does not show 
physical abilities such as no rolling over at six months old, not sitting even with support 
by eight months old and not walking by 18 months old. Other than that, the delayed 
motor also causes a fisting after five months of age and there are also discrepancies 
between intellectual and motor development (Bennett et. al., 1999; Jones et. al., 2007). 
Neurological abnormalities test is to examine for persisted ankle clonus which is a 
series of involuntary, rhythmic, muscular contractions, and relaxations beyond 12 
months old; brisk deep tendon reflex (hyperreflexia) examination that describes the 
increase speed in reflex. Examination for muscle tone which is also known as muscle 
tension control. Two states of muscle tension that are noticeable at rest are called 
hypertonia and hypotonia which are the increasing and decreasing muscle tone 
respectively. Another muscle tension is dystonia, a condition of increased muscle tone 
that is noticeable through repetitive involuntary movement with abnormal posture 
(Bennett et. al., 1999; Jones et. al., 2007). Abnormal muscle tone leads to abnormal 
posture reactions such as head lag, poor head control, adducted thumbs, 
hyperextension trunk, opisthotonus (abnormal posture due to muscle spasm) and lower 























Figure 1.1: The early signs that are obvious in infants or toddlers. A and B 
were extracted from Carney et. al., 2007 
(https://neurology.mhmedical.com/content.aspx?bookid=459&sectionid=41027






The diagnosis also involves primitive reflexes persistence assessment to observe any 
clinical reflection signs that occur due to malfunction in nervous system control. 
Instead of supposedly integrated within four to eight months old, the primitive reflexes 
are observed to be persisted until adulthood. The primitive reflexes are asymmetrical 
tonic-neck reflex, Moro reflex, extensor thrust on vertical suspension and absence of 
normal parachute reaction after 11 months (Jones et. al., 2007; Agarwal Et. al., 2012). 
This persistence later influences the muscle tone change and limbs which causes 
interference with voluntary motor movement (Bennett et. al., 1999; Jones et. al., 2007). 
 
Both delayed motor milestones and primitive reflexes persistence signs are helpful for 
diagnosis on CP children with no brain damage incident (Jones et. al., 2007). The non- 
progressive condition of CP means that the original malfunction in the brain does not 
get worsen by age. However, CP children’s physical manifestations will change with 
age. This physical changing may be misunderstood to be worsen by time, while it is 
actually the result of physical feature deficit signs that are detected during diagnosis 
phase and become more obvious as the CP children grow (Jones et. al., 2007). 
 
1.5 Types of Cerebral Palsy 
Motor dysfunction in CP is divided into three major types of CP physiology which are 
spastic, dyskinetic and ataxic (Figure 1.2). CP is classified according to the damage on 
different parts of the brain (cerebral cortex, basal ganglia and cerebellar) affecting 
different parts of the body (Figure 1.2). The detail explanation on Figure 1.2 can be 














Figure 1.2: The classification of CP according to its affected area distribution 
(Extracted from Parvizi, 2010). 
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1.5.1 Spastic CP 
Spastic CP is the most common CP, diagnosed in 75% cases (Jan et. al, 2006). It is a 
condition of muscle stiffness due to incorrect relayed messages to the muscle from the 
malfunction brain parts of cerebral cortex and corticospinal tracts (Norton, 2007) as 
available at https://www.sciencedirect.com/topics/pharmacology-toxicology-and 
pharmaceutical- science/cerebral-palsy. While performing an activity by a normal 
muscle state, a group of skeletal muscles is contracting while the opposite skeletal 
muscle group is relaxing when a normal person bending his/her arm. On a contrary, in 
spastic CP child, both groups of muscles are contracting together while performing 
any activities. This is referred as increasing muscle tone which will result in 
exaggerated reflexes that lead to stiffness, jerky and awkward movement (Ranatunga 












Figure 1.3: The spastic diplegia CP individuals with stiffness and foot inversion 
(A) and scissor gait (B). (Extracted from Borchers, 2015 at 
https://studfile.net/preview/7605613/page:38/. 
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Spastic CP is divided into three subtypes according to topographical pattern of affected 
limbs (refer Figure 1.2). For spastic hemiplegia subtype one side of the body limbs, 
either left or right side, is affected and the upper limb is worse affected than the lower 
limb. This subtype is unnoticeable until the child tries to grasp objects (Rapin, 2000; 
Norton, 2007). Spastic hemiplegic child has a poor motor coordination that causes the 
unstable walking with tiptoeing, slower speed, obvious swing and longer gait cycle 
(Wang et. al., 2012). Spastic diplegia subtype affects all four limbs. However, the 
lower limbs are predominantly affected compared to upper limbs that show slightly 
affected signs. Diplegic children walk with “scissors gait” but some are unable to walk 
or immobilized without ambulatory devices (Rapin, 2000) (Figure 1.3 (B)). Spastic 
quadriplegia is the most severe subtype for a CP child with paresis of all four limbs. 
The quadriplegic children are unable to mobilize or sit without the help of wheelchair 
with neck and trunk support (Rapin, 2000). 
 
1.5.2 Dyskinetic CP 
Dyskinetic CP (Figure 1.2) is a condition of abnormal involuntary movements due to 
affected basal ganglia that controls automatic movement, movement related to posture 
and fine digital movement (Norton, 2007). Dyskinetic child has a probability of unable 
to speak due to facial dyskinesia, has hearing impairment and less or no use of hands 
at all, yet may have normal intelligence (Rapin, 2000). Dyskinetic CP is divided into 
two subtypes which are dystonia and athetosis. Dystonia is a condition of sustained 
muscle contraction that frequently causes twisting and repetitive movements or 
maintained-abnormal postures or either both. The dystonic features are foot inversion, 
wrist ulnar deviation or lordotic trunk postures (Sanger et. al., 2010).  
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The severity and quality of these involuntary movements are influenced by body 
position, consciousness level, emotional state and any tasks being attempted by the 
child (Jones et. al., 2007). Opposite to dystonia, athetosis is a condition of unable to 
maintain a stable posture. It is also accompanied with a slow and continuous 
involuntary extra movement, which occur particularly at the arms, feet, hands, face, 
neck and trunk (Sanger et. al., 2010). It is noticeable when a CP child is particularly 
starting to move and also will appear floppy when being carried by another person 
(Aguiar et. al., 2013). 
 
1.5.3 Ataxic CP 
The third CP main classification is another non-spastic called ataxic CP (Figure 1.2) 
which is the least common type of CP accounting for less than 1 in 10 CP individuals 
(Chen et. al., 2020). The ataxic CP is due to abnormalities in cerebellum (Rapin, 2000). 
An ataxic child has body imbalance issue which leads to shaky and tremor movement 
(Aguiar et. al., 2013) and it is apparently observed in gait and trunk (Rapin, 2000). 
Besides these three main types, there are also cases of CP children with mixed CP 
types due to having more than one type with several movement patterns. 
  
1.6 Gross Motor Function Classification System (GMFCS) 
Palisano’s team (1997) built up GMFCS to define how severe the movement problem 
by describing the motor function range from mild to severe in a CP child. There are 
five levels of GMFCS classification system based on parameters of gross motor skill, 
truncal control (sitting ability), walking, mobilize with wheelchair and assistive 
18 
devices dependent. The CP children within level I are able to walk, climb the stairs 
without limitation and are also capable of performing gross motor skills such as 
running and jumping (Figure 1.4). However, the speed, balance and coordination are 
impaired. Level II category is for CP children who are also able to walk independently 
however need to hold onto a rail while climbing stairs. 
 
They also experience limitation when walking on uneven surface, in crowds or in a 
confined space (Figure 1.4). Level III categorizes CP children who walk indoors or 
outdoors on even surface with assistive mobility devices. They are able to climb stairs 
while holding onto a rail and also able to propel a wheelchair manually (Figure 1.4). 
The CP children within level IV walk in a short distance and rely more on walk 
assistive devices (Figure 1.4). Whereas, level V is for CP children with all motor 
function areas being affected and are completely dependent on aid devices with no 
means of independent mobility. The voluntary control of movement, trunk and head 
















Figure 1.4: The levels of GMFCS classification system for CP children (Palisano 
et. al., 1997). 
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1.7 Cerebral Palsy Comorbidities 
Besides clinical spectrum of movement difficulties as discussed earlier, CP individuals 
are also accompanied with other several comorbidities such as epilepsy, visual and 
hearing impairment, speech and communication problem, intellectual disability, 
autism, cardiac anomalies, urogenital abnormalities, skin problems with pressure sore 
or friction area, nose of air-way space problem and musculoskeletal anomalies 
including hip dislocation, contractures and scoliosis (Figure 1.5) (Odding et. al., 2006; 




















ebral_P alsy and © Mayo Foundation For Medical Education And Research). 
 
22 
Besides those, muscle impairments of pharynx and larynx are reported to lead to 
aspiration with feeding that causes the CP children having difficulty in swallowing, 
whereas oral muscle impairment causes drooling (Jones et. al., 2007; Amoghimath et. 
al., 2016). Apart from that, there are several CP comorbidities that are commonly 
reported. These include intellectual disability in 30-65% (Pakula et. al., 2009), epilepsy 
in 20-40% (Odding et. al., 2006), visual impairment in 40%, hearing impairment in 5-
15%, seizures in 30-50% and speech deficit in 40% of CP cases (Moreno-de-luca et. 
al., 2012). All of these comorbidities are compiled and illustrated in a bar chart as in 













Figure 1.6: The prevalence and comorbidity types in CP individuals. These are 
compiled from several studies as (Odding et. al., 2006; Pakula et. al., 2006 and 
Moreno-de-luca et. al., 2012). 
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1.8 Management and Therapy For Cerebral Palsy Children 
As a lifelong condition, CP is not curable but it is treatable in order to improve the CP 
children’s quality of life. The treatments for CP children are based on the aspects of 
movement problems, associated medical problems and functional and cognitive 
abilities. 
 
1.8.1 Movement Problem Treatment 
In order to encourage motor development, treatments such as physiotherapy (body 
movement) and occupational therapy (ability to perform daily activities) should be 
done. There are several devices, alternatives and medications available to counter 
movement problems. Orthosis or also known as braces is an orthotic device that is used 
for lower limbs in CP children. It is used for standing, walking and preventing muscle 
contracture and deformity (Knutson et. al., 1991; Morris C., 2002). There are many 
types of orthosis such as foot orthosis to oppose foot pronation (collapsed foot arch), 
supramalleolar orthosis for malleoli support and plantar flexion and dorsiflexion, 
ankle-foot orthosis to provide support from fibula in children with excessive flexible 
knee flexion posture, and knee-ankle-foot orthosis provides support from knee to 
calcaneus to make the knee joint be in the gait line progression. There are also multiple 
of hip-gait orthosis support such as reciprocating gait orthosis to hold pelvis into 
butterfly-shape pelvic band which maximizes reciprocal action by both hip sides thus 
helps in sitting ability, hip guidance orthosis to help in walking faster however shows 
higher energy expenditure and parapodium orthosis for a child with swivel walking 
(Knutson et. al., 1991). There is also plaster cast alternative to calf the muscle and 
improve foot position during walking (Zachazewski et. al., 1982; Domalgaska et. al., 
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2006). For upper limb extremities, splint devices are used to facilitate better grasp and 
maximize the arm and hand functions in CP children. Splinting prevents contracture 
and deformity by supporting the wrist and thumb in the functional position (Imms et. 
al., 2011). Next treatment for movement problems is Botulinum Toxin A (BoNT-A) 
injection for either lower limb or upper limb with the spastic or tight muscles problem. 
This treatment reduces muscle spasticity and lasts for between 3 and 6 months. In some 
CP children, there is also gait improvement but in a small magnitude. However, in 
ambulatory CP children, BoNT-A injection causes muscle atrophy (Multani et. al., 
2019). Few oral medications are also prescribed for spasticity that restrict the 
movement. These include diazepam, dantrolene and baclofen. Diazepam is the most 
cost-effective medication and applicable to initiate afterward physical therapy in a 
newly CP diagnosed infant and young CP children (Mathew et. al., 2005). 
 
Dantrolene decreases the stiffness by acting directly on contractile mechanism of 
skeletal muscle. Long term use of dantrolene causes liver problem (0.07% to 1.0%). It 
causes less sedation compared to diazepam (Pinder et. al., 1977). Baclofen is applied 
to CP children with severe spasticity to reduce the spasticity in CP children as well as 
spinal spasticity in adult. Diazepam, dantrolene and baclofen are similar in efficacy 
but have different spectrum of adverse effects (Lataste et. al., 1994). The orthopaedic 
surgery is another undertaken treatment to overcome the movement problems in CP 
children. There are various surgical techniques for different form of deformities and 




1.8.2 Associated Medical Conditions 
Epilepsy, constipation, gastro-oesophageal reflux and drooling are the common 
medical problems associated with CP children. Epilepsy is a common medical 
condition in CP children with 20-40% occurrence (Moreno-de-Luca et. al., 2012). 
There are multiple established anticonsulvants used for this medical problem, such 
carbamazepine, sodium valproate, lamotrigine, phenytoin, phenobarbitone, 
clonazepam, topiramate and levetiracetam. These medications have various side 
effects such as drowsiness, nausea and sedation. Constipation is also a common 
problem in CP children (74%) and other disorders with neurological impairment. It 
may be influenced by disruption of the neural modulation of colonic motility 
(Veugelers et. al., 2010). Besides constipation there are few examples of intestinal 
motility problems which include oral-motor dysfunction, gastro-oesophageal reflux, 
delayed gastric emptying and slow intestinal transit (Staiano et. al., 1994; Ravelli et. 
al., 1998). The medical treatments depend on different categories of how severe the 
constipation form is. 
 
Next is gastro-oesophageal reflux, another intestinal motility problem in which the 
lower oesophageal sphincter (LES) is affected. This results in an involuntary passage 
of gastric contents into the oesophagus. It has been found in a higher prevalence which 
is up to 75% in CP patients (Su et. al., 2003). To lower the reflux there are non- 
pharmacological alternatives such as raise the head of the bed, reduce weight, limit 
secondary exposure to smoke, take high-pectin diet, avoid taking diet containing 
caffeine, spicy foods, fatty foods, and chocolate. These also prevent further 
complications (Espocito et. al., 2015; Fernando et. al., 2019). Pharmacological 
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treatments to significantly reduce acid reflux are proton pump inhibitors, H2 antagonist 
baclofen medication, and prokinetic agents like mosapride (Kawai et. al., 2004; 
Whitworth et. al., 2012). A medical condition of uncontrolled saliva that is resulted 
from impaired swallowing and poor lip closure. The incidence is 48.7% to 58% in 
which 17.7% are having severe drooling (Tahmassebi et. al., 2003; Hedge et. al., 
2009). Speech pathologists can help improve the ability to control mouth closure to 
overcome drooling problem (Hedge et. al., 2009). However, if the speech therapy is 
not effective, the benzhexol hydrochloride is suggested (Reddihough et. al., 2008a). 
The severity of drooling is reported to be reduced with age due to maturation of the 
oral muscle. However, persistent drooling problems can be fixed by surgical treatment 
to remove the sublingual glands (Burton, 2008). 
 
1.8.3 Functional and Cognitive Abilities 
Multiple therapy programs are to improvise CP children’s progresses. As the early 
intervention programs for CP disorder, these therapy programs also involves the 
caregivers to make them knowledgeably participate in maximizing CP children 
abilities. Neuro-developmental therapy or Bobath Therapy is to maximize the CP 
children’s functional abilities. It focuses on making any desirable movements more 
possible and preventing any undesired movements. It improves functional motor level 
and functional independency by improving postural control and balance (Tekin et. al., 
2018). Second is Conductive Education program to overcome the learning disabilities. 
This program educates on how to develop life skills including daily living, physical, 
emotional, social and cognitive and communication skills. This program also educates 
parents on how to assist their CP children with mentioned skills (Reddihough et. al., 
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2008b). Next is Constraint Induced Movement (CIMT) therapy which is applicable for 
hemiplegic CP children. This therapy encourages them to use their hemiplegic arms 
and hands in doing activities by constraining their non-hemiplegic arms and hands 
(Hoare et. al., 2007). It successfully sustain the improvement in motoric function in 
young hemiplegic CP children (Taub et. al., 2004). Another functional abilitytraining 
program is called goal directed training. The families and the CP children themselves 
are trained to identify which specific task that CP children want to perform at a 
particular time. The principle is repeating the attempt for the same task. Families and 
therapists can assess the children’s ability in performing the task. 
 
1.9 Genomic Approaches to Identify Gene Alterations in Cerebral Palsy 
Multiple studies had shown that CP is a complex disorder that is genetically 
heterogeneous. It is not a single gene disorder and DNA variants are discovered to be 
associated with CP. By definition, “DNA variant” means any gene alterations that 
occur in comparison with the “reference genome” sequences. This “variant” term is 
further categorized into two different types which are single nucleotide 
polymorphisms (SNP) and mutation (Karki et. al., 2015). “SNP” is referring to any 
gene alterations in DNA base sequences that occur at any single position in the 
genome, and it is abundantly (>1%) found in a population (Brookes, 1999). 
Meanwhile, “mutation” which is found in less than 1% in a population, is referring to 
any kind of gene alterations in the DNA sequence and it also refers to gene copy 
number variation (CNV) (Condit et. al., 2002; Brooker, 2012). In order to identify gene 
alterations in CP, several approaches had been applied such as Homozygosity Mapping 
29 
(HM) (section 1.9.1), analyses of candidate genes through association study (section 
1.9.2) and next generation sequencing (NGS) (section 1.9.3).  
 
1.9.1 Homozygosity Mapping (HM) and Linkage Analysis Approaches 
It is also known as autozygosity mapping, a type of genome-wide analysis that 
involves genotyping and linkage analysis. It is mostly applicable for identifying 
recessive variants by mapping for DNA markers identical by descent in 
consanguineous families (Seelow et. al., 2009), for Mendelian diseases with a 
homozygous autosomal recessive pattern of inheritance and for an extended family 
with more than one affected family members (Vahidnezhad et. al., 2018). The principle 
of HM is to search for genetic regions of homozygosity (ROH) in patient’s DNA that 
is varying from a few to several megabase pairs (Mb). Thus minimizes the overall cost 
and time (Alkuraya et. al., 2010). The HM technique involves procedures of 
polymerase- chain reaction (PCR) followed by genotyping to identify any ROHs 
presence (McHale et. al., 2000).  
 
ROH containing mutated genes of rare recessive traits will be detected from that SNP-
based genotyping. However, ROH also can be detected from NGS data (Vahidnezhad 
et. al., 2018). This HM analyses can be useful for both research and clinical purposes 
with the case of multiple affected relatives. Associated with HM is the linkage analysis 
which localizes a region in genome where a locus or loci that regulate the expression 
of a trait may be harboured (Ferreira, M. A R., 2004). Linkage analysis determines 
whether or not the regions are linked to the disease (Seelow et. al., 2009). 
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 Several CP studies which used the HM method were successfully discovering several 
gene alterations that are implicated in CP such as single locus mutation on 
chromosome 9p12-q12 (refer subsection 1.9.1(a)), GAD1 gene mutation Adaptor 
Protein 4 Complex gene mutations (refer subsection 1.9.1(b)), Adducin 3 Gamma 
(ADD3) gene mutation (refer subsection 1.9.1 (d)) and ANKRD15 or KANK1 deletion 
(refer subsection 1.9.1(e)). 
 
1.9.1(a) Single Locus Mutation of Chromosome 9p12-q12 
A study by McHale’s team (2000) was done involving an Asian family pedigree with 
two consanguinities sub-families producing two different sibships respectively. The 
first sibship consists of two ataxic CP of son and daughter out of four children 
meanwhile the second sibship consists of two ataxic CP daughters out of three 
daughters. All the diagnosed CP children were idiopathic CP cases and were born at 
term on spontaneous vagina delivery (SVD). They were also delayed in motor 
milestones, however, were in normal range of intelligence. The genome search using 
the linkage mapping kit with 343 autosomal dinucleotide markers was done for all 
affected children and their unaffected parents respectively. Another genotyping was 
applied to the other three unaffected children to check for any homozygosity regions. 
This was followed by statistical analysis of Linkage analysis which later discovered a 
mutation at single locus of chromosome 9p12-q12. A homozygous region of 23 cM 
near to centromere on Chromosome 9 was present in all affected individuals. This 
study confirmed the finding as single gene disorder and proposed that the pattern of 
inheritance for this familial CP case as autosomal recessive (AR). 
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1.9.1(b) Missense Mutation of GAD1 Gene 
Lynex & colleagues (2004) studied two different consanguineous families with 2 and 
four individuals of congenital spastic CP of unknown specific cause, respectively. All 
of the six CP individuals had global developmental delay, moderate to severe 
intellectual disability, poor or absent speech. The second family consists of two pairs 
of twin children. Only one son of the eldest pair of dizygotic twins that were born by 
Caesarean section is CP affected. The linkage mapping was done for 290 polymorphic 
DNA markers of which 0.5cM region was found on chromosome 2q24-25. This is 
followed by direct sequencing for all affected and unaffected individuals which later 
confirmed the presence of homozygous missense mutation in glutamate decarboxylase 
1 (GAD1) gene segregating with CP individuals. The GAD1 gene encodes for the 
brain-expressed isoform of glutamate decarboxylase that is responsible for the 
production of gamma aminobutyric acid (GABA) from its excitatory counterpart 
glutamate. GABA is the major inhibitory neurotransmitter in CNS (Bu et. al., 1992) 
and is crucial for normal brain development (Martin et. al., 2000) and synaptic 
plasticity (Hyde et. al., 2011). 
 
1.9.1(c) Mutations in Adaptor Protein 4 Complex Genes (AP-4) 
The AP-4 complex is expressed in CNS during embryologic and postnatal 
development (Yap et. al., 2003; Verkek et. al., 2009). The AP-4 complex genes with 
subunits of M1 (μ1), E1 (ɛ1), B1 (ß1) and S1 (σ1) are basically involved in intracellular 
trafficking of glutamate receptors (Yap et. al., 2003). The AP-4 proteins play a rolein 
membrane protein vesicular trafficking to selectively sort the proteins from trans- 
Golgi network to the postsynaptic somatodendritic domain in order to establish the 
32 
neuronal polarity (Matsuda et. al., 2009). In 2009, Verkek and team reported a study 
on a consanguineous Moroccan family with 5 CP siblings of infantile hypotonia which 
later evolved to spastic quadriplegia within first year of life. The HM was done on the 
candidate region of 14Mb of chromosome 7q22. They found the homozygous mutation 
in intron of AP4M1 gene (c.1137+1G→T) in all CP affected children. This AP4M1 
encodes for μ subunit. The mutation leads to truncated carboxyl (COOH) terminus, a 
cargo binding site. Verkek’s team hypothesized that this mutation contributes to defect 
during brain development which leads to congenital spastic quadriplegia and its pattern 
of inheritance is AR. In 2011, another mutation was discovered in another AP-4 
complex gene, AP4E1, in Palestinian-Jordanian inbred kindred with two CP spastic 
tetraplegic children (Moreno-De-Luca et. al., 2011). Through copy number array 
analysis, they identified a homozygous deletion on chromosome 15q12.2 specifically 
on exons 1-11 of AP4E1 gene that is presents in both CP children. 
 
The AP4E1 encodes for ɛ1 subunit. Jamra et. al., 2011 studied eight individuals with 
spastic paraplegia from three consanguineous Syrian families. Using autozygosity 
mapping, Sanger sequencing and next-generation exome sequencing they discovered 
mutations in AP-4 complex genes in those affected individuals. The mutations are a 
nonsense mutation (c.124C>T) in AP4S1 gene (encodes for σ1 subunit), a frameshift 
mutation (c.487_488insTAT) in AP4B1 gene (encodes for ß1 subunit) and a splice 
mutation (c.542þ1_542þ4delGTAA) in AP4E1 gene (encodes for ɛ1 subunit) (Jamra 
et. al., 2011). Disruption of any one of the aforementioned four subunits of AP-4 
complex genes would result in the AP-4 complex dysfunction resulting in AR of CP 
(Moreno-De-Luca et. al., 2012).  
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1.9.1(d) Mutation in Adducin 3 Gamma (ADD3) Gene 
In 2013, Kruer and team studied a consanguineous family that consisted of three 
spastic quadriplegia children and one spastic diplegia child from unaffected parents. 
Using the HM, exome sequencing and Sanger sequencing, a homozygous mutation of 
c.1100G>A (p.G367D) in ADD3 was discovered. They also did an in vitro study to 
observe the loss of function of ADD3 in drosophila and found out that the mutation in 
ADD3 disrupts the normal actin-capping function of adducin, leading to abnormal 
proliferation and migration. This has confirmed a critical role for adducin in 
locomotion including to regulate the actin cytoskeleton. They suggested that disrupted 
adducin function may lead to neuromotor impairment and implicating abnormalities 
of the dynamic cytoskeleton as a pathogenic mechanism contributing to CP. 
 
1.9.1(e) Deletion on KANK1 Gene 
A study by Lerer’s team (2005) involved an extended family of four large-generation 
pedigree with seven CP children who are in third generation and two who are in fourth 
generation. The CP individuals’ clinical features are intellectual disability (moderate 
to severe), nystagmus, brain atrophy, ventriculomegaly and congenital hypotonia that 
evolved to spastic quadriplegia. Linkage analysis identified a 225 kb deletion on 
chromosome 9p24.3 involving KN motif and ankyrin repeat domain 1 (KANK1) gene 
(previously known as ankyrin domain 15 (ANKRD 15) gene) in all affected individuals 
in an extended family, but was absent in 210 control individuals. KANK1 is 
ubiquitously expressed during foetal development and also adult life. This gene 
involves brain development and also important for cytoskeleton structure and plays 
roles in protein-protein interaction and signalling complexes (Lerer et. al., 2005). 
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1.9.2 Candidate-Genes Association Study Approach 
This approach focuses on the candidate genes that are known for their functions which 
are relevant to the particular studied disease or disorder (Zhu et. al., 2007). Several 
association studies with different techniques discovered multiple SNPs such as 
cytokine SNPs (refer subsection 1.9.2(a)), induciblenitric- oxide synthase and 
lymphotoxin α SNPs (refer subsection 1.9.2(b)), Interleukin-6 SNPs (refer subsection 
1.9.2(c)) and apolipoprotein E (refer subsection 1.9.2(d)) which contribute to CP 
susceptibility during foetal development. 
 
1.9.2(a) Cytokine Single Nucleotide Polymorphisms (SNPs) 
A case control study by Gibson et. al., (2006) involving 443 CP white infants and 883 
control white infants using DNA isolation and amplification had shown the association 
of two inherited cytokine polymorphisms with CP. The two polymorphic groups of 
cytokines are mannose- binding lectin of exon 1 at codon 54 (MBL-54) and tumor 
necrosis factor-2 (TNF-2) polymorphism in the promoter region. These two 
polymorphic groups had been genotyped to determine the polymorphic base at the 
interest site based on the genotyping standard reference samples. TNF-alpha (TNF-α) 
acts as proinflammatory cytokine to promote inflammatory and immunology response. 
However, its TNF-2 polymorphism at codon 308 increases the circulating level of 
TNF-alpha (TNF-α) protein which becomes toxic to neurons, specifically contributing 
to pathogenesis of white matter brain damage. Meanwhile, the MBL protein acts as 
anti-infectious agent by identifying and removing the pathogens from the body 
(Kilpatrick et.  al., 1999). The MBL-54 polymorphism causes the low level of MBL 
protein resulting in deleterious effect on the foetus. This study proved that these two 
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cytokine polymorphisms contribute to CP pathogenesis by affecting the foetal brain 
and these polymorphisms are associated with an increased risk of CP occurrence. 
 
1.9.2(b) SNPs of iNOS and LTA 
An association study by Gibson et. al., 2008 was carried out to re-evaluate 28 candidate 
SNPs that had been shown to be associated with CP as reported previously.  In this 
study, Gibson and team applied the technique of 5’ nuclease assay with 2-fluorescent 
dye oligonucleotide probes for amplification and genotyping purposes. However, from 
a total of 28 SNPs, only two SNPs were shown to be associated with CP in the total 
white Australians population of 413 CP children and 856 control children who were 
born in specified time range of year 1986 to 1999. These two SNPs are inducible nitric-
oxide synthase (iNOS) gene SNP on chromosome 17q11.2-12 and a SNP of 
lymphotoxin α (LTA) gene or also known as tumor necrosis factor-beta (TNF-ß) on 
chromosome 6p21.3. Both genes are involved in inflammatory response. 
Overexpression of iNOS causes injury in white matter region in both infant and adults’ 
brains (Boullerne et. al., 2006). Gibson et. al., 2006 proposed that heterozygous T 
allele of iNOS and homozygous variant of LTA influence the risk of CP. 
 
1.9.2(c) SNPs in Interleukin-6 (IL6) 
Khankhanian and team (2013) studied 250 CP infants randomly selected from the 
Kaiser Permanente Medical Care Program (KPMCP) against 305 controls. The 
subjects were African American, Asian, Hispanic, white, and others including mixed 
and unknown races. The team executed the Sanger sequencing for the targeted IL6 
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gene since it had been proposed to be associated with increased risk of CP (Djukic et. 
al., 2009; Wu et. al., 2009; Wu et. al., 2011). This study discovered seven SNPs in IL6 
gene which are rs1800795 in promoter region, rs2069832 (intron), rs2069833 (intron), 
rs1474348 (intron), rs1474347 (intron), rs1554606 (intron) and rs2069845 (CpG site). 
These SNPs were shown to be associated with CP pathogenesis by increasing the IL6 
protein level. High IL6 protein level in amniotic fluid, cord plasma and brain lesions 
lead to CP risk of periventricular leukomalacia (PVL). 
 
1.9.2(d) SNP in Apolipoprotein E (ApoE) Gene 
ApoE is a lipid transport protein, abundantly found in brain cells. Based on the study 
of 350 CP and 242 control individuals in a Chinese population, ApoE gene with 
rs769446 SNP of C allele was detected using MassARRAY platform-based 
genotyping. Multiple association analysis showed that ApoE SNP is associated with 
CP (Xu et. al., 2014). 
 
1.9.3 Next Generation Sequencing (NGS) 
In genome search analysis specifically to identify gene structures and functional 
characteristics that are implicated in diseases or disorders, several technologies have 
been developed such as Sanger sequencing, DNA microarray and the newest 
technology called Next Generation sequencing (NGS). Sanger sequencing is a 
convential method that sequences one gene or a small group of targeted genes at a time 
(Brooker, 2012). This is completely opposite to NGS that is capable of simultaneously 
sequencing thousands of nucleotides in a whole genome side by side at a large-scale 
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(McCombie et. al., 2019). In accordance to its high yield of sequencing reads, NGS is 
also wordwidely known as a massively parallel sequencing technology or high-
throughput sequencing (Brooker, 2012). DNA microarray or gene chip technology is 
able to analyze the expression of thousands of genes simultaneously (Wiltgen et. al., 
2007). Microarray principle which is using a small glass slide dotted with many 
different DNA sequences, is able to detect sequences in known genes only (Brooker, 
2012).  
 
On the other hand, NGS’s sequencing ability is beyond that of microarray since it 
captures and sequences the genome at a large scale as stated earlier. Thus, this gives 
the possibility of obtaining any new variants in wider DNA regions besides known 
genes region such as unknown genes, untranslated regions (UTRs), as well as 
downstream, upstream and splicing regions. Using NGS, many previous studies had 
discovered variants such as single nucleotide variants (SNVs), small DNA insertions 
or deletions (indels), copy number variations (CNVs), stopgains and stoplosses that 
are present in different DNA regions (Rabbani et. a., 2013; Belkadi et. al., 2015; Yano 
et. al., 2016). Thus, NGS supersedes both conventional Sanger sequencing and 
microarray in genome search field. Following that, many different platform 
technologies have been developed and offered to be applied to run the NGS work. 
Some platforms that have been widely used are Agilent, Nimblegen, Illumina Nextera 
and Illumina Truseq whereby each of them has different specifications, performances 
and principles (Chilakumari et. al., 2014). These platforms are applicable for both 
techniques in NGS which are whole genome sequencing (WGS) (refer subsection 
1.9.3(a)) and whole exome sequencing (WES) (refer 1.9.3(b)). 
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1.9.3(a) Whole Genome Sequencing (WGS) 
WGS sequences the whole genome, is applicable for detection of variants in non-
coding DNA regions too and is considered as more advance compared to WES 
(Belkadi et. al., 2015). However, it is more costly compared to WES. WGS is a 
common technology that is used in Genome Wide Association Studies (GWAS) that 
determine the association of specific genetic variations with particular diseases (Bush 
et. al., 2012). GWAS principle is scanning the genomes of many different individuals 
to detect any genetic markers that can be used to predict the presence of a disease in a 
particular studied population (Tam et. al., 2019). Previously, many studies have been 
reported showing that identification of related genetic markers helps to understand the 
genes contribution to a particular disease which later led to the development of 
preventions and treatment strategies. 
 
1.9.3(b) Whole Exome Sequencing (WES) 
WES technology provides the sequencing coverage of > 95% in which 85% are 
mendelian-causal mutations and the rest are SNPs that cause the diseases (Rabbani et. 
al., 2013). It is expected that this WES analysis would sufficiently cover the most 
possibilities where and how mutations may occur. On 3rd November 2015, the Human 
Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php) documented 
174,999 pathogenic mutations that cause human diseases. Of these, 97,626 (55.8%) 
are missense/nonsense, 15,990 (9.1%) are splicing abnormalities and 39,537 (22.6%) 
are small (< 20 bases) insertion/deletions. These types of mutations (87.5%) are 
expected to be covered by WES. There are 3297 mutations (1.8%) affecting regulatory 
arrangements and located in non-coding regions that may be missed by this method. 
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Nevertheless, most of this type of mutations could be located in 5’ UTR, 3’UTR or 
near to exon-intron boundaries which will be targeted by WES at high sensitivity 
through sequence captured by hybridization techniques using the exome-capture kit 
such as Nextera Rapid Capture Expanded Exome Kit (Illumina Technology, USA) that 
has been applied in this current study. Other than that, WES also has been 
acknowledged as a cost-effective method for facilitating the identification of genetic 
variants in neurological disorders that overlap with CP such as brain malformation, 
cerebellar ataxia, intellectual disability, autism and epilepsy (Bilgüvar, et. al., 2010; 
Wang et. al., 2011; De Ligt, et. al., 2012; Sanders et. al., 2012). 
 
1.9.3(c) WES detected De Novo Mutations in 3 Known Ataxic Genes  
The NGS of exome sequencing study was conducted by Parolin et. al., 2015 for 57 
ataxic known genes involving 10 cases whereby four cases had showed the finding of 
four de novo mutations from three genes of voltage-gate potassium channel activity 
Kv3.3 (KCNC3) (n=1), inositol triphosphate receptor (ITPR1) (n=2) and ß-III spectrin 
(SPTBN2) (n=1). The KCNC3 with p.T428I mutation was found in an ataxic CP child 
(cases 1) of a non-consanguineous family who was born from uneventful pregnancies 
and birth, and normal brain imaging. A functional study of p.T428I mutation showed 
a severe negative loss-of-function, whereby 50% potassium channel activity was 
reduced in the p.T428I mutant compared to wild type. The KCNC3 mutation was 
previously shown to be associated with spinocerebellar ataxia type 13 (Figueroa et. al., 
2011). Two de novo mutations were shown in ITPR1 in two different cases of two 
different consanguineous families. The mutations were P.N602D and P.S1487D of 
ITPR1 in case 2 and case 3 respectively in which both brain imaging were normal 
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(Parolin et. al., 2015). The ITPR1 encodes for intracellular receptor for inositol 1,4,5-
triphosphate, it is also associated with spinocerebellar ataxia type 15 (Van de Leemput 
et. al., 2007) and autosomal dominant cerebellar ataxia (Huang et. al., 2012). The third 
gene with one de novo mutation (P.R480W) found in this Parolin’s study was SPTBN2. 
The mutation was discovered in the fourth child of a non-consanguineous family from 
a normal pregnancy but was born through emergency caesarean due to foetal distress. 
The encoded protein-spectrin beta non-erythrocytic 2 or also known as beta-III 
spectrin, stabilizes the glutamate transporter at the plasma membrane surface and 
directly regulates the glutamate signalling pathway. STPBN2 was also shown to be 
associated with spinocerebellar ataxic type 14 (Lise et. al., 2012). 
 
1.10 Bioinformatics Analysis 
Bioinformatics is a computational analytical program completed with computational 
languages, tool and software to analyse WES raw data. Bioinformatics analysis 
involves five analytical steps which are raw quality assessment, pre-processing, 
alignment, recalibration and variant analyses (detection, filtering and annotation) (Bao 
et. al., 2014). Raw quality assessment followed by pre-processing are the two steps to 
inspect for problematic sequencing raw data and prepare the trimmed sequence data 
for the next alignment procedure. Third analytical step is sequence alignment where 
the filtered good quality sequences of read are aligned to a reference human genome 
(hg19) using the Burrows-Wheeler Aligner (BWA-MEM) aligner, producing the 
BAM format files output. Throughout the alignment and recalibration analytical steps, 
few bioinformatics tools are involved such as SAMtools and picard tools. The 
SAMtools is to produce sorted bam file, which is a binary format of the alignment file 
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whereas the picard tool then is to remove duplicates from the PCR amplification. 
Variant analysis step is the last analytical procedure which the goal is to filter the 
sequenced data against multiple genomic databases and annotating them according to 
few prediction tool programs that sort the variant according to protein changing. For 
example, Sorting Intolerant From Tolerant (SIFT) tool that gives the variants score in 
range of intolerant to tolerant (Ng et. al., 2001; Kaminker et. al., 2007), Polymorphism 
Phenotyping (PolyPhen) tool that predicts human disease-mutation whether or not it 
is deleterious (Ramensky et. al., 2002), Genomic Evolutionary Rate Profiling Rejected 
Substitution (GERP++_RS) that uses maximum likelihood evolutionary rate 
estimation for locus specific scoring (Davydov et. al., 2010). Another prediction tool 
is Combined Annotation-Dependent Depletion (CADD) (Kircher et. al., 2014) which 
is to measure deleteriousness of the variants that correlates with the pathogenicity and 
molecular function. The principle and procedures of bioinformatics analysis are 
explained in detail in Chapter 2. 
 
1.11 Rationales of The Study 
CP cases with unknown causes are found to be associated with genetic alterations 
which either directly cause CP or contribute to CP susceptibility. This is supported by 
several studies that showed multiple genetic factors contribute to the CP causals 
(Verkek et. al., 2009; Moreno-de-luca et. al., 2012; McMichael et. al., 2015). 
Previously, genetic association studies (case-control approach) have failed to produce 
strong, replicable results when applied to complex, multi-factorial, and highly 
heterogeneous groups of disorders, such as CP (Moreno-De-Luca et al., 2012). Thus, 
this current study adopted the WES approach to explore possible variants that are 
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implicated in studied CP cases. Several studies had shown the capability of WES in 
discovering variants in neurological disorders that overlap with CP features (Bilguvar 
et. al., 2010; Wang et. al., 2011; De Ligt et. al., 2012; Sanders et. al., 2012).  The 
contribution of genomic abnormalities for CP cases has not been researched widely in 
Malaysia, hence the identification of specific causes of the disorder would be very 
helpful. This may provide a better understanding of the disorder, accurate assessment 
of recurrence risk, and early intervention. Our preliminary study provides insights into 
the genetic cause of CP in selected Malaysian patients, and also provides a basis for 
fundamental studies into molecular pathologies of CP through the identified mutations. 
It may eventually encourage further research into the development of molecular 
targeted drug and therapeutic interventions for CP. 
 
1.12 General Objective 
This is an exploratory study whereby no hypothesis of specific loci was proposed since 
the main objective was to explore the genomic of CP cases. This preliminary study 
focused on idiopathic CP patients in Kelantan with defined genetic underlying factors 
using WES technique.  
 
1.12.1 Specific Objectives 
(a) To screen the CP families which fulfil the inclusion and exclusion criteria. 
(b) To determine the pathogenicity of discovered variants in subjects. 
(c) To investigate the inheritance of discovered variants. 
43 

















Figure 1.7: Flowchart showing the study dissected into two phases.   
Expert Focus Group Discussion (FGD)  
Screening of Patients’ records and First Home 
Visit  
Recruitment and Consent  
Second Home Visit and Specimen Collection 
DNA Library Preparation  
Whole-Exome Sequencing (WES)  
Bioinformatics Analysis  

















 MATERIALS AND METHOD 
2.1 Materials and Chemicals 
2.1.1 Chemicals and Reagents 
 
All chemicals and reagents used in this study are listed in Table 2.1. 
 
Table 2.1 List of chemicals and reagents. 
Name and Brand Supplier 
Absolute Ethanol (90%) Elite Advance Material, Malaysia 
Agarose Powder Sigma Aldrich, Merck, Germany 
DNA Marker (100bp) Promega Corporation, USA 
Elute Target Buffer 2 (ET2) Illumina Technology, USA 
Elution Buffer (AE) Gene All Technology, Seoul Korea 
Enrichment Amplicon Mix (NEM) 
PCR 
Illumina Technology, USA 
Enrichment Elution Buffer 1 (EE1) Illumina Technology, USA 
Enrichment Hybridization Buffer 
(EHB) 
Illumina Technology, USA 
Enrichment Hybridization buffer 
(EHB) 
Illumina Technology, USA 
Enrichment Wash solution (EWS) Illumina Technology, USA 
Ethidium Bromide (EtBr) Sigma Aldrich, Merck, Germany 
Expanded Exome Oligos (EEX) Illumina Technology, USA 
Index 1 (i7) Adapters Illumina Technology, USA 
Index 2 (i5) Adapters Illumina Technology, USA 
Library Amplicon Mix (NLM) Illumina Technology, USA 
Loading Dye Thermo Fisher, USA 
Lysis Buffer (BL) Gene All Technology, Seoul Korea 
Primer Cocktail (PPC) Illumina Technology, USA 




Table 2.1: Continued. 
Name and Brand Supplier 
Resuspension Buffer (RSB) Illumina Technology, USA 
Sample Purification Beads (SPB) Illumina Technology, USA 
Stop Tagment Buffer (ST) Illumina Technology, USA 
Streptavidin Magnetic Beads (SMB) Illumina Technology, USA 
Tagment DNA Buffer (TD) Illumina Technology, USA 
Tris-Borate-EDTA (TBE) 5X Sigma Aldrich, Merck, Germany 
Washing Buffer Solution B (BW) Gene All Technology, Seoul Korea 





All consumables used in the study are listed in the table below. 
 
Table 2.2: List of consumables 
Name and Brand Supplier 
BD Alcohol (70%) Swab Beckton & Dickinson, USA 
EDTA Tube, BD Vacutainer Franklin Lakes NJ, USA 
Electrophoresis Gel Casting Tray 
with Well Slots Comb 
Labnet, Malaysia 
Microtubes (1.5ml) Eppendorf, Germany 
Min Elute Column Gene All Biotechnology, Seoul Korea 
Needle Terumo, USA 
PCR tubes Eppendorf, Germany 






The kits that had been used in the study are listed in Table 2.3 below. 
 
Table 2.3: List of the commercial kits 
Name and Brand Supplier 
Gene All DNA Extraction kit Gene All Biotechnology, Seoul, 
Korea 
Nextera Rapid Capture Expanded Exome kit Illumina Technology, USA 
NextSeq 500 High Output v2 Kit (300 cycles) Illumina Technology, USA 




2.1.4 Laboratory Apparatus 
All apparatuses that had been used for laboratory works are listed in Table 2.4. 
 
Table 2.4: List of laboratory apparatuses. 
Laboratory Apparatus Supplier 
Waterbath (Memmert) Camlab, UK 
Bioanalyzer Agilent, USA 
Centrifuge Eppendorf 5810R 
Electrophesis Gel Imaging System Bio-Rad, USA 
Electrophoresis Tank with Cable Labnet International, Woodbridge 
UV Transilluminator A Labnet International, Woodbridge 
Gel Imager Uvitec, UK 
Magnetic Stand Illumina, USA 
Microheating System Microheater Illumina, USA 
Microplate Reader Thermo Scientific, USA 
Microwave ELBA, Malaysia 
Plate Shaker Thomas Scientific, USA 
Qubit DNA Reader Thermo Fisher Scientific, USA 
Mixture Short Spinner Gaia Science, Malaysia 
Thermal Cycler Bio-Rad, USA 
Vacuum Concentrator Thermo Fisher Scientific, USA 




2.2 Overall Study Design 
 
This was a cross-sectional study design with no hypothesis needed. It was an 
exploratory study whereby the genomics of idiopathic CP was determined and 




2.3 Subjects and Subjects’ Criteria 
Families in Kelantan were selected primarily through patients’ records available at 
Hospital Universiti Sains Malaysia (Hospital USM), Hospital Raja Perempuan Zainab 
II (HRPZ II) and Yayasan Orang Kurang Upaya Kelantan (YOKUK). All affected 
members and at least 2 unaffected members (preferably the parents) per selected family 
were recruited for this study based on the following inclusion and exclusion criteria. 
Ethical approval was sought from the Human Research Ethics Committee, USM 
(approval code: USM/JEPeM/14090310) and the Medical Research Ethics Committee, 




2.3.1 Inclusion Criteria 
 





















2.3.2 Exclusion Criteria 
 








3. Evident infection during pregnancy. 
OR 
4. Parental history of identifiable genetic disorder. 
 
OR 
5. Family history of identifiable genetic disorder. 
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2.4 Subjects Selection and Recruitment 
2.4.1 Screening of Patients Records 
Screening was done retrospectively through YOKUK CP database which then 
generated a list of 330 CP patients all over Kelantan. This list of CP patients was then 
screened against the Hospital USM and HRPZ II medical records to produce a list of 
patients that fulfil the inclusion and exclusion criteria. 
 
 
2.4.2 Family Data Collection (First Home Visit) 
After the attending pediatric neurologist informed the shortlisted families, the first home 
visit was done to collect the family data including the three generational pedigree charts 
and patients’ physical examination data using the data collection sheet (Appendix A). 
The three generation pedigree charts are to observe for any history of CP in the previous 
two generations which are parent and grandparent levels. During the physical 
examination, a pediatrician examined the CP children for the body area that were 
affected, the type of motor dysfunction (spastic or non- spastic), muscle tone, functional 
abilities, mobility, any deformities and any comorbidities. The pediatrician also 
gathered the family history to see for consanguinity and any previous history of 
identifiable genetic disorder. 
  
 
2.4.3 Expert Focus Group 
A focus-group discussion (FGD) was conducted, involving pediatric neurologists, 
molecular biologists and members of the USM-CPRC research team. Eight families 
were identified by the FGD then as they fulfilled inclusion criteria and exclusion 
criteria. 
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2.5 Sample Size and Subject List 
Consent was taken from the parents prior to enrolment into the study. Since this study 
was focusing on CP individuals with suspected underlying genetic factors due to no 
causal event occurred, thus CP affected children and both unaffected parents were 
recruited from each family. At the beginning of the study, only six out eight shortlisted 
families were consented for inclusion into the study. Meanwhile the other two families 
were not willing to commit for the next study phases due to their personal reasons. Thus, 
this made up a study provisional total number of 25 subjects as recorded in Table 2.5. 
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Table 2.5: Provisional list of 25 identified subjects in the beginning of the phase I study. 
 Fam 1 Fam 2 Fam 3 Fam 4 Fam 5 Fam 
6 
Father D1 D2 D3 D4 D5 D6 
Mother M1 M2 M3 M4 M5 M6 
Child 1 B1-1 G2-1 G3-1 B4-T1 B5-1 B6-1 
Child 2 NA B2-2 B3-2 B4-T2 G5-2 B6-2 
Child 3 B1-3 NA G3-3 NA NA NA 
No. of 
Subjects 




D: Father, M: Mother, B: Boy, G: Girl, T: Twin and NA: Not Available Alphanumeric 
code: 
Fam 1: Family 1, Fam 2: Family 2, Fam 3: Family 3, Fam 4: Family 4, Fam 5: Family 
5 and Fam 6: Family 6. 
Whereas, -1, -2 and -3: Sibling order for recruited CP children per family Numerical 
code: 
1 to 6 (next to B, D, G and M): Family Identification code (ID) 
  
55 
However, the final total number of sample that were analyzed were 20 samples only 
(listed in result chapter) after two times sample reduction for reasons as explained in 
subsection 2.9.1 and subsection 2.9.6. The sample size in this study is comparable to 
those of other studies reported. A previous study that recruited only four affected 
individuals in three independent kindred succeeded to identify the cause of Mendelian 
disorder using exome sequencing (Ng et. al., 2010b). Small sample size were also used 
to investigate the Kabuki Syndrome (10 individuals) (Ng et al., 2010a) and Hereditary 
Spastic Paraparesis (three individuals) (Erlich et al., 2011) using WES. Different from 
case- control association studies that require significant number of cases and controls 
to generate sufficiently powered analysis, these studies and the current study 
investigated each family independently and determined the genetic cause in each 
family. It is comparable with determining disease-causing mutation of beta-globin gene 
in a case of beta-thalassemia whereby decision on whether or not the mutation causes 
the disease will rely on the effect of the mutation on protein production, not on the 
difference in frequency between case and control. 
 
 
2.6 Specimen Collection (Second Home Visit) 
The CP children and their parents eligible for Phase II study were approached for 
enrolment through their attending pediatric neurologists. Home visits were also done to 
facilitate the families with bedridden CP children. The pediatrician collected 3 ml of 
blood from each subject into ethylenediaminetetraacetic acid (EDTA) Tube, BD 





2.7 DNA Extraction and Quantification 
DNA extraction was carried out using Gene All kit (Gene All Biotechnology, Seoul, 
Korea). Each DNA extraction was started with lysis process by pipetting 20 µl 
proteinase K solution (20 mg/ml) into a 1.5 ml tube, followed by transferring the 200 
µl blood sample into that tube. The mixture was mixed thoroughly, subsequently 200 
µl lysis buffer (BL) was added and again followed by vortex-spinning. The mixture was 
then incubated at 56 ºC for 1 hr 15 min. After incubation, short spin was done to collect 
any liquid drop inside the lid. Next, 200 µl absolute ethanol (EtOH) was added into the 
mixture, followed by vortex and short-spin. The lysed sample was then transferred into 
Min Elute Column using pipette. Centrifugation was done at 19-20 ºC, ≥8000 rpm 
(≥6000 x g) for 1 min and the collection tube attached at the bottom of the Min Elute 
Column was replaced with a new one to avoid any contamination with the sample. The 
washing process began at this stage, when 600 µl of washing buffer (BW) was added to 
the Min Elute Column followed by centrifugation ≥8000 rpm (≥6000 x g) at 19-20 ºC 
for 1 min. The collection tube was again replaced.  
 
Washing buffer solution T (TW), 700 µl was added prior to 19-20 ºC centrifugation at 
≥8000rpm (≥6000 x g) for 1min. The pass- through was discarded and the collection 
tube was reinserted, followed by centrifugation at full-speed (13000 x g) for 1 min to 
remove the residual wash buffer. The Min Elute Column was then placed in a new 1.5 
ml tube. Next, the elution step started by adding 30 µl elution buffer (AE) into the Min 
Elute Column followed by sample incubation at room temperature for 1 hr. This was 
then followed by centrifugation at full-speed (13000 x g) for 1min. Subsequently, 
second elution was done by adding another 10 µl AE buffer and the same incubation 
routine was applied before the full-speed centrifugation was done. All these steps 
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produced the gDNAs with minimum concentration of 60ng/µl in at least 30 µl volume. 
Using the microplate reader (Termoscientific, USA), the gDNAs in the collected 
solution were then measured for their concentrations (A260:A280) and purity values 
(A260:A230) within the range of optical density (OD) of 1.7 – 2.2 and 2.0 – 2.2 




2.8 Gel Electrophoresis 
Agarose gel electrophoresis was done to check for DNA integrity. Per each run, the 2% 
agarose gel was prepared by dissolving 0.8 g of agarose powder in 40 ml 1X TBE in 
conical flask for 2 min microwave heating. The gel electrophoresis was run in 500 ml 
10X Tris-borate-EDTA (TBE) buffer at 90 V for 35 min. Pre-staining using ethidium 
bromide was applied. The samples were prepared for the gel loading as followed. Each 
sample well was loaded with 1 µl loading dye and 2 µl gDNA sample, whereas marker 
well consisted of mixture of 1 µl loading dye, 1 µl Ladder (100bp) and 1µl TBE. 
 
 
 2.9 DNA Library Preparation 
Prior to sequencing, the DNA library preparation was carried out at Malaysian Genome 
Institution (MGI) (Bangi Selangor) used the Nextera Rapid Capture Expanded Exome 
kit (Illumina Technology) which was an enrichment-based library preparation method. 
This meant that the method was capturing some off-target regions apart from the exons, 
which included the untranslated regions (UTRs) and microRNAs (miRNAs). The total 
covered targeted regions made up to 62 Mb of the genome size. This kit consisted of 
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transposome enzyme activity and it worked by the Tagmentation principle as described 
in subsection 2.9.3. The DNA library preparation steps were done simultaneously for 
all samples so as to reduce any biases and human errors. The whole carried out steps 
were carried out following the manual book provided by Illumina Technology. 
 
 
2.9.1 gDNA samples – WES slots Fitting 
In this study of six families at the beginning, each family represented by both parents 
and two CP children, except for Family 3 that had the most subjects of five including 
both unaffected parents and three CP children (one CP son and two CP daughters), 
which made up to provisionally 25 total subjects (Table 2.5). However, there were only 
two sequencing kits provided in this study with a total of only 24 sample slots. 
Therefore, due to limited sequencing slots, Family 3 of originally five subjects was 
reduced to only four, including both unaffected parents, one CP son and only one CP 
daughter with higher DNA concentration. Thus, all six families at this stage were 
currently represented by four subjects respectively, resulting in total 24 samples to be 
proceeded for the next procedures that fit to the provided 24 sequencing slots. 
  
 
2.9.2 Preparation Steps: Index Determination, Quantification and Normalization 
of gDNA Samples 
Prior to Tagmentation step (refer subsection 2.9.3), a few preparation procedures were 
carried out to prepare the gDNAs for Tagmentation. As explained in section 2.9.1, at 
this stage only 24 gDNA samples were proceeded, those gDNAs were later organized 
during the index determination step. In this step, each gDNA sample was assigned with 
a unique index adapter using Illumina Experiment Manager (IEM) software version 4.0 
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by following the manual provided in that software. Index determination step was done 
to distinguish each gDNA as the index acted as unique identifier (tagger) for each 
gDNA since all gDNA samples that passed the DNA quality test later would be pooled 
together into two separate pools of DNA library. Indexing was also for the purpose of 
WES, since multiple gDNA samples with no target gene were processed parallel. The 
sample index determination details are available in Appendix C. 
 
Next were DNA quantification and normalization, in minimizing the gDNA samples 
input variability into the Tagmentation step. Illumina Technology strongly recommends 
a two-step method of gDNA normalization. The gDNAs were quantified using a 
fluorometric-based method of Qubit. The gDNAs were then diluted and normalized in 
Elution Buffer (EB) to 10 ng/µl. The first normalized gDNAs were again re-quantified 
using the same fluorometric-based method. The steps were repeated for the second 
normalization to a final volume of 10 µl at 5 ng/µl, resulting in 50 ng total of the DNA, 
as recommended by Illumina Technology. 
  
 
2.9.3 Genomic DNA Tagmentation 
Tagmentation process is a process where the fragmentation and the adapter ligation 
steps occur simultaneously. While fragmenting the DNA, the transposome will also 
automatically tag the DNA with the adapter sequences. Up to this stage, all the 24 
gDNA samples were still processed simultaneously. In the 96-well midi Nextera 
Library Tagment (NLT) plate, 10 µl normalized gDNA, 25 µl TD and 15 µl TDE1 were 
mixed together in each labelled well for each gDNA sample. All of the items were stored 
at -25 ºC to -15 ºC and thawed on ice before use. The gDNA concentration at this early 
step was 5 ng/µl in 10 µl EB making up to 50 ng of gDNA per sample. The plate 
60 
containing 24 wells of mixture was shaken at 1800 rpm for 1 min, followed by 
centrifugation at 280 x g for 1 min. The plate was placed on the 58 ºC microheating 
system with the lid closed, for 10 min. Each well was then added with 15 µl of ST to 
stop the tagmenting process, followed by shaking of the mixtures at 1800 rpm and 




2.9.4 Tagmented DNA Clean Up 
The tagmented gDNAs were then cleaned-up using Sample Purification Beads (SPB). 
The clean-up step was done to purify the tagmented DNAs from the Nextera 
transposomes. The SPB functioned to capture the tagmented gDNA and remove the 
Nextera Transposome that might still bind to gDNA ends that could interfere with the 
downstream processes. For this purpose, 65 µl SPB was added to each well, and the 
plate was again shaken at 1800 rpm for 1 min followed by incubation at room 
temperature for 8 min and 280 x g for 1 min centrifugation accordingly. The plate was 
placed on a magnetic stand for 2-5 min until the liquid was clear, indicating that the 
beads were pulled out from the SPB. The supernatant was discarded from each well, 
and the tagmented gDNA in each well was washed 2 times by adding 200 µl freshly 
prepared 80% EtOH to each well. The plate was left on the magnetic stand for 30 s 
incubation at room temperature, followed by discarding the supernatant from each well 
of plate later. The pipetting was continued to remove the residual EtOH in each well 
from the washing step. The plate was air-dried for the 10 min on the magnetic stand. 
After that, the plate was removed from the magnetic stand and 22.5 µl resuspension 
buffer (RSB) was added to each well, followed by plate shaking for1 min at 1800 rpm 
and incubation at room temperature for 2 min. The plate was then centrifuged at 280 x 
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g for 1 min. Again, the plate was placed on the magnetic stand for 2-5 min until the 
liquid in each well was clear. The clear liquid (supernatant) now contained the gDNA. 
From each well, 20 µl supernatant (gDNA input) was transferred into the polymerase 
chain reaction (PCR) tube respectively. All together were 24 PCR tubes containing 20 
µl gDNA sample per tube. 
 
 
2.9.5 Tagmented DNA Amplification 
The purified tagmented gDNAs were then amplified using a 10-cycle PCR. In this step 
the 2 groups of Index 1 [i7] and Index 2 [i5] together with the sequencing primer were 
applied to each gDNA during a cluster amplification. Prior to amplification, the 
Illumina Nextera Index adapters (i5 and i7) were thawed at room temperatures for 20 
min and the Library Amplification Mix (NLM) was thawed on ice. The indexes were 
arranged accordingly and placed on the Truseq Index Plate Fixture to avoid index-
swapping. Next, 5 µl of each i7 and i5 was added into the PCR tube of gDNA 
accordingly, followed by addition of 20 µl of NLM making up to 50 µl mix in total per 
PCR tube for the amplification (Table 2.6). Each gDNA now has been flanked by 2 
groups of Index adapters, (i7) and index 2 (i5). The PCR mixes were shaken at 1200 
rpm and centrifuged at 280 x g for 1 min respectively. The 10-cycle PCR was 
programmed on the thermal cycler as in Figure 2.1. 
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Table 2.6: The 50 µl PCR mix per tube. The [gDNA] = 2.5 ng/µl in 20 µl RSB with a 
total of 50 ng gDNA. 
 






















Figure 2.1: PCR Profile according to NLM AMP program on the thermal cycler 
recommended by Illumina, with option of preheat lid at 100 ºC. 
 
64 
Since the DNA library preparation was a cascading procedure that took more than a day 
for more than 10 samples, several safe stopping points were available throughout the 
work. The first safe stopping point was after completing the amplification. The plate 
was left on the thermal cycle overnight or be stored at 2 ºC – 8 ºC for up to 2 days.  
 
 
2.9.6 First DNA Quality Checking (QC)  
After completing the amplification step, we found that 4 out of 24 samples did not pass 
the amplification Quality Checking (QC). These 4 gDNA samples had volumes of ≤ 45 
µl which were less than the required volume of 50 µl according to Nextera Illumina 
recommendations for WES. This indicated that these 4 gDNA samples contained < 50 
ng gDNA input while the optimum input for WES is 50 ng as recommended by Illumina 
technology. Therefore starting from this step, from 24 samples, these abovementioned 
4 samples that failed the QC were excluded, resulting in  only 20 gDNA samples that 
were proceeded with the next steps and subjected to WES analyses. 
 
 
2.9.7 Amplified DNA Clean Up 
This step is to purify the DNA libraries. Similar to tagmented DNA clean-up step, the 
amplified DNA clean-up was also done using the SPB while the plate was placed on 
the magnetic stand. The qualified 20 PCR products from previous step (subsection 
2.9.6) were centrifuged at 280 x g for 1 min before being transferred to the 20 
corresponding wells of Nextera Library Clean-up (NLC) plate. Into each well of 50 µl 
PCR product, 90 µl SPB was added and the plate was shaken at 1800 rpm for a minute 
before being incubated at room temperature for 10 min. The plate was then centrifuged 
at 280 x g for 1 min before being put on the magnetic stand for 2-5 min, the supernatant 
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was discarded from each well. Continued with adding 200 µl freshly prepared 80% 
EtOH into each well, followed by a 30 s incubation on magnetic stand and lastly the 
supernatant was discarded. These 3 steps, were repeated. Using 20 µl pipette, the 
residual 80% EtOH was removed from each well, and the plate was air-dried on the 
magnetic stand for 10 min. The RSB of 27 µl was added into each well before the plate 
was shaken at 1800 rpm for 1 min and incubated at room temperature for 2 min followed 
by 1 min of 280 x g centrifugation. The plate was then placed on the magnetic stand for 
2 min until the liquid in each well was clear. These clear supernatants in all 20 different 
wells were our gDNA inputs. From each well, 25 µl of the supernatant was transferred 
into 20 PCR tube respectively for the next probes hybridization step. 
 
 
2.9.8 First Probes Hybridization and capturing 
This step randomly combined the uniquely-indexed 20 gDNA libraries into two separate 
pools in which there were 10 gDNA samples per pool using 1.5 ml tubes. Each pool 
was concentrated using a vacuum concentrator with no heat and a medium drying rate 
to achieve the volume range of 40 µl ≤ X ≤ 50 µl according to Illumina technology 
recommendation. Each pool now contained a mixture of uniquely- indexed 10 gDNAs 
at 45.1 ng/µl gDNA input in pool 1 (PO1) and 40.2 ng/µl in pool 2 (PO2) respectively. 
Next, the following items in the order listed in Table 2.7 were added into each of the 
two PCR tubes. 
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Table 2.7: PCR mixture tube prepared for the subsequent Hybridization process. 
 
Item Volume (µl) 







The PCR mixture was re-suspended for 10 times followed by centrifugation at 280 x g 
for 1 min. The PCR tubes containing 100 µl mixture/supernatant were then placed on 
the programmed thermal cycler and the Nextera Rapid Capture Hybridization (NRC 
HYB) program was set up to 100 ºC with the preheat lid option and setting of 95 ºC for 
10 min. There were 18 cycles started at 94 ºC then decreasing 2 ºC per cycle, each cycle 
was a 1 min run. The reaction was held at 58 ºC for at least 90 min or up to a maximum 
of 24 hr. Followed by hybridized probes capturing step in which the targeted regions of 
the DNA were bound with the captured probes. The capturing step used Streptavidin 
Magnetic Beads (SMB) to capture probes hybridized to the targeted regions of interest. 
The two-heated washing principle was used to remove nonspecific binding from the 
beads producing the enriched libraries. Next, the enriched libraries were eluted from the 
beads for the second hybridization later. The PCR tubes consisting of probe hybridized 
mixtures were centrifuged at 280 x g for 1 min.  
 
 
2.9.9 Second DNA Quality Checking (QC)   
Again, the QC was done which was currently to check the DNA quality after first probes 
hybridization step by excluding the pool that lost >15% of the 100 µl volume (Table 
2.7). Greater loss of more than 15% of the actual volume would disqualify the gDNA 
input from proceeding to the next steps. After passing the QC, 100 µl of PO1 and PO2 
was transferred to a well of NEW1 plate, 25 µl SMB was then added into each well. 
The plate was shaken at 1200 rpm for 5 min, centrifuged at 280 x g for 1 min and then 
placed on the magnetic stand and was left for 2- 5 min until the liquid was clear. The 
supernatant was discarded from each well. The plate was left on the magnetic stand for 
the 2X washing procedure. Next, 200 µl EWS was added into each well, the plate was 
then shaken at 1800 rpm for 4min and continued with re-suspending the bead pellet in 
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EWS. The plate was placed on the 50 ºC microheating system with the lid closed for 30 
min and placed again on the magnetic stand for 2-5 min until the liquid was clear. The 
supernatant from each well was again discarded. Those steps starting from EWS 
addition were repeated for the second time washing. Finishing the second time washing, 
the plate was removed from the magnetic stand for the elution process. The elution 
premix for each library pool was prepared in the 1.7 ml microcentrifuge tube by mixing 
57 µl of enrichment elution buffer 1 (EE1) with 3 µl of two-normality sodium hydroxide 
(2N NaOH or HP3). The 60 µl premix was mixed thoroughly before 23 µl of it was 
added into each well containing PO1 and PO2 respectively. 
 
 
The plate was then shaken at 1800 rpm for 2 min, incubated at room temperature for 2 
min and again being centrifuged at 280 x g for 1 min. The plate was placed on the 
magnetic stand again for 2min until the liquid was clear. From each well, 21 µl 
supernatant was transferred to the corresponding PCR tube. Into each PCR tube 
containing PO1 and PO2, 4 µl of elution target buffer 2 (ET2) was added and the 25 
µl mixture per tube were shaken at 1200 rpm for 1 min and centrifuged at 280 x g for 1 
min. For the purpose of postponing the procedures till the next day, here was the second 
Safe Stopping Point whereby the 25 µl supernatant of eluted hybridized probes (PO1 







2.9.10 Second Probe Hybridization and Capture 
This step bound targeted regions of the enriched gDNAs (DNA libraries) in PO1 and 
PO2 with captured probes for the second time in ensuring high specificity of the 
captured regions. Second capturing process used the SMB to capture the probes 
hybridized to the targeted regions of interest. Again, two-heated washing removed the 
non-specific binding from the beads and the enriched DNA libraries were then eluted 
from the beads. The same reagents of Enrichment Hybridization Buffer (EHB) and 
Expanded Exome Oligos (EEX) were used for both first and second hybridization steps. 
However, for the second hybridization RSB was used re-suspend the enriched DNA 
libraries.  
 
The second hybridization was done to each 25 µl libraries supernatant of PO1 and PO2 
by adding the reagents as in Table 2.8. After adding the reagents, each PCR tube of PO1 
and PO2 now consisted of 100 µl supernatant. Each tube was shaken at 1200 rpm for 1 
min and followed by centrifugation at 280 x g for also 1 min. It was next placed on the 
preprogrammed thermal cycler for NRC HYB run process as in the first hybridization 
step, then followed by capturing step. Both second hybridization and capturing 
procedures were exactly the same steps as in subsection 2.9.8. However, a different 
plate was used to transfer the captured libraries supernatant. For the second 
hybridization step, the well-plate used at this stagewas NEW2 instead of NEW1. After 
completing the all procedures, each well now consisted of eluted 25µl supernatant of 
PO1 and PO2 respectively. 
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Table 2.8: The list of reagents to be added into each PCR tube containing 25µl of PO1 
and PO2 respectively. 
 








2.9.11 Captured Library Clean Up 
All cleaning protocols were similar to those described in section 2.9.4 except for some 
reagent volumes. To clean the captured library, less reagent volumes were applied for 
example, 45 µl SPB and 25 µl RSB. After finishing all the cleaning protocols, 25 µl of 
supernatant was transferred from each well (PO1 and PO2) into the PCR tubes. Here 
was the third Safe Stopping Point as the supernatant could be stored for up to a week at 
-25 ºC to – 15 ºC. 
 
 
2.9.12 Enriched Library Amplification 
Into each PCR tube consisting 25 µl of PO1 and PO2, 5 µl PPC and 20 µl Enrichment 
Amplification Mix (NEM) were added accordingly, resulting in 50 µl of 
mixture/supernatant per tube. Next followed by amplification steps with the same PCR 
profile as illustrated in Figure 2.1 of section 2.9.5. Here, was the fourth Safe Stopping 
Point by storing the processed samples at 2 ºC to 8 ºC for up to 2 days. 
 
 
2.9.13 Amplified Enriched Library Clean Up 
The clean-up protocols for the amplified enriched library were the same as described in 
section 2.9.7 except for the plate used. In this section, the supernatant had been 
transferred from PCR tubes into the NEC2 midi well-plate. Completing the clean-up 
protocols, 30µl of supernatant from each well was transferred to the PCR tubes and 






2.9.14 Enriched Library Quantification 
Before being subjected to sequencing, the libraries were checked for quality and size 
using the Qubit Quantification and Bioanalyzer. The enriched libraries of PO1 and PO2 
were checked for quality using Qubit Quantification to ensure optimum cluster densities 








The optimum average library size was 400bp as recommended by Illumina               
Technology for Nextera Expanded Exome Kit that had been used in this study. The PO1 
and PO2 libraries were next sent for library size check using Bioanalyzer. This  was 
done to obtain the actual insert (gDNA library) size after deducting 120bp  adapter size 
from transposome activity earlier that flanked our gDNA input. 
 
 
2.10 Whole Exome Sequencing 
The gDNA libraries were sent to UKM Medical Molecular Biology Institute (UMBI) 
(Cheras, Selangor) for sequencing. For this purpose, Illumina system was employed. 
The libraries of PO1 and PO2 were subjected to the NextSeq 500 sequencer (High 






The sequencing coverage per gDNA was calculated using the formula: 
                               
62 Mb = Nextera kit standard Genome size covered (Nextera targeted regions) 
0.65 = Nextera Kit Capturing Efficiency 
0.75 = NextSeq Pass filtered range 
 
Using the Illumina system, each base pair was sequenced one cycle at a time. For 
example, 100 cycles produced 100 bp reads. The read length (L) is equivalent to the 
number of bases sequenced. Details of sequencing coverage and read length are 
described in the Results chapter (section 3.7.1). The WES generated pair-end 
sequencing read (raw data) were stored in a compressed zip format file (fastq.gz). The 
Illumina sequencer (NextSeq) also provided the FASTQC inspected raw data reports in 
fastqc.html files format. The read files showed that one sample had four lanes ({1..4}). 
Each lane had both forward (R1) and reverse (R2) reads resulting in eight Fastqc file 
reports per sample. An example of the report file format is shown below. 













2.11 Bioinformatics Analysis 
WES raw data were interpreted and analyzed using computational codes/languages and 
tools to discover the variants in multiple genes. Bioinformatics analysis consists of three 
main processes which are pre-processing, variant discovery and callset refinement. A 
brief worldwide standard bioinformatics analyses pipeline is illustrated in a workflow 
in Figure 2.2. Our studied case was CP with underlying genetic factors which indicate 
that this potentially genetic CP is a germline variant disorder. Hence, we applied the 
Genome Analysis ToolKit (GATK) package version 4.0 command (available at 
https://software.broadinstitute.org/gatk/), which specifically started at base 
recalibration step until variant annotation step (Figure 2.2). The earlier steps of raw read 
analyses, reads alignment and duplicate marking were performed using the worldwide 
standard pre-processing command with Picard tool package version 2.15.0, (available 
at https://broadinstitute.github.io/picard/). 
 
WES analyses were carried out in collaboration study with Perdana University, Kuala 
Lumpur. Related raw data, folders and file locations were stored in their server. Since 
our operating system (OS) was a Microsoft Windows, PuTTY terminal (version 0.70, 
Simon, Tatham, UK) was used. This terminal is compatible with various versions of 
Microsoft Windows. The PuTTY terminal acts as a typing interface to access to server, 
which is termed as Secure Shell (SSH) communication in bioinformatics. Besides that, 
PuTTY terminal interface was also used for scripting (typing) and executing the 
bioinformatics instructions for our variant analyses work. In bioinformatics, a scripted 
computational code instruction that is later executed to analyze the sequence raw data 
is termed as “command”.  
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In our study, we also used the Editpad Lite version 7.3.8.0 (Just Great Software) to draft 
the commands before officially scripting and executing them on the terminal. The 
command scripting is subject to change according to the file locations, WES sample 
names/ID and input files that are set by the data owner. A set of multiple bioinformatics 
commands or also known as bioinformatics coding for this study analyses are available 








Figure 2.2: The illustration of the standard bioinformatics pipeline for Germline Variants in Whole Exome
 Sequencing. (https://software.broadinstitute.org/gatk/) 
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2.11.1 Raw Read Analyses 
The pre-processing process was carried out to prepare the sequencing raw data, FastQC 
files (section 2.10) prior to further advance analyses steps. The first step in pre-
processing process is raw read analysis which is to check for quality of raw sequencing 














Figure 2.3: The workflow of raw reads preparation prior to further 
bioinformatics analyses steps. 
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The current study had two groups of sequencing raw reads which were “batch 1 
fastq.gz” and “batch 2 fastq.gz” representing PO1 and PO2, respectively. Starting at 
this point of raw read analyses, the bioinformatics commands/arguments for the steps 
of FastQC, trimming and other further steps were scripted and executed on the terminal 
interface while accessing to the server via SSH. The FastQC inspection was carried out 
by scripting FastQC tool argument in order to access to fastqc.html files and display the 
raw sequencing data reports. This was followed by checking for problematic raw reads 
that were indicated with red circle alert symbol (X). In the current study, original raw 
data from WES were in two file formats which were the compressed format fastq.gz 
file (non- viewable) and fastqc.html (viewable report) file. For the computational 
command purpose, we assigned batch 1 as “array” and batch 2 as “array2” (refer 
Appendix D.1). 
 
All of the sample reads for 20 subjects had similar base percentage graph that were 
reported in (.html) file with two biases of base percentage. Therefore, the Trim Galore 
trimming was carried out to remove unnecessary sequences (biases) and leaving only 
the gDNA sample sequence. The FastQC tool was again scripted in the command for 
second FastQC step to access to the report (.html) file after trimming, this is to check 
for residual low-quality sequences after all the trimming process was completely done. 
All the scripted commands for the raw read analysis steps are described in Appendix 









2.11.2 Read-Reference Alignment 
This is the second step in pre-processing process which is also known as an assembly 
(align and merge) step. This step is to map the filtered read sequences input to the 
reference database. The input read batches of the current study were in compressed 
fastq.gz files (section 2.11.1) at this phase and currently termed as “{element}.gz” for 
batch 1 reads and “{element2}.gz” for batch 2 reads in the scripted command (refer 
Appendix D.2). Prior to the assembly step, the human genome database (hg19) or also 
known as Genome Reference Consortium Human genome build 37 (GRCh37) was 
downloaded to the server in the indexed hg19 format from the University of California 
Santa Cruz (UCSC) Genome Browser, a worldwide downloadable browser. The 
indexed hg19 is a human genome database that is available in Fasta file format (.fa) 
with companion files of dictionary file format (.dict) and index file format (.fai). The 
Fasta file is a text-based nucleotide sequence format. 
 
As mentioned earlier in section 2.11, this study applied the GATK bioinformatics 
pipeline for our germline variants in CP. Thus, GATK pipeline required the indexed 
hg19 downloaded in the file formats as mentioned above to allow for efficient random 
access to the reference bases throughout the analysis steps. Next, the {element}.gz file 
and {element2.gz} file were manifested to unmapped Binary Alignment Map (uBAM) 
files, in order to re-format the compressed (.gz) files into the intermediate output of 
compatible files   format   (.bam)   using   FastqToSam   tool   of   Picard   bioinformatics   
program (https://broadinstitute.github.io/picard/). This was followed by checking    
read changed quality to produce the clean (.bam) files with forward and reverse pair-
reads using the SamToFastq and MarkIlluminaAdapter picard tools with few default 
parameters.  
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According to the standard guideline that is available at the website of 
https://javadoc.io/static/org.broadinstitute/gatk/4.1.4.1/picard/sam/SamToFastq.html, 
few default parameters are used such as Clipping_Attribute, Clipping_Action and 
Interleave as in scripted command in order to extract read sequences and qualities from 
the input SAM/BAM file and make a record into the original fastq (.gz) compressed 
(non-viewable) file. Throughout the analyses of our data, there was also temporary 
directory (TMP_DIR) command argument in related steps to temporarily store its 
resources (intermediate output) before processing in the next steps. The next steps were 
merging and aligning the clean (.bam) files to reference read of hg19 (.fa). These steps 
were carried out using Burrows-Wheeler Aligner (BWA-MEM) software. The BWA 
software aligned the {element}, {element2} reads of (.bam) or (.gz) files to various type 
of genomic variations in hg19 database including Single Nucleotide Polymorphism 
(SNP), Single Nucleotide Variant (SNV), Insertion and Deletion using 
MergeBamAlignment picard tool (version 2.15.0). All the commands for the above 
bioinformatics step were recorded as in Appendix D.2. The intermediate output for this 
read-reference alignment step were compressed (non-viewable) BAM files of 




2.11.3 Duplicate Marking 
This was part of BAM file cleaning phases whereby the input for this step were the 
previous {element}_L00${i}_merged.bam and {element2}_L00${i}_merged.bam 
files containing the reads that had been aligned to a hg19 reference genome. This step 
was carried out to mark any possible duplicated reads resulting from the sequencing 
step due to possible uneven amplification of DNA libraries. The duplicate marking was 
82 
done using MarkDuplicates tool from Picard program (http://.picard.sourceforge.net). 
The standard principle for duplicate marking is determining the duplicated reads by 
their 5’ mapping coordinates and their genome orientation. Within this step, Picard tool 
also generated the metrics file (.txt) to distinguish the duplicated reads and index file 
(.bai), a companion file that acted as an external table of contents which allowed any 
necessary programs to jump directly to specific parts of the (.bam) files without reading 
through all the sequences. The intermediate outputs for this analysis step were 
{element}_L1- 4.bam, {element}_L1- 4.txt and {element}_L1-4.bai for batch 1 reads 
and {element2)_L1- 4.bam, {element2}_L1-4.txt and {element2}_L1-4.bai for batch 2 
reads. The scripted commands for Duplicate Marking are available in Appendix D.3. 
  
 
2.11.4 Base Recalibration 
Besides duplicate marking step, this Base Quality Scores Recalibration (BQSR) was 
also part of BAM file cleaning phases whereby it also ended the raw data pre-processing 
process as illustrated earlier in Figure 2.2. This BQSR step is a commonly used GATK 
quality control program to detect systematic errors that are produced by the sequencing 
machine which increases the base read calling scores reported from sequencing. This 
was carried out through four tasks accordingly which were analyzing covariation pattern 
in sequence dataset, second analyzing on the remaining covariation, generating before 
and after recalibration plots and applying the recalibrated scores to the sequence data. 
The {element}_L1- 4.bam for batch 1 and {element2)_L1-4.bam for batch 2 from the 
duplicate marking step were the current input for BQSR step. The first analysis on 
covariation pattern was to check for similar pattern of sequence data with the reference 
sequences, followed by adjusting the quality scores accordingly. This analysis was done 
using the BaseRecalibrator GATK tool. The process was to build up a model of 
83 
covariation based on sequence dataset and a set of known variants database (dbSNP and 
Mills_and_1000G_gold_standard.indels) and the downloadable list of targeted region 
(62Mb) of Nextera Rapid Capture Expanded Exome kit in Browser Extensible Data 
(.bed) file format which is available at 
support.illumin.com/sequencing/sequencing_kits/Nextera-rapid-capture-exome-
kit/downloads.html. The raw outputs for this step were {element}_L1-4_recal data.table 
file and{element2}_L1-4_recal_data.table file for batch1 and batch 2 reads, 
respectively. This covariation pattern analyzing was repeated for the second checking 
on both intermediate outputs and generated the next intermediate outputs of 
{element}_L1- 4_post_recal_data.table file and {element2}_L1-
4_post_recal_data.table file, respectively.  
 
This was followed by the third task which was generating before and after recalibration 
plots to compare between the outputs of first recalibration and second recalibration 
process using the AnalyzeCovariates GATK tool, in order to see whether or not there 
was any bias between these two plots. The BQSR recalibrated scores model then, had 
been applied in the next fourth task. In this task the recalibrations scores in  the 
{element}_L1-4_recal_data.table file and {element2}_L1-4_recal_data.table file were 
applied to input data of ({element}_L1- 4.bam and {element2)_L1-4.bam) using the 
PrintReads GATK tool which then produced the intermediate output files of 
{element}_L1-4_recal_reads.bam and {element2}_L1-4_recal_reads.bam 





2.11.5 Variant Calling 
This is the first step of variant discovery process in Bioinformatics pipeline. The step 
was carried out to simultaneously call various possible variants that are present in each 
sample of {element}_L1-4_recal_reads.bam and {element2}_L1-4_recal_reads.bam 
inputs, since the current study had two sequencing read batches of 10 samples per batch. 
Firstly, the HaplotypeCaller GATK tool analyzed multiple individual samples at a time 
against the reference hg19 and targeted regions of Nextera Rapid Capture Expanded 
Exome kit to call for variants. This was carried out using the Genome Variant Calling 
Format (GVCF) mode with genotyping_mode DISCOVERY tool argument to produce 
the intermediate file format (g.vcf) containing alternate alleles per sample. To run this 
step, few GATK standard parameters were included such as Standard Emit Confidence 
10 (stand_emit_conf.10), Standard Call Confidence (stand_call_conf.30), 
genotyping_mode DISCOVERY and variant_index_type LINEAR. The 
stand_emit_conf.10 (minimum variant confidence) and stand_call_conf.30 are the 
thresholds that determine whether a particular site is a low or high quality variant. 
 
The emit confidence allows the variant to be emitted (presented) in the (.vcf) files. The 
call confidence then defines the variant quality. For example, if a particular site of 
variant quality is 10 (QUAL=10), it will be presented in the (.vcf) output files but will 
be defined/filtered as low quality due to the QUAL that is lesser than the call confidence 
(QUAL=30). Up to this extent, all the 20 samples of both batch 1 and batch 2 with 10 
samples respectively were analyzed resulting into multiple separate individual 
intermediate (g.vcf) files of genotype likelihood data. The outputs were {element}_L1- 
4_raw_snps_indels.g.vcf and {element2}_L1- 4_raw_snps_indels.g.vcf. The 
commands are available in Appendix D.5.1.  
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2.11.6 Joint Genotyping 
The next step in Variant Discovery process is a Joint Genotyping step that was executed 
to combine all the individual sample (g.vcf) files into one (.vcf) file. The inputs for this 
step were {element}_L1- 4_raw_snps_indels.g.vcf that contained 10 Sample_L1- 
4_raw_snps_indels.g.vcf files of batch 1 and {element2}_L1-4_raw_snps_indels.g.vcf 
that contained another 10 sample_L1-4_raw_snps_indels.g.vcf files for batch 2 
sequence. The GenotypeGVCFs GATK tool was used to combine all 20 sample_L1- 
4_raw_snps_indels.g.vcf files which later resulting in one 
CombinedBatch1_2AfterJoinGeno.vcf call set file. This was currently an intermediate 
output in the middle of Variant Discovery process. The commands for this joint 
genotyping step can be obtained in Appendix D.5.2. 
 
 
2.11.7 Variant Filtering 
Variant filtering is the last step in Variant Discovery process (Figure 2.2). The variants 
in raw call set which is in (.vcf) file format are filtered using the Variant Quality Score 
Recalibration (VQSR) model, a machine learning system that identifies the variant 
profiles and reduces the amount of false-call positive. The VQSR model separates the 
“good” scored variants from “bad” scored variants using the VariantRecalibrator GATK 
tool. Variant filtering involves four tasks which are building the SNP recalibration 
model, applying the desired level of recalibration to the SNPs in the call set, building 
the Indel recalibration model and applying the desired level of recalibration to the Indels 
in the call set. In this current study, variant filtering was carried out to filter the raw call 
set of CombinedBatch1_2AfterJoinGeno.vcf files that was generated from previous 
joint genotyping step (section 2.11.6). Started with first task of building the SNP 
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recalibration model, few databases arguments were scripted in the execution command. 
The VQSR used the gold-standard validated variants from resources such as Haplotype 
Mapping (HapMap) database (http://www.hapmap.org), Omni database 
(omnidb.org/en/), SNP (dbSNP) database (http://www.ncbi.nlm.nih.gov/SNP/) and 
1000 Genome (1000G) project database (doi:10.1038/nature15393) together with hg19 
as reference input. Besides that, to build up the VQSR SNP recalibration model, the 
GATK “truth and training set” for the recalibration model was implemented for each 
resource as in the following Table 2.9. 
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Table 2.9: Description of each database as resource for building SNP VQSR 
recalibration model as recommended by GATK pipeline package (Version 4.0). 
 
Database Argument in Command Description Phred Scale 




The dataset was 
used as the training 
resource 
 
SNVs in this dataset 





The dataset was 
used as the training 
resource 
 
SNVs in this dataset 






The dataset was used 
as the training resource 
 
SNVs in this dataset 
could be both true or 
false- positive variants 
Prior=10.0 




The dataset was used 
as the known sites 
resource 
 
SNVs in this dataset 
could be both true or 





These resources in (.vcf) files format are also available in GATK bundle files 
(https://software.broadinstitute.org/gatk/documentation/article?id=11050). Involved 
in this SNP VQSR recalibration model are few default variant annotation parameters 
for germline WES sample. There are Quality by Depth (QD), Sequencing 
Depth/Coverage (DP), Fisher Strand (FS), Strand Odds Ratio (SOR), Mapping Quality 
(MQ), Mapping Quality Rank Sum test (MQRankSum), Read Position Rank Sum test 
(ReadPosRankSum) to evaluate the likelihood of true positive calls. For the current 
study VQSR threshold parameter (tranches) of 100%, 99% and 90% arguments were 
included to obtain the threshold of VQSR Log Odds (VQSRLOD), a threshold of true 
variant score versus false variant score. Followed by the second task, this SNP VQSR 
recalibration model was then applied to the study dataset, 
CombinedBatch1_2AfterJoinGeno.vcf file using the SNP mode by ApplyRecalibration 
execution tool with SNP mode. 
 
During this process, the VQSR searched for variants in the 
CombinedBatch1_2AfterJoinGeno.vcf input file against all these resources to trace the 
SNP variants that overlapped with the validated SNP variants across the resource 
datasets. At this stage, all the SNPs were already annotated with their recalibrated 
quality scores whereby their “PASS” or “FILTER” outcome depended on whether or 
not they were included in the tranches set up earlier. The intermediate output for this 
step was recalibrated_snps_raw_indels.vcf file which was later used as input for the 
next step for variant recalibration model. The above two steps of building the model 
and applying it to SNPs in dataset were repeated as the third and fourth tasks of variant 
filtering process in order to filter Indels in dataset. The involved databases to build the 
Indels recalibration model are listed in Table 2.10.  
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Table 2.10: Description of each database as a resource for building an Indels VQSR 
recalibration model as recommended by GATK pipeline (Version 4.0). 
 





The dataset was used as 
the training resource 
 
SNVs in this dataset were 






The dataset was used as 
the known sites resource 
 
SNVs in this dataset 






In this third task of building the Indels recalibration model, the same parameters as in 
SNP recalibration model building process were used. Besides that, an additional 
parameter of Maximum Gaussians (maxGaussians) was also used. The Gaussians is the 
probability distribution for the statistical model, whereby for the VQSR model it is used 
for variants positive call model with smaller sample size. The default distribution value 
of maxGaussians is eight. However, in this study GATK recommended to lower to four 
in order to increase the number of positive variants call since the number of samples 
study was less than 30 (WES sample size according to GATK requirement). This was 
done to avoid any error reported when executing the command. Similar to second task 
earlier, this current fourth task was carried out to apply this Indels recalibration model 
to filter the Indels in dataset. This was carried out by using the Indel mode argument in 
scripted commands. The full command for Variant Filtering was available in Appendix 




2.11.8 Genotype Refinement 
This is the first step of the third main bioinformatics pipeline of Call set Refinement as 
illustrated in Figure 2.2 earlier. This step involves three tasks which are deriving 
posterior probabilities of genotypes, filtering low quality genotypes and annotating 
possible de novo mutations. The first task was carried out to derive posterior 
probabilities of genotypes using CalculateGenotypePosteriors tool. This was to improve 
the accuracy of genotype calls in our recalibrated_variants.vcf file by analyzing against 
an additional database as provided in GATK pipeline, 1000G_phase3_v4_20130502 
database. Besides that, in fulfilling this task, the pedigree (.ped) file format was 
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generated using the EditpadLite version 7.3.8.0 (Just Great Software) for all families in 
this study. This (.ped) file was also another additional supporting generated data for the 
analyses since the current study was not represented by only affected children but also 
included the unaffected parents. This required (.ped) file described the familial 
relationship between samples. This task then, generated an intermediate output of 
recalibratedVariants.postCGP.vcf file which was later being processed in the second 
task called filtering low quality genotypes. In this second task, the VariantFiltration 
GATK tool was used to filter genotype calls that were uncertain whether or not carrying 
the variants. Below than 20 score of Genotype Quality (GQ<20) in 
recalibratedVariants.postCGP.vcf dataset will be filtered as “lowGQ” indicating that 
these particular genotypes were not suitable for the next downstream analysis steps. 
This was followed by the third task which was annotating possible de novo mutations 
in the recalibratedVariants.postCGP.vcf dataset using the VariantAnnotator GATK 
tool, as per scripted in the command available in Appendix D.7. This produced the 
recalibratedVariants.postCGP.Gfiltered.deNovos.vcf output file that also contained a 
list of affected children samples with possible de novo mutations. 
  
 
2.11.9 Variants Annotation 
Variants annotation is the final step for the Bioinformatics pipeline which was executed 
using the Annotate Variations (ANNOVAR) software tool version 2018 (frequently 
updated version) to annotate the data of chromosome (chr), start position, end position, 
reference nucleotide and observed nucleotides in (.vcf) dataset of the study, resulting in 
ANNOVAR table of annotated CP SNPs and Indels. The ANNOVAR annotation was 
carried out through four operations which were gene-based annotation (g), region-based 
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annotation (f) and filter based annotation (f) databases that provided by ANNOVAR as 
in Table 2.11. 
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Table 2.11: The list of default databases provided in the ANNOVAR software which 







hg19 1000g2015aug_all The 1000G team fixed bug in 
chrX frequency calculation. 
f 
hg19 avsift Whole exome SIFT scores for 
non- synonymous variants 
f 
hg19 cg69 Allele frequency in 69 human 
subjects sequenced by Complete 
Genomics organization. 
f 
hg19 clinvar_20140929 CLINVAR database with Variant 





response) and Variant disease 
name. 
f 
hg19 clinvar_20170130 CLINVAR version 20170130 with 
separate columns (CLINSIG 
CLNDBN CLNACC CLNDSDB 
CLNDSDBID) 
f 
hg19 cosmic70 COSMIC database version 68 on 
Whole Genome Sequencing 
(WGS) data 
f 
hg19 cytoBand Specific genomic regions 
(chromosome band) of genes 
r 
hg19 ensGene FASTA format sequences for all 
annotated transcripts in 
ENSEMBL gene database 
g 
hg19 esp6500siv2_all Exome Sequencing Project (ESP) 
with 6500 exomes, including the 











hg19 exac03 ExAC 6500 exome allele frequency 
data for all (ALL), African (AFR), 
Admixed American (AMR), East 
Asian (EAS), Finnish (FIN), Non-
finnish European (NFE), South Asian 
(SAS) and other (OTH). 
f 
hg19 exac03nontcga ExAC on non-TCGA samples f 
hg19 hrcr1 40 million variants from 32K samples 
in haplotype reference consortium 
f 
hg19 icgc21 International Cancer Genome 
Consortium version 21 
f 
hg19 kaviar_2015092 3 Compilation of SNVs, Indels, 
complex variants in human 
f 
hg19 kgXref Known gene cross-reference, which is 
opened by default below the 
knownGene table in ANNOVAR 
annotation. 
f 
hg19 knownGene FASTA format sequences for all 
annotated transcripts in USCS 
known gene database 
g 
hg19 ljb26_all ANNOVAR generic database f 
hg19 nci60 NCI-60 human tumor cell line panel 
exome sequencing allele frequency 
data. 
f 
hg19 refGene FASTA sequences for all annotated 
transcripts in RefSeq gene 
database. 
g 
hg19 snp137 The variants with reference SNP 
cluster ID (rs number) (version 
GRCh37) 
f 
hg19 snp138 The variants with reference SNP 






In this step, the applied databases were termed as “protocol” (Table 2.11), meanwhile 
the term “symbol” was called as “string” for command scripting purpose. The dot (.) 
string that defines “not available string” (nastring) was used in scripted command to 
annotate any scores and/or data that are not available in database. The full command for 
this step is available in Appendix D.8. The ANNOVAR annotation was displayed on 
the terminal in table (.annovar) format. By generating the final output from ANNOVAR 
annotation, this ended the bioinformatics analysis phase. This bioinformatics analysis 
final output was then interpreted to generate the main study results. 
 
 
2.12 Data Interpretation 
The ANNOVAR output was then translated into an excel file (.xlsx) format consisting 
of a big data annotated variants list. However, this output was not the official study data 
since this big data consisted of variants include the SNPs and mutations. For this 
preliminary study of CP related genes, the limit was set to focus on the mutations only 
and exclude the SNPs since SNPs were known to be easily polymorphic and abundantly 
present (>1%) in the population. The variants were also checked for their domains and 
protein sequences through online database, ensemble.org. The selected variants were 
then determined for their pathogenicity according to American College Medical 







3.1 Subject Details 
Instead of provisional 25 subjects (Table 2.5) at the beginning of the study, the main 
study output was generated from 20 final subjects only (Table 3.1) due to two-time 
sample reductions. The chronologies of two-time sample reductions are as explained in 
detail in subsection 2.9.1 and subsection 2.9.6. These final list of 20 study subjects are 
comprised of Family 1, Family 2, Family 4 and Family 5 with four subjects per family, 
whereby each of these four families are represented by both unaffected parents and two 
CP children. However, Family 3 with three subjects only, i.e. both unaffected parents 
and a CP daughter. Family 6 contributes only one CP son as a subjects with no parents’ 
WES data, due to fail the DNA quality test (refer subsection 2.9.6). 
 
  
3.1.1 Identification Code for Final Study Subjects 
These 20 study subjects consist of five unaffected mothers, five unaffected fathers, three 
CP daughters and seven CP sons were randomly grouped into two different pools for 
two separate sequencing batches (Table 3.1). Pool 1 (PO1) was assigned for batch 1 and 
Pool 2 (PO2) was for batch 2. In order to distinguish these 20 final study subjects from 
the provisionally 25 recruited subjects (Table 2.5), their IDs are currently improvised 
















3.2 Family Pedigree 
 








Figure 3.1 shows the three-generation pedigree of Family 1 with 10 children of both 
unaffected parents in a non-consanguineous marriage. Out of these 10 siblings there are 
four male siblings with CP in which only two of them are surviving. They are 34 years 
old CP son and 18 years old CP son who were born via spontaneous vagina delivery 
(SVD) with no antenatal, intrapartum and postpartum events. The other two CP sons 
were the fifth and sixth children who passed away at the age of 31 years old and 11 
years old respectively. 
 
 
Both unaffected parents (D1_S3 and M1_S2) and these two CP sons of spastic diplegia, 
B1-1_S1 and spastic quadriplegia, B1-3_S4 were included in the final list of 20 subjects. 
These two CP sons are bedridden with no means of mobilizing on their own and fully 
dependent on caregivers. None of the family members in the previous generation was 
affected by CP nor having other identifiable genetic disorders. However, there is 
another ataxic CP grandson (a son of the third female child) which is in the fourth 
generation, but he is not included in this third-generation pedigree. This however 









Figure 3.2 shows three-generation pedigree of non-consanguineous Family 2 with two 
children. Both siblings are spastic diplegia CP of 3 years old female and 2 years old 
male. These CP children were born via SVD with no risk factor incidents. They are also 
mobilizing using wheelchair with help from caregivers, do not need the trunk support 
device and able to grasp objects. Both unaffected parents (D2_S7 and M2_S6) and both 
CP children (G2-1_S8 and B2-2_S5) are also included in the final list of 20 study 
subjects (Table 3.1). There was no CP history nor other identifiable genetic disorders in 
the previous generations. However, since both children in Family 2 are CP affected 
despite of uneventful delivery and no risk factors, this indicates that this neurological 









The Family 3 three-generation pedigree shows a pair of normal parents in a non- 
consanguineous marriage with nine children. Five out these nine siblings are CP 
affected, however only three CP children are still surviving. Meanwhile, the other two 
CP children who were first son and youngest daughter died at 6 months old and 7 years 
old respectively. All of these spastic CP children who were born through SVD with no 
mechanical factors are bedridden and fully caregivers-dependent. Only both parents 
(D3_S9 and M3_S6) and one CP daughter (G3-3_S10) are included in the final list of 
20 subjects (Table 3.1). Regardless of no risk factors and no CP history in the past 
generations, having multiple CP children from a same parental line suggests that this 









Figure 3.4 shows three-generation pedigree of Family 4 with a pair of monochorionic 
diamniotic (monozygotic) seven years old male twins of B4-T1_S1 and B4-T2_S2. The 
twins together with their parents (D4_S4 and M4_S3) are all included in the 20 final 
study subjects that generated the main study output. The twins are classified with 
different CP type which are spastic diplegia B4-T1_S1 and spastic left hemiplegia B4-
T1_S2. The spastic diplegia B4-T1_S1 is mobilizing using wheelchair and able to 
propel it himself meanwhile the spastic hemiplegia B4-T2_S2 is walking with 
hemiplegic gait. Their divorced parents were a non-consanguineous pair who also had 
no CP history from past generations of each family line. The twins were born via 
emergency caesarian at gestational age of 30 weeks, whereby prematurity is one of the 
subject inclusion criteria for this current CP genetic study. They also fulfilled another 
two inclusion criteria which are CP diagnosed confirmation and more than one family 









Family 5 three-generation pedigree in figure 3.5 shows that two out of five children are 
CP affected who were born to non-consanguineous unaffected parents. Both unaffected 
parents (D5_S9 and M5_S8), a spastic diplegia son (B5-1_S7) ages 14 years old and a 
spastic diplegia (G5-2_S10) daughter ages 10 years old are the subjects for this current 
study. These two CP children have the same CP type however show different physical 
manifestations. B5-1_S7 child is able to walk but with abnormal gait and has functional 
hands, meanwhile G5-2_S10 child is mobilizing using wheelchair and able to propel 
wheelchair by herself. They were both born via SVD with no causal event occurs. 
However, B5-1_S7 was born as a premature infant at 33 weeks. Even though there was 
no CP history in the previous generation, this family is considered as familial genetic 
CP since they fulfilled more than three inclusion criteria which are CP diagnosed 









Figure 3.6 shows Family 6 three-generation pedigree of non-consanguineous unaffected 
parents with two spastic quadriplegia CP sons (12 years old and 11 years old) that were 
born via SVD and another three unaffected children. Both CP sons are bedridden and 
fully caregivers-dependent with no means of mobilizing themselves. Besides Family 3, 
this Family 6 also had some WES excluded subjects/samples which were both parents’ 
(D6 and M6) and second CP son (B6-2) because of did not pass the DNA quality test. 
Hence, from this family only one subject (B6-1_S5) is included in the 20 final study 
subjects to generate study output (Table 3.1). The pedigree shows that there was no 




3.3 Clinical Features of CP Subjects 
The clinical data of CP subjects were recorded from during home-visit for physical 
examination and from hospital medical records especially for the diagnosis phase (≤5 
years old) data. These clinical data are summarized in Table 3.2. In total, there are 10 
CP subjects ranging from 2 years old to 34 years old in this study in which seven are 




Table 3.2: The summary of clinical features (DD, LD, and muscle conditions) of all 10 CP affected subjects. 
 
Case Gender Age DD LD Muscle T one Deep T endo n Muscle Muscle 
(y /o) Reflex \Vasting W eakness 
Family 1 
Bl-l_S l o' 34 I I r T I I 
Bl-3_S4 o' 18 I I r T I I 
Family2 
u L - J _ :::.!S ~ ~ I NA r T I I 
1::!2-L_ S ::> a· 7. I NA T T I I 
Family 3 
<JC>-3_S l U ~ u; I I T T I I 
Family4 
J::S4- J J _ :::.J o' I I Mlld T T I I 
1::!4- TL _ SL o' f I I T T I I 
Family 5 
J::S:l - 1_ :::. 1 ci' 14 I X r T I I 
u::>-z _ :::. Ju ~ 1U I X T r I I 
Family 6 
J::Sb- 1_ :::.::> 0 1L I f T r I I 
.. 
{Note: DD= Developmental Delay , }vfR- Mental Retardation; LD- Learrung D tsabtlity; ~- F emale; & - Male ; T- hyper; ! - hypo; 1~ Yes {problem 
present) ; X= K o {problem absent) ; NA= N ot applicable for children< 5 y ears old) . 
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Table 3.2 shows the clinical data for each CP subjects in this study that are tabulated 
according to family group. Medical records for these CP subjects show that they were 
observed for their nervous system function by examining for delay in their 
developmental milestones. The developmental delay assessment is done during the 
phase of ≤ 5 years old. Based on hospital medical records, it is shown that all of these 
CP subjects have developmental delay problem that are reflected by few inabilities such 
as unable to roll over, unable to sit even with support, delay and/or unable to walk and 
hand fisting. They were also assessed for the higher mental function (learning disability 
assessment). Both CP sons in Family 1 (diplegic B1-1_S1 and quadriplegic B1-3_S4), 
CP daughter (quadriplegic G3-3_S10) in Family 3 and single subject of Family 6 
(quadriplegic B6- 1_S5) have learning disability. 
 
In Family 4, both CP twins have learning disability, but it is milder in B4-T1_S1 
compared to B4-T2_S2. Both diplegic children in Family 5 (B5-1_S7 and G5-2_S10) 
have no learning disability. Meanwhile, both CP children in Family 2 who are 3 years 
old G2- 1_S8 daughter and 2 years old B2-2_S5 son do not have any records for learning 
disability assessment (NA) as in Table 3.2. This is because the assessment is not 
applicable for patients aged < 5 years old. From these 10 CP subjects, only four (B4-
T1_S1, B4-T2_S2, B5-1_S7 and G5-2_S10) who are able to talk, however only B5-
1_S7 and B4-T1_S1 who are attending normal school. Besides obtaining the clinical 
data from hospital medical records, physical examination data were collected during the 
home visits to check for their current physical conditions. The physical examination 
was done for muscle conditions (Table 3.2), motor dysfunction types and motor 
function that includes sensory problem, cerebellar dysfunction, cranial nerve 
abnormalities and (Table 3.3). As for muscle tone as shown in Table 3.2, all CP subjects 
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have hypertonic muscle tone. Hypertonia causes them to have increased muscle tension 
while hypotonia caused them to have decreased muscle tension. Both muscle tone 
conditions are noticeable although the patient is at rest without doing any movements. 
As recorded in Table 3.2, these 10 CP subjects are showing hyperreflex of deep tendon. 
Hyperreflex tendon is a condition of an increasing speed in their reflex or also known 
as excessive response. All of these CP subjects also have both muscle wasting 






Table 3.3: The summary of clinical features (motor function, type of plegia, type of motor dysfunction and mobility) of all 10 CP affected subjects. 
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Table 3.3 shows clinical data for motor function (cerebellar dysfunction, sensory 
problem and cranial nerve abnormalities), topographic distribution, type of motor 
dysfunction (flaccid/spastic) and mobility. All of these 10 spastic CP subjects have no 
cerebellar dysfunction observed. They also show no sensory involvement and cranial 
nerve abnormalities as recorded in Table 3.3. There are four bedridden CP subjects with 
impaired truncal and fully caretaker-dependent, which are both CP sons in Family 1 
(B1_1_S1 and B1-1_S1), G3-3_S10 of Family 3 and 6-1_S5 of Family 6. Oher four CP 
subjects that mobilize using wheelchair and/or stroller are both children in Family 2 
(G2- 1_S8 and B2-2_S5), B4-T1_S1 of Family 4 and G5-2_S10 of Family 5. Among 
these wheelchair-CP subjects, only B4-T1_S1 and G5-2_S10 are able to propel the 
wheelchair on their own. There are also two CP children, B5-1_S7 (Family 5) and B4-














Table 3.4 show other medical records that are obtained from hospital medical records. 
There are eight CP subjects who were born via SVD, whilst the twins of Family 4 were 
born via emergency caesarean. Three were premature babies, they are the twins who 
were born at 30 weeks of gestational age and also B5_1_S7 (Family 5) who was born 
at 33 weeks. Overall, few insights could be obtained from these clinical data in Table 
3.2, Table 3.3 and Table 3.4. Firstly, in this current study, all of these 10 CP subjects 
are classified under the same CP physiology which is spastic but with different 
topographic distribution such as six are diplegia (B1-1_S1, B2-1_S5, B4-T1_S1, B5-
1_S5, G2-1_S8 and G5- 2_S10), three are quadriplegia (B1-3_S4, G3-3_S10 and B6-
1_S5) and one is hemiplegia (B4-T2_S2) subjects. 
 
This phenotype difference also happens among CP siblings from the same parental 
line. For example, Family 1 has two bedridden CP sons with spastic diplegia and 
spastic quadriplegia and Family 4 with a pair of monozygotic twins with spastic 
diplegia and spastic hemiplegia. Apart from that, as recorded in Table 3.2, it is obvious 
that individuals with the same CP phenotype do not necessarily share the same clinical 
features or comorbidities. They also show different gross motor function. Despite are 
classified under the same CP type, these CP individuals show different skill or ability. 
For example, in particular to diplegic CP as the most CP type that is present in this 
current study, diplegic CP subjects show different ability whereby some of them are 
able to utilize the hands such as to grasp an object and to propel the wheelchair but 
some are poor in hands functionality. Some diplegic CP subjects are also able to walk 
with abnormal gait and some are bedridden. All of the bedridden patients in this current 
study show poor head control. Thus, in order to mobilize them, it requires the 
ambulatory aid device that has truncal support function. In this current study, CP 
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subjects are ranging from 2 years old to 34 years old, this shows a possible normal life 
span for CP individuals. However, it still is depending on whether or not they are 
associated with any medical conditions as well. Lastly, besides not having facial 
dysmorphic features, all of these CP subjects who were born from uneventful 
pregnancies and deliveries also have no other known genetic disorders. This indicates 
that their CP conditions are not their secondary medical condition but a possible result 
of genetic underlying factors. 
 
 
3.4 Concentration and Quality of Extracted DNA Sample 
The DNA extracted from the blood samples of all subjects had good concentration of 
≥ 60 ng/µl as recommended by Illumina technology for WES. The concentration 
ranged from 61.243 ng/µl to 213.475 ng/µl in 30 µl volume (four readings taken per 
sample). All extracted DNA samples achieved the optimum optical density (OD) of 
A260/280 within the range of 1.7– 2.2 and OD of A260/230 within the range of 2.0 - 
2.2. This indicated that, all of the DNA samples were free from any contaminations 
such as protein, salt or residual alcohol. The list of DNA concentration ([DNA]) can 
be obtained in Appendix B. The DNA samples were also of good integrity as indicated 
by a thick band with no smear in each well (Figure 3.7). This Agarose gel 
electrophoresis image also double confirmed that no contamination occurred in 




Figure 3.7: The gel image of all 20 gDNA samples. (Marker: mixture of 1 µl Ladder 




3.5 DNA Libraries 
The final Qubit values for libraries in pool 1 (PO1) was 19.0 ng/µl of 71.97 nM and 
libraries in pool 2 pool (PO2) was 19.6 ng/µl of 74.24 nM pool concentration. The 
average library size of PO1 was 347 bp and PO2 was 325 bp respectively. The actual 
insert sizes after deducting the size of adapters (120 bp) that flanked the insert (input 
gDNA) were 227 bp and 203 bp for PO1 (batch 1) and PO2 (batch 2) respectively. 
 
 
3.6 Whole Exome Sequencing (WES) Data 
Each sequencing batch contained 10 gDNA samples which yielded 96 Gb sequencing 
data per batch. This indicated that each gDNA data size was 9.6 Gb (96 Gb/10 gDNA 
samples per sequencing batch). Using the formula in section 2.10, the sequencing 
coverage was 75X, which means the whole exomes were sequenced for an average of 
75 times. The reported sequencing read length was 2 x 150 bp. The Illumina 
Technology applied the Phred Quality Score of Q30 for sequencing reads. It is 
logarithmically related to the base calling error probabilities of an incorrect base call 
of 1 in 1000 times with 99.9% accuracy. According to Illumina, the study read length 
of 2 x 150bp had Q30 of minimum 75% bases is considered a standard score 
(https://www.illumina.com/systems/sequencingplatforms/nextseq/specifications.html)
. For the current study, the sequencing raw data was therefore reliable. An example of 
















Figure 3.8: The format for the sequencing reads output files. 
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Figure 3.8 shows the example of WES raw data for one sample that was reported into 
eight fastq.gz files, a compressed zip file format. As explained in section 2.10, each 
sample of pair-end sequencing had four lanes and each lanes had two reported files 
making up to eight reported sequencing reads files in total. Each sequencing batch has 
80 sequencing reads, thus there are 160 sequencing reads in total from two batches in 




3.7.1 Assigned Sample Codes 
As explained in section 2.11.1, for computational command purpose the sequencing 
reads for batch 1 and batch 2 were assigned as “array” and “array2” respectively. Then, 
a group of 10 samples in “array” was termed as {element} and another group of 10 
samples in “array2” was termed as {element2} (Table 3.5). These “array”, “array2”, 
{element} and {element2} terms are standardized as computational languages/codes 
to be used throughout bioinformatics processes for this current study. This is to avoid 
any analysis error due to failure to distinguish sample read groups since this analysis 
was done simultaneously for both sample groups with multiple sequencing reads. 
Basically, Table 3.5 and Table 3.1 earlier show similar content but with different 
purposes. Table 3.1 describes 20 study samples that were grouped into two sequencing 
batches to produce raw reads data, whereas Table 3.5 describes the produced raw reads 
batches that were coded with computational languages for bioinformatics analysis to 
generate variants output. 
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Table 3.5: Assigned sample codes for further analyses using the bioinformatics 
command. 
 
Sequencing reads Assigned Bioinformatics 
Code 
List of Element 
Batch 1 “array” and {element} B2-2_S5, G2-1_S8, B1-1_S1, 
M2_S6, G3-3_S10, D2_S7, 
D1_S3, B1-3_S4, 
D3_S9 and M1_S2. 
Batch 2 “array 2” and {element 
2} 
D4_S4, M4_S3, B4-T2_S2, B4-
T1_S1, D5_S9, G5-2_S10, B5-





3.7.2 Fastqc Inspection 
Each sequencing raw data was inspected for any low quality sequences by accessing 
to fastqc.html report as described in section 2.11.1. Fastqc inspection was done on raw 
read files and received the problem alert (X in red circle symbol) which showed that 
the sample had biases of base percentage as in Figure 3.9. There were two biases of 
sequence (fluctuate peaks) located at the front and at the end of read. These biases 
occurred in all reads of the 20 samples due to tagmentation adapters by transposome 
activity of Nextera kit that was used during the gDNA library preparation procedure, 
whereby the adapters flanked each of gDNA as explained in subsection 2.9.3. 
Therefore, to remove these biases the trimming process is required. Trimming was 
done by scripting the computational codes to give a command of cutting off the biases 
base sequence from sequencing read sequences, leaving only the gDNA input 























Figure 3.9: Example of fastqc.html report files of raw read sequence obtained from 
WES showing the base percentage in sequencing reads. 
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After trimming, we re-inspected the fastqc.html file again and received the good alert 
(√ in green circle), indicating that we managed to obtain the standard base percentage 
plot which was the parallel lines plot as in Figure 3.10. These line plots that run parallel 
to each other indicated that the proportion of each of the four bases remain relatively 
constant over the length of the read with %A=%T and %G=%C, which was acceptable 






















Figure 3.10: The optimum base percentage after trimming (clipping) the 
fluctuating peaks. 
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3.7.3 Pedigree File (PED) 
The PED file was a generated tabular text file containing 1 row per person/sample and 
6 mandatory columns that described the familial relationship between samples in 
alphanumerical and numerical codes respectively, to be used in the last process of 
bioinformatics, i.e genotype refinement (Table 3.6). The family ID in PED file was 
totally different from the family ID of the whole study (Figure 3.11), since the PED 
file has its own standard code. 
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Table 3.6: The generated PED file as supporting data for genotype refinement step. 
Family ID ID Father Mother Gender Phenotype 
Fam01 B1-1_S1 D1_S3 M1_S2 1 2 
Fam01 D1_S3 0 0 1 1 
Fam01 M1_S2 0 0 2 1 
Fam02 B1-1_S1 D1_S3 M1_S2 1 2 
Fam02 D1_S3 0 0 1 1 
Fam02 M1_S2 0 0 2 1 
Fam03 G2-1_S8 D2_S7 M2_S6 2 2 
Fam03 D2_S7 0 0 1 1 
Fam03 M2_S6 0 0 2 1 
Fam04 B2-2_S5 D2_S7 M2_S6 1 2 
Fam04 D2_S7 0 0 1 1 
Fam04 M2_S6 0 0 2 1 
Fam05 G3-3_S10 D3_S9 M3_S6 2 2 
Fam05 D3_S9 0 0 1 1 
Fam05 M3_S6 0 0 2 1 
Fam06 B4-T1_S1 D4_S4 M4_S3 1 2 
Fam06 D4_S4 0 0 1 1 
Fam06 M4_S3 0 0 2 1 
Fam07 B4-T2_S2 D4_S4 M4_S3 1 2 
Fam07 D4_S4 0 0 1 1 
Fam07 M4_S3 0 0 2 1 
Fam08 B5-1_S7 D5_S9 M5_S8 1 2 
Fam08 D5_S9 0 0 1 1 
Fam08 M5_S8 0 0 2 1 
Fam09 G5-2_S10 D5_S9 M5_S8 2 2 
Fam09 D5_S9 0 0 1 1 
Fam09 M5_S8 0 0 2 1 







In PED file in Table 3.6, each family was designated in tabulated trio relationship 
consisting of mother, father and one child only. Thus, if a family has two CP subjects, 
this family was then stratified into two groups of trio separately with two different 
“Family ID”. By referring to Table 3.6, there were 4 families (Family 1, Family 2, 
Family 4 and Family 5) that have two CP subjects thus resulting in two trios of PED 






3.7.4 Annovar Annotated Variants 
After completing the bioinformatics, a big data of 172428 (~172k) annotated variants 
which consists of SNPs and mutations was obtained after being filtered against 
multiples databases. These annotated variants were reported in excel files with 111 




3.8 Interpreted Data 
As explained in section 2.12, this annotated ~172k variants are not the main study 
output. Since this current study produced a big variants data within limited time 
available, thus at this preliminary study stage we decided to focus the interpreation on 
the mutation only. In order to obtain only mutations that are related to CP in this study, 
further data interpretation was done for this big data by multiple screening/selection 
processes according to few criteria such as variants located on exonic regions, variants 
that are present in CP subjects only, variants that are present in all subjects including 
unaffected parents, null variant types (frameshift, stopgain and stoploss) and non-
synonymous variants based on pathogenicity scores in variant effect prediction tool 





I Original Annovar output list (172428 variants) I 
I Selection of variants in exonic region only (42096 v ariants) I 
I I 
Selection ofYariants present in all 20 subjects Selection ofYariants present in any affected 
(1 0 affected subjects & 10 unaffected parents) children and absent in their unaffected parents 
l Selection ofYariants with ! 
I 154 7 variants I no rs ID in dbSNP138 I 215 Yariants I 
I 18 mutations I. I 128 mutations I 
! I I I I ! 
Selection of null v ariants (frameshift, stopgain, stop loss) with/without ..,·ariant effect scores and non-synonymous (SNV) 
Yariants with Yariant effect scores 
ri 8 inherited variants i 
29 sporadic Yariants 
! (mutations) (mutations) 
I Variants pathogenicity determined according to AC:YIG standard guidelines (Richard et. al, 2015) I 
Figure 3.12: Workflow of variants data analysis. (ACMG : American College Medical Genetics variant pathogenicity standard 
guidelines, dbSNP138: SNPs database, rs ID: indicates the variant is SNP not mutation and variant effect scores: Polyphen2_HDIV , 
Polyphen2_HV AR, SIFT , CADD and GERP++ _RS). 
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As stated earlier (section 2.11.9), few widely used variant effect prediction tools such 
as SIFT, Polyphen2_HDIV, Polyphen2_HVAR, CADD_phred and GERP++_RS were 
applied during Annovar annotation in this current study. The variant effect prediction 
tool interpretations are available in Table 3.8. The main output generated from this 
analysis consists of eight inherited variants (Table 3.9) and 29 sporadic variants (Table 
3.10), which are defined as mutations since all of them have no rs ID number indicating 
that they are not classified as SNPs. Both inherited and sporadic variants pathogenicity 
were determined according to multiple criteria available in worldwide standard 
variants pathogenicity guideline established by ACMG (Richard et. al., 2015). 
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Multiple prediction tools are functioning to predict a variant deleteriousness such as 
whether or not a particular variant have a damaging impact due to protein changing. 
According to Table 3.8, the SIFT score range is 0 to 1 whereby a variant that has score 
< 0.05 is predicted to be deleterious meanwhile a variant with score of > 0.05 is 
predicted to be tolerated or benign variant. The Polyphen2 (HDIV & HVAR) ranging 
from 1 to 0, whereby a variant with Polyphen 2 score of > 0.05 is considered 
deleterious or also termed as “damaging” in Polyphen2 program, whereas a variant 
with < 0.05 score in Polyphen is considered benign. CADD_phred score range is 0 to 
35, a variant with > 15 score is considered deleterious in protein function.  Meanwhile, 
the GERP++_RS score range is -12.3 to 6.17, whereby a variant with > 0.047 is 
considered deleterious or also specifically termed as “less conserved” in this prediction 
tool. These variant effects determine the molecular functionality score of each variant 
of all 37 variants discovered in this current study as tabulated in Table 3.9 and Table 
3.10. Both inherited (section 3.8.1) and sporadic (section 3.8.2) variant pathogenicities 
were determined according to multiple criteria available in worldwide standard 













3.8.1 Inherited Variants 
Table 3.9: List of 8 inherited variants with some details from Annovar output and ACMG classification. 
No Mutated 
Gene 
Position (hg19) Mutation 
Type 















(deletion of 32 
nucleotide) 
. . . . . Likely 
Pathogenic 
2 CTDSP2 chr12_58220811_ 
58220811_G_T 
Non SNV exon4:c.C322A: 
p.L108I 
0 1 0.999 21.4 0.817 Uncertain 
Significance 
3 CTDSP2 chr12_58220831_ 
58220831_C_G 
Non SNV exon4:c.G302C: 
p.R101T 
0 0.68 0.473 22.7 4.92 Uncertain 
Significance 







. . . . . Likely 
Pathogenic 
(Notes: Genes of CTBP2 (C-Terminal Binding Protein 2), CTDSP2 (Carboxy-Terminal Domain Small Phosphatase 2) and ANKRD36 (Ankyrin Repeat 
Domain 36); Position= Mutation position in chromosome (chr) in hg19 database; ins= insertion; del= deletion; SIFT (< 0.05) = Deleterious, SIFT (> 
0.05) = Benign; Polyphen2_ (HDIV and HVAR) (> 0.05) = Deleterious; CADD_phred (> 15) = Deleterious; GERP++_RS (> 0.047) = Deleterious; “.” 





Table 3.9: Continued. 
No Mutated 
Gene 
Position (hg19) Mutation 
Type 






















. . . . . Likely 
Pathogenic 






. . . . . Likely 
Pathogenic 






. . . . . Likely 
Pathogenic 
(Notes: Genes of ANKRD36 (Ankyrin Repeat Domain 36), KRTAP19-6 (Keratin Associated Protein 19-6) and FAM104B (Family With Sequence 
Similarity 104 Member B); Position= Mutation position in chromosome (chr) in hg19 database; ins= insertion; del= deletion; SIFT (< 0.05) = 
Deleterious, SIFT (> 0.05) = Benign; Polyphen (HDIV and HVAR) (> 0.05) = Deleterious; CADD_phred (> 15) = Deleterious; GERP++_RS (> 







Table 3.9 shows eight mutations that are categorized as inherited variants since they 
are present not only in all CP affected children but also in all unaffected parents. They 
comprise of two non-SNV variants, four frameshift deletion and two frameshift 
insertion mutations of total five genes (Table 3.9). In the Annovar output, six out of 
eight variants which are c.2228_2259del:p.G743fs, c.1183_1184del:p.A395fs, 
c.1186_1187insTT:p.V396fs, c.171delC:p.F57fs, c.182_183insA:p.S61fs and 
c.179delC:p.A60fs are denoted as “.” in molecular functionality prediction tool 
columns of SIFT, Polyphen 2_HDIV, Polyphen2_HVAR, CADD_phred and 
GERP++_RS indicating that these variants have no score available in these molecular 
functionality prediction tool database programs. However, according to ACMG 
classification these six variants are all likely pathogenic. Only two variants have the 
scores in prediction tool programs which both are non-SNV of CTDPS2 gene. The 
mutations are exon4:c.C322A:p.L108I and exon4:c.G302C:p.R101T. 
 
In particular to these two mutations of CTDSP2 gene, exon4:c.C322A:p.L108I 
mutation has 0 score for SIFT, 1 score for Polyphen2_HDIV, 0.999 score for 
polyphen2_HVAR whereby these three scores show that this mutation is deleterious. 
It also shows a pathogenic score (21.4) for CADD_phred and less conserved score 
(0.817) for GERP++_RS. Another CTDSP2 mutation, exon4:c.G302C:p.R101T 
shows the same deleterious prediction but with slightly different score values such as 
0 for SIFT, 0.68 for Polyphen2_HDIV, 0.473 for polyphen2_HVAR, pathogenic score 
(22.7) for CADD_phred and less conserved score (4.92) for GERP++. These 
prediction tool scores show a possibility of protein function changing due to these 
variants. However, the ACMG classified these two variants as of uncertain 
significance. 
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3.8.2 Sporadic Variants 
From the data interpretation, we discovered 29 sporadic variants of total 25 genes 
which are as following, Mucin 16, Cell Surface Associated (MUC16) (two variants; 
n=2), Human Leukocyte Antigen-Major Histocompatibility Complex Class II Beta 
Chain 1 (HLA- DRB1) (four variants; n=4), whereas one variant (n=1) for each gene 
of ANKRD36, Family with Sequence Similarity 163 Member A (FAM163A), 
Tetratricopeptide repeat domain protein 13 (TTC13), Bestrophin 3 (BEST3), 
Glyoxylate Reductase 1 Homolog (GLYR1), Fragile X Mental Retardation 1 
Autosomal Homolog 2 (FXR2), Dynein Axonemal Heavy Chain 17 (DNAH17), 
Microtubule Associated Protein RP/EB Family Member 3 Gene (MAPRE3), Collagen 
Type VI Alpha 6 Chain Gene (COL6A6), Asteroid Homolog 1 (ASTE1), Collagen 
Type VII Alpha 1 Chain Gene (COL7A1), Human Leukocyte Antigen- Major 
Histocompatibility Complex Class II Beta Chain 5 (HLA-DRB5), Potassium Voltage-
Gated Channel Subfamily Q Member 3 Gene (KCNQ3), Cysteine And Histidine Rich 
1 Gene (CYHR1), Potassium Two Pore Domain Channel Subfamily K Member 18 
(KCNK18), Centrosomal Protein 164 (CEP164), Adhesion G Protein-Coupled 
Receptor (GPR97), Cyclin Dependent Kinase Like 2 (CDKL2), RNA Binding Motif 
Protein X- Linked (RBMX), Lysosomal Trafficking Regulator (LYST), Anoctamin 5 
(ANO5), Dachsous Cadherin-Related 2 (DCHS2) and Delta Like Canonical Notch 









Table 3.10: The list of 29 Likely Pathogenic sporadic variants with their few extracted details from Annovar output. 
No Mutated 
gene 
Position (hg19) Mutation 
type 
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. . . . . 






. . . . . 






. . . . . 






. . . . . 
(Note: Position= Mutation position in chromosome (chr) in hg19 database; ins= insertion; del= deletion; dup= duplication; SIFT (< 0.05) = Deleterious, 
SIFT (> 0.05) = Benign; Polyphen (HDIV and HVAR) (> 0.05) = Deleterious; CADD_phred (> 15) = Deleterious; GERP++_RS (> 0.047) = Deleterious; 






Table 3.10: Continued. 
No Mutated 
gene 
Position (hg19) Mutation 
type 
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1 . . 41 2.37 




exon1:c.25delG:p.D9f s . . . . . 






. . . . . 







. . . . . 






. . . . . 
 
15 






. . . . . 
(Note: Position= Mutation position in chromosome (chr) in hg19 database; ins= insertion; del= deletion; dup= duplication; SIFT (< 0.05) = Deleterious, 
SIFT (> 0.05) = Benign; Polyphen (HDIV and HVAR) (> 0.05) = Deleterious; CADD_phred (> 15) = Deleterious; GERP++_RS (> 0.047) = Deleterious; 








Table 3.10: Continued. 
No Mutated 
gene 
Position (hg19) Mutation 
type 
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1 . . 51 3.74 




1 . . 26.2 -0.435 




1 . . 40 4.25 






. . . . . 
(Note: Position= Mutation position in chromosome (chr) in hg19 database; ins= insertion; del= deletion; dup= duplication; SIFT (< 0.05) = Deleterious, SIFT 
(> 0.05) = Benign; Polyphen (HDIV and HVAR) (> 0.05) = Deleterious; CADD_phred (> 15) = Deleterious; GERP++_RS (> 0.047) = Deleterious; and “.” = 








Table 3.10: Continued. 
No Mutated 
gene 
Position (hg19) Mutation 
type 
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1 . . 51 3.74 




1 . . 26.2 -0.435 




1 . . 40 4.25 






. . . . . 
(Note: Position= Mutation position in chromosome (chr) in hg19 database; ins= insertion; del= deletion; dup= duplication; SIFT (< 0.05) = Deleterious, SIFT 
(> 0.05) = Benign; Polyphen (HDIV and HVAR) (> 0.05) = Deleterious; CADD_phred (> 15) = Deleterious; GERP++_RS (> 0.047) = Deleterious; and “.” = 
Indicates that the variant does not have score for variant effect in prediction tool programs). 
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Table 3.10 shows only a total of five stopgain mutations that have the molecular 
functionality scores in the prediction tool database programs. The first stopgain 
mutation is exon20:c.C2295A:p.Y765X (ANO5 gene) with benign/tolerated SIFT 
score (1), highly pathogenic (41) CADD_phred score, less conserved (2.37) 
GERPT++_RS score with no scores (.) available in Polyphen2 databases. Next is 
stopgain mutation of exon9:c.C1796A:p.S599X (DCHS2 gene) with tolerated SIFT 
score (0.84), highly pathogenic (41) CADD_phred score, less conserved (4.35) 
GERPT++_RS score with no scores (.) available in Polyphen2 databases. Thirdly, 
exon40:c.C9558A:p.Y3186X (LYST gene) with SIFT score 1 (tolerated), highly 
pathogenic (51) CADD_phred score, less conserved (3.74) GERPT++_RS score with 
no polyphen2 scores. 
 
This if followed by exon19:c.C1441T:p.Q481X stopgain mutation of ANKRD36 with 
tolerated SIFT score (1), pathogenic (26) CADD_phred score, very less conserved (- 
0.435) GERPT++_RS score with no Polyphen2 database scores. The fifth stopgain is 
exon4:c.C663A:p.C221X in DLL1 gene with SIFT score 1 (tolerated), highly 
pathogenic (40) CADD_phred score, less-conserved (4.25) GERPT++_RS score with 
no polyphen2 scores. These scores of proteins changing prediction of mentioned 
stopgain mutations sometime show a contra prediction score pattern, for example 
predicted to be tolerated according to SIFT but predicted to be highly pathogenic 
according to other prediction tools. However, all of these sporadic variants including 
the mutations with no prediction (.) score in databases were classified as likely 
pathogenic according to ACMG standard guideline (Richard et. al., 2015). Other 
additional prediction tools such as Mutation Taster, Mutation Assessor and Functional 
Analysis through Hidden Markov Models (FATHMM) 
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were also applied yet these frameshift variants for both inherited and sporadic 
categories are still denoted as “.” indicating that they have no deleteriousness 
prediction scores for these aditional prediction tool programs. Therefore, since this is 
a preliminary study, other studies with independent analysis on each of the platform 
are recommended for both inherited and sporadic variants that have no score (.) for the 
molecular functionality prediction tool program (platform). 
 
 
3.8.2(a) Sporadic Variants As De Novo Mutations in Family 
After comparing the sporadic variants in each family, these 29 sporadic variants 
(Figure 3.12) are only present in the CP children and are totally absent in unaffected 
parental samples. They are then considered as de novo mutations (Oliveira et. al., 
2001; Richard et. al., 2015). However, there is no de novo mutation in the CP child of 
Family 3. Besides that, the variants in CP child (B6-1_S5) of Family 6 could not be 
determined as de novo mutations through parent-child variants comparison due to no 
parental variant data, since the parental samples did not pass the DNA quality test for 
WES as explained earlier. Overall, only eight CP subjects have de novo mutations. 
Unlike the inherited variants, these mutations are not shared among the CP subjects 
nor among the same CP plegia subtype (Table 3.11). For example, the mutated 
COL7A1 gene of exon69:c.5749delG:p.E1917fs mutation is only present (/) in B2-
2_S5 (diplegia) and B4- T1_S1 (diplegia), while the other four diplegic and other 
plegic CP subjects do not have 
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(NA) this mutation. Even for the monozygotic twins in Family 4 with different plegia 
type, they do not share the same sporadic variants between themselves. The profile of 

























Table 3.11: Profile of 29 de novo mutations in CP subjects in the siblings. 

























NA NA / NA NA NA NA / / 
KCNK18 
exon3:c.361dupT:p.G120fs 
NA NA NA NA NA NA NA / / 
MAPRE3 
exon5:c.536delC:p.A179fs 
/ NA NA NA NA / NA NA / 
FAM163A 
exon5:c.400delC:p.P134fs 
NA NA NA NA NA NA / NA / 
GLYR1 
exon13:c.1140delG:p.G380fs 
NA NA NA NA NA / NA NA / 
KCNQ3 
exon12:c.1599delA:p.K533fs 
NA NA NA NA NA / NA NA / 
GPR97 exon9:c.1022dupG:p.R341fs NA NA NA / NA NA NA / NA 
DNAH17 
exon27:c.4235delA:p.K1412fs 
NA NA NA NA NA NA NA / NA 
ANO5 exon20:c.C2295A:p.Y765X / NA NA NA NA NA NA NA / 
FXR2 exon1:c.25delG:p.D9fs NA NA NA NA NA NA NA / NA 
(CP subtypes are dip= diplegia, quad= quadriplegia, hemi= hemiplegia; / = De novo variant present; and NA= De novo variant absent). 
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Table 3.11: Continued. 





















NA NA NA / NA / NA NA NA 
CYHR1 exon3:c.430delG:p.A144fs NA NA / NA NA / NA NA NA 
HLA-DRB1 
exon2:c.118_119insT:p.P40fs 
NA NA / NA NA NA / NA NA 
HLA-DRB1 
exon2:c.115delC:p.Q39fs 
NA NA / NA NA NA / NA NA 
HLA-DRB1 
exon2:c.111delG:p.L37fs 
NA NA / NA NA NA / NA NA 
HLA-DRB1 
exon2:c.109delC:p.L37fs 
NA NA / NA NA NA / NA NA 
CDKL2 exon3:c.222dupA:p.R75fs / NA NA NA NA NA / NA NA 
DCHS2 exon9:c.C1796A:p.S599X / NA NA NA NA / NA NA NA 
RBMX 
exon9:c.905_906insCC:p.P302fs 
NA / NA NA NA / NA NA NA 
BEST3 exon7:c.773delT:p.L258fs NA / NA NA NA NA / NA NA 
COL6A6 
exon19:c.4620delC:p.G1540fs 
NA / NA NA NA NA / NA NA 
(CP subtypes are dip= diplegia, quad= quadriplegia, hemi= hemiplegia; / = De novo variant present; and NA= De novo variant absent). 
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Table 3.11: Continued. 





















NA / NA NA NA / NA NA NA 
ASTE1 exon7:c.1969delA:p.R657fs NA / / NA NA NA NA NA NA 
TTC13 exon12:c.1339delC:p.L447fs NA / / NA NA NA NA NA NA 
LYST exon40:c.C9558A:p.Y3186X NA / NA / NA NA NA NA NA 
ANKRD36 
exon19:c.C1441T:p.Q481X 
NA NA NA / NA NA NA NA NA 
DLL1 :c.C663A:p.C221X / NA NA NA NA NA NA NA NA 
CEP164 exon5:c.337dupA:p.K113fs NA / NA NA NA NA NA NA NA 




4.1 General Discussion 
NGS specifically WES technology is widely used as a diagnostic tool for diseases and 
disorders, varying from single gene disorders to the more complex genetic disorder of 
cancers and traits (Majewski et. al., 2011). Bioinformatics analysis helps in discovering 
the variants in WES data, and in our study, we applied the GATK pipeline, a standard 
bioinformatics pipeline for the germline variants case. The multi-filtering against the 
public databases such as dbSNP, 1000 Genome Project and HapMap helped to produce 
the initial raw data of ~172k annotated variants. For the data interpretation and analyses 
purpose, this Annovar output was then displayed in an excel file format. 
 
Our Bioinformatics analysis yielded a number of variants found in various regions as 
the following: exonic (~73k), UTR (~84k), Splice site (93), Upstream (113), 
Downstream (109), intronic (579), and other known regions (~13k). From this 
premature raw bioinformatics data, further interpretation was done according to the 
criteria of variant selection as described in the Figure 3.12. Genetics of CP has not yet 
been established in Malaysia, thus we decided to prioritize our data filtering on the 
exonic region only. Exons are DNA regions where multiple specific proteins are 
encoded. Besides that, there are two types of variants we are currently focusing on. 
Firstly, the inherited variant type, a situation where a particular variant is observed to 
be shared by all subjects including affected children and unaffected parents per family. 
Secondly, the sporadic variant type, a situation where variants are scattered among the 
CP subjects only. These sporadic variants are present only in the affected children for 
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the first time in a family but absent in the normal parents, thus they are considered as 
de novo mutations. This study revealed 37 novel variants from 29 genes that are present 
in our subjects including both CP children and unaffected parents, whereby each subject 
is shown to be having multiple mutations. Only the mutated ANKRD36 has both types 
of variant which are sporadic (n=1) and inherited (n=2) variants. Meanwhile, the other 
28 genes have only one variant (n=1) type whether it is a sporadic or inherited variant 
type accordingly. There are eight inherited variants from five genes which are 
ANKRD36 (n=2), CTBP2 (n=1), CTDSP2 (n=2), FAM104B (n=2) and KRTAP19-6 
(n=1). All of these CP subjects together with all the unaffected parent subjects are 
sharing all the same eight inherited variants regardless of their different CP phenotypes. 
For the record, six of inherited variants are classified as Likely Pathogenic variants 
whereas the other two inherited variants are classified as Uncertain Significance 
according to the ACMG classification criteria (Richard et. al., 2015). The details for 
this inherited variant classification criteria will be highlighted in the subsequent 
paragraphs per gene and variant respectively. 
 
Meanwhile, there are 29 de novo (sporadic) mutations from 25 genes (ANKRD36 (n=1), 
ANO5 (n=1), ASTE1 (n=1), BEST3 (n=1), CDKL2 (n=1), CEP164 (n=1), COL6A6 
(n=1), COL7A1 (n=1), CYHR1 (n=1), DCHS2 (n=1), DLL1 (n=1), DNAH17 (n=1), 
FAM163A (n=1), FXR2 (n=1), GLYR1 (n=1), GPR97 (n=1), HLA-DRB1 (n=4), HLA- 
DRB5 (n=1), KCNK18  (n=1), KCNQ3 (n=1), LYST  (n=1), MAPRE3 (n=1),  
MUC16(n=2), TTC13 (n=1) and RBMX (n=1)). These 29 sporadic variants they are all 
Likely Pathogenic according to ACMG classification guideline as they fulfilled two 
criteria of “a null variant” and “assumed as de novo but without paternity and maternity 
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confirmation test”. None of the sporadic variants have been uniformly shared by all the 
affected subjects, either among CP subjects with the same phenotypes nor between the 
monozygotic twins in Family 4. However, a pair of sibling with different phenotypes in 
Family 5 (B5-1_S7 and G5-2_S10) share three de novo mutations which are frameshift 
deletion in MUC16 of exon56:c.40674_40677del:p.K13558fs, frameshift insertion in 
MUC16 of exon56:c.40672_40673insTCGG:p.K13558fs and frameshift insertion in 
KCNK18 of exon3:c.361dupT:p.G120fs.  
 
For the purpose of checking the status of all the variants reported, we used the online 
Leiden-Open Variant Database (LOVD) available at https://www.lovd.nl to check 
whether or not these specific variants had been reported before. This status checking 
step was done repeatedly as this LOVD database is regularly updated. The LOVD is a 
reliable database and has been used in many studies to check for the locus specific 
variant reported. Its system of locus-specific databases (LSDBs) is maintained 
according to the Human Genome Variation Society (HGVS) recommendations 
(Fokkema et. al., 2005; Fokkema et. al., 2011). All the eight inherited variants found in 
our study are previously not reported to be related to CP and are also not available in 
LOVD, indicating that these variants are new and have never been reported to be 
associated with any diseases or disorder previously. Similar with the inherited variants, 
all of sporadic variants are also not found to be associated with CP previously. Almost 
all of them are also not reported in LOVD except for two variants of 
g.135956571_g.135956572insG RBMX mutated gene and 
g.32552137_g.32552138insA HLA-DRB1 mutated gene. With such result summary, we 
can clearly see that there is no definite pattern of correlation between these 37 variants 
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and CP phenotypes due to limited variants analysis available in this study. Plus, 
throughout the literature, none of these 37 variants has been reported to be contributing 
to the CP pathology. However, we noticed that a few genes belong to the CNS-related 
genes category (~31.03%), immune system-related genes category (~31.03%), 
potentially immune-related genes category (~10.34%) and other category genes 
(~27.59%). We are anticipating that these immune- and CNS-related genes are 
implicated in our CP subjects. This assumption is supported by two evidences which 
are the CP definition itself and the association of autoimmune disease with CP. CP as a 
chronic disability of CNS origin (Grether et. al., 1992) is also discovered to be 
associated with autoimmune disorder whereby autoimmune plays important role in CP 
etiology (Nelson et. al., 1998). This literally opens up for more potential studies in the 
future since all of these variants have never been previously reported to be CP related 
variants/genes. Since these 37 variants of 29 genes that we discovered in our CP data 
have never been reported before, they will be discussed in more detail based on specific 
gene categories instead of dissecting strictly only on the obtained novel variants, by 
expecting at least some plausible pathway or mechanism of any genes related that might 
have potential to be associated with CP. 
 
4.2 CNS-related Genes Category 
For the CNS-related genes category, there are nine genes that are implicated in our data. 
Eight of them are CDKL2, CEP164, FAM104B, FAM163A, FXR2, KCNK18, KCNQ3, 
MAPRE3 and RBMX in which each gene shows one de novo mutation (n=1). Meanwhile 
another gene is FAM104B with two inherited variants (n=2). CDKL2, also known as 
protein kinase P56  KKIAMRE is discovered with only one sporadic frameshift  variant, 
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exon3:c.222dupA:p.R75fs (4q21.1) that is present in two subjects i.e B1-1_S1 
(diplegia) and B4-T2_S2 (hemiplegia). This gene was found to be expressed in human 
fetal brain (Taglienti et. al., 1996; Fang et. al., 2018). It was also discovered as a member 
of CDC2-related serine/threonine protein kinases family (Milanesi et. al., 2005). This 
CDKL2 together with the other CDK domains are localized at the base and/or tip of 
primary (non-motile) cilia which are directly involved in regulating primary cilia length 
and function by influencing the Intraflagellar Transport (IFT) activity (Niwa et. al., 
2012; Canning et. al., 2018). Besides CDKL2, CEP164 is identified as a marker for the 
primary cilia structure formation and it is localized at the matured centriole (Graser et. 
al., 2007). CEP164 expression occurs throughout the brain development (Devlin et. al., 
2020). In our study, a variant of CEP164 of frameshift insertion, 
exon5:c.337dupA:p.K113fs (11q23.3) is present in B1-3_S4 (quadriplegia). Primary 
cilia that are found in most eukaryotic cells including neurons, play essential roles in 
cell signaling, human sensory physiology, and development (Oh et. al., 2012; May- 
Simera et. al., 2012; Mukhopadhyay et. al., 2014).  
 
It is also significant for cerebellar sonic hedgehog (Shh) dependent expansion (Spassky 
et. al., 2008; Boddaert, et. al., 2010) that has multiple roles during brain development 
(Ingham et. al., 1998; Spassky et. al., 2008), this includes the importance of primary 
cilia during the embryonic development (Wheway et. al., 2018). Based on many studies 
that showed the significance of primary cilia in brain development, we suspect that any 
mutations in CDKL2 and/or in CEP164, could affect its role in regulating primary cilia 
function and structure which can result in primary cilia defect. This defect could be a 
potential pathomechanism which might lead to CNS defect. This assumption is 
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supported by the finding of primary cilia dysfunction that has been shown to cause CNS 
defect (Lee et. al., 2011), which indirectly reminded us of CP as a CNS disability origin. 
Furthermore, the primary cilium is classified as a cell structure and metabolism 
organelle, therefore the deficiency in this organelle because of the gene error may 
contribute to metabolic problem which is also a part of CP comorbidities (Gupta et. al., 
2001). Further functional studies of these CDKL2 and CEP164, CNS-related genes in 
our CP data are suggested since not many studies are found for CP related genes, plus 
both variants detected in our study are not reported in LOVD, indicating that they are 
new variants. Apart from CP, this CDKL2 was also discovered as a novel promoter of 
breast cancer progression (Li et. al., 2014) while CEP164 was discovered as 
nephronophthisis related gene (Chaki et. al., 2012; Slaats et. al., 2014). Both are 
epithelial-mesenchymal transition (EMT) related genes (Li et. al., 2014; Slaats et. al., 
2014). 
 
FAM104B has two inherited variants in our data which are 
exon3:c.182_183insA:p.S61fs (frameshift deletion) and exon3:c.179delC:p.A60fs 
(frameshift deletion) at Xp11.21 chromosome band. Both variants are present in all 
affected children and unaffected parents. These variants are classified as Likely 
Pathogenic according to ACMG classification standard guideline (Richard et. al., 2015) 
and have never been reported in LOVD showing they are new variants. However, 
currently it seems that the variants have been reported but are not related to the 
development of CP. According to Non-Human Primates Reference Transcriptome 
Resource (NHPRT project), this gene was reported in NCBI database as ubiquitously 





FAM163A with a sporadic frameshift variant of exon5:c.400delC:p.P134fs (1q25.2) is 
present in B4-T2_S2 (hemiplegia) and G5-2_S10 (diplegia), whereby the variant was 
not reported previously. This gene is also known as Cebelin or neuroblastoma derived 
94 secretory gene (NDSP) which is located at chromosome band 1q25.2 that encodes 
for 167AAs protein with a putative signal peptide and previously was shown to be 
associated with neuroblastoma cases (Vasudevan et. el., 2009). A study by Miwa’s team 
(2018) showed that mouse Cebelin gene is actually an ortholog of the human Cebelin 
gene. They found that human cebelin amino acid (AA) sequence (167 AAs) with a 
putative secreted signal sequence (30 AAs) is almost similar to mouse cebelin protein 
by ~85% AA identity. This gene expression in the cerebellum is influenced by its own 
encoded cellular protein (167 AAs) (Miwa et. al., 2018). Thus, we anticipate that the 
mutation in this gene might influence its expression in the cerebellum which later may 
affect cerebellum role as a motor system central component that is closely related to 
muscle tone, motor activity coordination and posture (Stoodley et. al., 2009) whereby 
these three mentioned motor systems are related to CP clinical features. No specific 
publication on these variants’ expression is found. Throughout previous studies that 
used NGS technology, FAM104B was shown to be related with some diseases, for 
example in the novel X-linked syndrome (Barboza et. al., 2013) and prostate cancer 
(Gambhira et. al., 2015). However, these NGS studies did not discuss in detail the 
function and pathophysiology of this gene. This gene function remains unknown 
(Barboza et. al., 2013; Kulecka et. al., 2017). Similar to the aforementioned studies, our 
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current preliminary analysis study cannot prove that the FAM104B gene is associated 
with CP as available information is limited. The FAM104B variants may have essential 
roles in CP diagnostic and/or prognostic. Further functional analysis studies are 
therefore needed in the future. Fragile X Mental Retardation 1 Autosomal Homolog 2 
(FXR2) gene was found to be expressed in brain, testis and prenatal tissue (Tamanini, 
et. al., 1997; Agulhon et. al., 1999). In our data, this CNS-related gene with a de novo 
mutation at exon1:c.25delG:p.D9fs of chromosome band 17p13.1 is present in B1-3_S4 
(quadriplegia) and B5-1_S7 (diplegia). This variant is not reported previously. 
Throughout the literature, the FXR2 role was found as a homolog to Fragile X Mental 
Retardation 1 (FMR1) gene, in which its protein will form a protein family with FMR1 
and FMR1 Autosomal Homolog 1 (FXR1) by structure and function. This interaction 
among these genes is related to Fragile X syndrome pathogenesis (Zhang et.al., 1995).  
 
Molecularly, with 60% identity that is similar to an unknown specific function FMR1 
gene, this FXR2 encodes a 74 kDa FXR2 novel protein which contains two KH domains 
that has RNA binding capability and is cytoplasm-localized just like FMR1 (Zhang et. 
al., 1995). The previous data was only showing the peripheral function of FXR2 as a 
homolog that supports the main functional gene, whereas the publication on its main 
function has been hardly found. Hence the FXR2 knockout study was done using mouse 
model that showed the FXR2 knockout mice was hyperactive, had motor coordination 
impairment, prepulse inhibition reduction and less sensitive to heat stimulus. These 
were collectively classified under CNS function (Bontekoe et. al., 2002). Other than 
that, microdeletion in FXR2 has been reported to be associated with disorders of 
dysmorphic features and developmental delay (Kumari et. al., 2019). Therefore, we 
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suspect that any pathogenic or possibly pathogenic mutations that happen to FXR2 
might impact its role in CNS which later may lead to CP specifically on developmental 
delay and motor coordination impairment. 
 
In our study, this KCNK18 shows a de novo mutation of exon3:c.361dupT:p.G120fs at 
10q25.3 that is present in both diplegic affected children of Family 5, BS-1_S7 and G5-
2_S10. This new variant has not been reported in LOVD. Previously KCNK18 was 
found to be associated with migraine with aura disease (Lafrenière et. al., 2010). Its 
function is to encode for the tandem of pore domains in a weak inward rectifying K+ 
channel (TWIK)-related spinal cord potassium (K+) channel (TRESK), a member of 
K+ channel superfamily proteins that contains two pore-forming P domain K+ (K2P). 
TRESK protein functions as an outward rectifying K+ channel and a background K+ 
channel that sets the resting membrane potential in spinal cord (Sano et al., 2003; 
Enyedi et. al., 2010). These K+ channels involve in many cellular processes such as the 
action potential maintenance (Maljevic et. al., 2013), muscle contraction (Petkov G. V., 
2011), hormone secretion (Ashcroft et. al., 2005; Cherki et. al., 2006; MacDonald et. 
al., 2006; Stojilkovic et. al., 2017), osmotic regulation (Andronic et. al., 2013; Xu et. 
al., 2016) and ion flow (Waxman et. al., 2014). The background K+ currents stabilize 
the negative resting membrane potential and counterbalance depolarization (Enyedi et. 
al., 2010). The hyperpolarization of resting membrane potential affects the individuals’ 
excitability properties (Klein et. al., 2015). This is consistent with other studies that 
showed CP individuals having hyperexcitable motoneurons (Barolat-Romana et. al., 
1980; Futagi et. al., 1985; O’Sullivan et al., 1998; Tekgul et al., 2013). By definition, 
hyperpolarization is a condition that makes the neuron to less likely transmit an impulse 
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(Martin et. al., 2008). Further study is suggested to investigate any effects of KCNK18 
mutation on its spinal cord background K+ channel function in setting up the resting 
membrane potential which might be responsible for hyperpolarization condition 
resulting in motor neuron impairment in CP. In our CP data, the KCNQ3 has a sporadic 
variant of exon12:c.1599delA:p.K533fs, a frameshift mutation at 8q24.22 that is 
discovered in B4-T1_S1 (diplegia) and G5-2_S10 (diplegia). KCNQ3 protein is 
expressed in the brain (Kanaumi et. al., 2008). This gene encodes for a subunit protein 
which later cooperates with another subunit encoded by KCNQ2 to make up the M- 
channel (current) (Wang et.al., 1998). The M-current regulates the neuron excitability 
and synaptic responsiveness (Brown D.A., 1988; Yamada et. al., 1998), which 
participates in behavior and cognition (Rutecki et. al., 1992).  
 
Thus, we anticipate that the mutation in KCNQ3 gene might affect its subunit protein 
function which later contributes to abnormal excitability resulting in brain electrical 
activity changes that lead to features of behavior and cognition problems in CP patients. 
This assumption is supported by a study by Klein and team (2015) that showed the 
neuron excitability in CP patients was found to be abnormal than the normal individuals, 
as explained earlier in KCNK18 part. Other than that, the mutation in either KCNQ2 or 
KCNQ3 genes was shown to cause inherited autosomal epilepsy (Lewis et. al., 1993; 
Biervert et. al., 1998; Charlier et. al., 1998; Singh et. al., 1998) and familial epilepsy 
(Miceli et. al., 2015), whereby epilepsy is a CP comorbidity with highly association 
(Knezević-Pogancev et. al., 2010). Several studies had shown that epilepsy is 
commonly present in hemiplegia and quadriplegia types of CP (Hadjipanyis et. al., 
1997; Kwong et. al., 1998; Odding et. al., 2006). However, this is slightly different to 
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our data when this KCNQ3 mutation is found in diplegia subjects instead of hemiplegia 
and quadriplegia. Therefore, more studies should come later to verify the KCNQ3 
mutation whether or not it contributes to epilepsy in CP and larger sample size is 
suggested for the purpose of analyzing the association between epilepsy and diplegia 
types of CP. 
  
MAPRE3, a gene that is previously reported to be associated with pulmonary 
hypertension (Atwal, 2017). It is expressed in the brain (Su et. al., 2001). Our result 
shows there is only one sporadic variant of MAPRE3 which is 
exon5:c.536delC:p.A179fs (2p23.3) that is present in three diplegic subjects of different 
families, B1-1_S1, B4-T1_S1 and G5-2_S10. This specific variant is not recorded in 
LOVD indicating it is a new variant. MAPRE3 expresses RP/EB protein family that 
promotes microtubules growth rate, whereby microtubules are involved in the spindle 
function (Yang et. al., 2017a). Spindle formation requires microtubules network to 
constantly alter its dynamics and organization as a cell supporting network during the 
cell division process. Microtubules as a cytoskeleton unit relatively acts together with 
the actin filaments as the intracellular transport tracks throughout the neuron (Nirschl 
et. al., 2017) and interacts with motor protein by binding to myosin and kinesin 
respectively (Woehlke et. al., 1997). In accordance to that, we assume that any possible 
mutations in KCNQ3 might affect the RP/EB protein expression which later may lead 
to malfunction of microtubules. Microtubules deficiency may contribute to poor 
binding interaction with kinesin and myosin motor proteins, resulting in interrupted 
function of intracellular transport tracks. This is supported by a study that showed 
implication of intracellular trafficking defect on an amyotrophic lateral sclerosis (ALS) 
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neurodegenerative disorder, a disorder which shares some common features with CP on 
limb paralysis and brain plasticity (Soo et. al., 2011). Besides that, the interrupted 
binding interaction between motor proteins and microtubules due to kinesin 
malfunction had shown to be contributing to neurodegenerative diseases called 
hereditary spastic paraplegia (HSP) (Reid et. al., 2002). HSP is a condition which 
appears as the most sensitive to the underlying mutations, where it is actually the result 
of degeneration of the longest motor and sensory axons on the spinal cord (Crosby et. 
al., 2002). Hence, we suspect that the mutation of the genes which encode for any of 
myosin, kinesin or microtubules itself might interrupt that binding interaction between 
them which then lead to dysfunctional motor protein in intracellular trafficking 
function. In parallel to that, further study is suggested in validating the implication of 
MAPRE3 mutation on microtubules growth rate, which might be contributing to CP 
features such as limb paralysis and brain problem.  
 
Heterogeneous Nuclear Ribonucleoprotein G (hnRNPG) or also called as RBMX with 
a sporadic variant of exon9:c.905_906insCC:p.P302fs at Xq26.3 is found in B1- 3_S4 
(quadriplegia) and B4-T1_S1 (diplegia). This variant is reported in LOVD database and 
marked by a clinical team of University of Medical Center, Netherland, however there 
is no class clinical reported plus it is recorded as “unpublished data”. RBMX is 
ubiquitously expressed in many organs such as brain, lung, heart, skeletal muscle, liver, 
pancreas, kidney, small intestine, colon, spleen, thymus, leukocytes, prostate, placenta, 
ovary, and testis (Lingenfelter et. al., 2001; Nasim et. al., 2003). From a study on RNA-
binding motif, Y chromosome gene (RBMY), it showed that human genome RBMX is a 
homologue to RBMY (Delbridge et. al., 1999). Both genes encode for RNA binding 
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protein that is involved in splicing (Soulard et al. 1993; Delbridge et al. 1999; Venables 
et al. 2000). A study by Tsend-Ayush et. al., 2015 showed that zebrafish rbmx cDNA 
(human RBMX orthologue) plays an essential role in the brain development whereby its 
loss of function leads to the Zebrafish brain morphology defect. Thus, any alterations 
in RBMX is suspected to influence RNA binding protein expression, whereby the RNA 
binding protein is involved in the transcriptional regulation (Omura et. al., 2009) and it 
plays important roles in the CNS (Sharifnia et. al., 2015). Further study on human 
RBMX protein functional study is suggested to confirm its association in any possible 
CNS defects especially in the brain. For additional information, RBMX was implicated 
in other cases such as cancer and viral infection (Elliot et. al., 2019) and also in human 
systemic lupus erythematosus (SLE) disease (Soulard et al., 2002). 
 
4.3 Immune-related Genes Category 
The immune system-related gene category includes nine genes (COL6A6 (n=1), 
COL7A1 (n=1), CYHR1 (n=1), DLL1 (n=1), GPR97 (n=1), HLA-DRB1 (n=4), HLA-
DRB5 (n=1), LYST (n=1) and MUC16 (n=2)) that are present in our CP data which are 
all 13 de novo mutations, indicating that these alteration are present in the CP subjects 
only. In our study, COL6A6 at chromosome band 3q22.1 of a de novo frameshift 
mutation of exon19:c.4620delC:p.G1540fs is present in two subjects of B1-3_S4 
(quadriplegia) and B4-T2_S2 (hemiplegia). This variant has never been reported. 
COL6A6 was found to be widely expressed in human body such as fetal and adult lung, 
kidney, liver, spleen, heart, skeletal muscle (Fitzegerald et. al., 2008) and skin (Sabatelli 
et. al., 2011; Soderhall et al., 2007). COL6A6 that has 36 exons and a coding region of 
6789bp is responsible to encode for a 2262-amino acid (alpha 6 chain) (Fitzegerald et. 
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al., 2008). Collagen VI (COL6) takes part as a connective tissue component by allowing 
the appropriate connection between muscle cells and extracellular matrix (ECM) 
through its binding to collagen IV and perlecan in the basal lamina (Kuo et. al., 1997). 
Despite its expression could be found abundantly in matrix of tissues and was also 
discovered to be associated with basement membranes, the precise role of COL6 with 
alpha chain 1 to 6 (α1 to α6) is still not clearly defined (Fitzegerald et. al., 2013). 
However, its presence in skeletal muscle was proven to be functionally impactful when 
the defect in its protein expression was pathogenically causing collagen VI-related 
myopathies, a subgroup of neuromuscular disease which is an autoimmune disorder 
(Tagliavini et. al., 2014; Hunter et. al., 2015). With its implication in our study data, we 
anticipate that besides contributing to skeletal muscle impairment, it may also develop 
a possibility of immune disease as secondary condition in CP individuals. 
 
Next, COL7A, with a sporadic variant of exon69:c.5749delG:p.E1917fs at 3p21.31 
chromosome band is present in diplegic subjects (B2-2_S5 and B4-T1_S1). This 
COL7A1 with the large exon number of 118 exons encodes for a 290 kDa α chain that 
makes up the collagen VII (COL7) (Christiano et. al., 1994b), making up a major 
component of the skin basement membrane component called anchoring fibrils (Chung 
et. al., 2010). COL7A1 was found to be expressed in the skin (Christiano et. al., 1994b), 
pituitary gland, pineal gland and choroid plexus (Paulus et. al., 1995). Multiple 
mutations in COL7A1 were previously found to be causing dystrophic epidermolysis 
bullosa (DEB), a disease of a fragile and vulnerable skin condition that occurs when the 
epidermis is not attached to the layer beneath it called dermis. This is due to the failure 
function of protein that is expressed by COL7A1 that is supposedly to act as an adhesive 
167 
agent which binds these two mentioned skin components (Christiano et. al., 1994a; 
Hovnanian et. al., 1997; Massé et. al., 2005; Uitto et. al., 2005). The DEB is an inherited 
skin disease named Epidermolysis Bullosa (EB), in which multiple COL7A1 mutations 
were found to be contributing to both dominant DEB andrecessive DEB types (Varki 
et. al. 2007). A study showed that interleukins and cytokines were both associated with 
COL7 regulation and their expression level were significantly high in DEB patients 
indicating the potential of autoimmune disease development (Esposito et. al., 2016). 
Other than that, cytokines level was significantly correlated with the skin lesion 
(Ludwig et. al., 2011). Despite our COL7A1 variant of c.5749delG is not reported as 
one of those COL7A1 mutations that caused autoimmune disease of DEB, however the 
aforementioned pathological information earlier gives us a notion that the presence of 
COL7A1 mutation in CP may also develop a potential comorbidity of immune disease 
in CP patients and it also might be a possible contributing gene for skin lesions problem 
in CP individual. Plus, the COL7 via animal model study was shown to be involved in 
autoimmune reaction (Woodley et. al., 2007; Ishii et. al., 2011).  
 
CYHR1 which is also known as Cysteine and Histidine Rich (CHRP) gene had never 
been found in any CP cases before. However, in our study, this protein coding gene 
with a sporadic frameshift deletion of exon2:c.430delG:p.A144fs is found in diplegic 
G2-1_S8 and B4-T1_S1. Through a study of two yeast hybrid systems, this gene was 
first discovered to be prominently localized in cytoplasm and perinuclear and its 
function is to assist in intracellular trafficking by binding itself to a galectin-3 molecule 
in a carbohydrate- independent manner in order to direct the lectin into the nucleus or 
into secretory pathways (Menon et. al., 2000). Similar to intracellular trafficking case 
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that has been discussed in MAPRE3 part in the CNS category (section 4.2), we suspect 
that, any defect in CYHR1 will also affect its protein binding activity, which then may 
lead to dysfunctional motor protein that contribute to CP features of limb paralysis. As 
an additional information, this CYHR1 was reported to be implicated in tumors with 
high microsatellite instability (Kim et. al., 2013). Besides that, CYHR1 mRNA 
expression was shown to be associated with lymph node metastasis (Desaki et. al., 
2017). It is well-known that the lymph node is a part of the immune system in human 
body (Cottier et. al., 1973). Thus, we consider this finding of CYHR1 as another 
immune-related gene that has the potential of being explored further in terms of its role 
in CP- immune disease association. This will indirectly increase the number of CYHR1 
study record for the future genomic database. Another immune-related gene found in 
our CP data is the DLL1 which is also known as Delta 1 at chromosome band 6q27, 
with a sporadic stopgain mutation of exon4:c.C663A:p.C221X that is present in 
diplegic B1-1_S1. This variant has never been reported in LOVD and none of the 
previous studies shows this gene to be associated with CP.  
 
This DLL1 with expression in bone marrow and dendritic cells (Sugimoto et. al., 2010; 
Huang et. al., 2011; Kelliher et. al., 2018) is encoding for the delta-like 1 ligand that has 
a binding interaction with the notch 3, one the four notch family receptors (Maekawa 
et. al., 2003; Amsen et. al., 2004; Mehrotra et. al., 2012). This notch-delta ligand 
binding induces its signaling function, which is well known as the conserved pathway 
in regulating cell differentiation and cell fate decisions (Greenwald, 1998; Artavanis-
Tsakonas et al., 1999; Jaleco et. al., 2001; Gridley T., 2003). The delta 1-notch 3 binding 
is known to be involved in immune system development of T-cells and B-cells (Jaleco 
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et. al., 2001). Another study also showed this binding interaction plays an important 
role in type 1 helper T cell (Th1) development, a crucial cell that is involved in 
immunity system (Maekawa et. al., 2003). Few studies showed that DLL1 alteration 
affects its ligand binding interaction with the notch 3 resulting in perturbed immunity 
responses and made it susceptible to visceral leishmaniasis, a fatal parasitic disease 
(Jamieson et. al., 2007; Miller et al., 2007; Fakiola et. la., 2011; Mehrotra et. al., 2012). 
With all the above details, it is clearly shown that DLL1 is an impactful immune-related 
gene, thus we presume that any alterations in its gene sequence may trigger an immunity 
problem in CP disorder as well since it is implicated in our CP data. The next immune-
related gene in our CP data is the GPR97 or also known as an orphan Adhesion G 
Protein-Coupled Receptor G3 (ADGRG3) that is present in diplegic (B2- 2_S5 and B5-
1_S7) with a sporadic frameshift insertion of exon9:c.1022dupG:p.R341fs at 16q21. 
This gene protein is expressed in B cells, thymocytes (Sleckman et. al., 2000) and 
granulocytes (Hsiao et. al., 2018). GPR97 protein is one of Adhesion G Protein-Coupled 
Receptor (GPCR) members. The Adhesion GPCR group is the second largest subgroup 
of GPCR groups that contains 33 members that are characterized by their unique 
combination of cell adhesion and signaling properties (Bjarnadóttir et. al., 2007). The 
GPR97 that was previously known as Pb99 was first isolated from a cDNA library 
derived from pre-B cells and thymocytes of mouse, this study was initially focusing on 
its potential function in the early lymphoid development. Nevertheless, they found out 
that the GPR97 loss of function had no effect on in vivo B and T cell maturation, which 
automatically indicated that there was likely a functional redundancy with another 
protein (Sleckman et. al., 2000). Hence, GPR97 functional study was continued by the 
other teams, which discovered its roles to regulate the B-cell development and 
lymphatic endothelial cells (LECs) migration (Wang et. al., 2013; Valtcheva et. al., 
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2013). The loss of function of GPR97 was shown to be causing the imbalance ratio of 
cell division cycle 42 (Cdc42) protein and Ras homolog family member A (RhoA) 
protein levels, which is enhancing the LECs migration (Valtcheva et. al., 2013). This 
migration of LECs is important for vessel growth (lymphangiogenesis) and vessel 
remodeling processes. These two processes are responsible in modifying the lymphatic 
network in response to developmental or pathological demands (William et. al., 2017). 
Another study showed its role in regulating the antimicrobial activity in human 
granulocytes via its ligation by the immobilized Immunoglobulin G1 (IgG1) or 
monoclonal antibody G97-A mAb (Hsiao et. al., 2018). To date, we do not find any 
published papers showing this gene as a causative gene which is associated with any 
diseases or disorders. Instead, a recent study showed the GPR97 is a potential 
therapeutic tool for the autoimmune disease (Wang et. al., 2018). It is well known that 
the GPR97/ADGRG3 role is actively involved in the immune system, however there is 
a review paper which proposes that the Adhesion GPCRs groups also play roles in CNS.  
 
According to in vivo reverse transcriptase-PCR (RT-PCR) study involving a large 
number of rat tissues for all the adhesion GPCRs, it showed that a large number of the 
newly discovered adhesion GPCRs members were abundantly expressed in CNS tissues 
(Bjarnadóttir et. al., 2007). Therefore, we would suggest for further characterization 
study to be done for this immune-related gene of GPR97 to confirm whether or not it is 
involved in CNS besides its capability as therapeutic tool for autoimmune disease. 
Following that, other immune-related genes that are implicated in our CP data are HLA-
DRB1 and HLA-DRB5 at 6p21.32. Shown in our data is the HLA-DRB1 with four 
sporadic variants which are one frameshift insertion and three frameshift deletions. The 
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frameshift insertion of exon2:c.118_119insT:p.P40fs and all the frameshift deletions of 
exon2:c.115delC:p.Q39fs, exon2:c.111delG:p.L37fs, exon2:c.109delC:p.L37fs are 
present in diplegic G2-1_S8 and hemiplegic B4-T2_S2. Meanwhile, there is only one 
frameshift deletion of HLA-DRB5 sporadic variant of exon2:c.171_172del:p.H57fs that 
is present in quadriplegic B1-3_S4 and diplegic B4-T1_S1. These HLA-DRB1 and 
HLA-DRB5 are known to be expressed in immune cells. The polymorphic HLA- DR is 
one of the molecules encoded by MHC class II which is expressed as α and β chain 
heterodimers (glycoproteins) on the cell surface. The glycoproteins are involved in 
binding and presentation of extracellular proteins peptides to T cells (TCRs) of T 
lymphocytes, whereby this activity is responsible to mediate the responses of cell-
mediated immune and humoral (Cullen et. al., 1997; Van den Elsen et. al., 2011; Van 
den Elsen et. al., 2004).  
 
For the record, this HLA-DRB1 is the first genotype identified to be the most potential 
genetic risk factor for rheumatoid arthritis (Gregersen et. al., 1987; Diogo et. al., 2014). 
HLA-DRB1 was also found to be associated with several immune diseases such as 
multiple sclerosis (Marrosu et. al., 2001; Rubio et. al., 2002; Dyment et. al., 2004) and 
systemic juvenile idiopathic arthritis (Ombrello et. al., 2015). However, its high 
expression in B-cells also was discovered to regulate the Chemokine Receptor Type 4 
(CXCR4) expression on memory T helper cells (CD4+ T). This indicates that it has a 
potential of becoming therapeutic target for rheumatoid arthritis (Nagafuchi et. al., 
2016). Meanwhile for HLA-DRB5, it was reported to be associated with scleroderma-
related interstitial lung disease with high expression in peripheral blood mononuclear 
cell (Odani et. al, 2012), human systemic lupus erythematosus (SLE) (Wu et. al., 2013) 
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and amyotrophic lateral sclerosis (ALS) (Yang et. al., 2017). The HLA-DRB5 variant in 
this study is a new variant since it has not been reported in LOVD. Meanwhile, one of 
four HLA-DRB1 mutations (c.118_119insT) is clinically classified as benign in in 
LOVD, however there is no further information available. According to ACMG 
guidelines (Richard et. al., 2015), all of these sporadic variants of HLA-DRB1 and HLA-
DRB5 are classified as likely pathogenic. 
  
LYST is the next immune-related gene found in our CP data, with a sporadic stopgain 
mutation of exon40:c.C9558A:p.Y3186X at chromosome band 1q42.3 in B1-3_S4 
(quadriplegia) and B2-2_S5 (diplegia). As an immune-related gene, recently it was 
discovered that this gene is required for the perforin‐containing granules terminal 
maturation process into secretory, cytotoxic granules (Sepulveda et. al., 2015). This 
gene has never been reported to be involved in CP cases. Over the past two decades, 
this human LYST with 98.6% similar identity was identified as a homolog for mouse 
Beige gene, and it was also previously known as chediak-higashi syndrome 1 (CHS1) 
gene. This gene which is expressed in cytoplasm of perinuclear region is known to be 
regulating the lysosome fission (Perou et. al., 1997). Further studies was done later 
showing that it was molecularly functioning to encode for regulatory protein of 
intracellular trafficking process (Spritz R.A., 1998; Kaplan et. 2008). Chediak- higashi 
syndrome (CHS) is an autosomal recessive genetic disorder due to severe immune 
deficiency that is associated with lymphoproliferative syndrome, bleeding tendency, 
oculocutaneous albinism, and neurologic abnormalities (Spritz R.A., 1998; Introne et. 
al., 1999; Shiflett et. al., 2002; Ward et. al., 2002; Holt et. al., 2006; Kaplan et. al., 
2008).  
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The encoded regulatory protein which previously called CHS1 protein contains a 
number of smaller sequence motifs comprised of a series ARM (ARMadillo) motif to 
mediate membrane associations (Peifer et. al., 1994) and repeat motifs of "HEAT" 
(huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A) regulatory A 
subunit, yeast-kinase (TOR1)) that were associated with vesicle transport (Andrade et. 
al., 1995). Meanwhile, the C-terminal region of this regulatory protein contains seven 
consecutive motifs called WD40 domain to mediate the protein-protein interactions 
(Neer et. al., 1994). Hence, we anticipate that, the mutation in LYST might impact the 
regulatory protein structure, whereby these perturbed motifs function may influence the 
regulatory protein pathway in intracellular trafficking process. Interrupted intracellular 
trafficking process is suspected to contribute to limb paralysis in CP. This anticipation 
is supported by a study that showed a missense mutation in LYST is implicated in HSP 
(Shimazaki et. al., 2014), a disorder that has similar limb paralysis feature with CP.  
 
MUC16 at 19p13.2, was found in our CP data with two de novo mutations which are a 
frameshift deletion of exon8:c.597_600del:p.K199fs, and a frameshift insertion of 
exon8:c.595_596insTCGG:p.K199fs that are present in three diplegic CP subjects 
which are G2-1_S8 and both CP children in Family 5, B5-1_S7 and G5-2_S10. These 
variants have never been reported. Previously, it was confirmed that MUC16 expresses 
the repeating peptide Cancer Antigen (CA125) molecule, a large glycoprotein of Mucin 
family (type 1 transmembrane) (O’ Brien et. al., 2001; Felder et. al., 2014). MUC16 
which is also known as CA125 was previously discovered to be promoting ovarian 
cancer cell proliferation (Rump et. al., 2004; Bast et. al., 2011). In corneal epithelial 
cells, the MUC16-Galectin-3 interaction acts as a barrier for bacterial and viral 
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infections in ocular epithelia (Argueso et. al., 2006; Argueso et. al., 2009). It was also 
shown that at the mucosal surfaces it serves as a protective, lubricating barrier against 
the particles and infectious agents (Gunn et. al., 2016). A few in vivo studies to 
investigate MUC16 pathogenesis were done, unfortunately, there was no obvious 
functional defect shown after knocking down this MUC16 gene (Wang et. al. 2008; 
Cheon et. al., 2009), indicating that its pathological impact is still unclear. However, 
since MUC16 is implicated in our CP data, with its involvement as protective agent in 
immune activities (Felder et. al., 2014), giving us a notion that this MUC16 might has 
potential as a therapeutic target for any possible infections toward any CP patients with 
a weak immunity system.  
  
In accordance to that, further studies are suggested to be conducted to reveal the CP-
immune system association which may add a new insight to the prediction of how likely 
CP patients to be susceptible to immune disease as secondary condition to them. Besides 
that, all of these nine immune-related genes with total 13 variants are all 100% de novo 
mutations whereby they are only present in CP affected subjects while are totally absent 
in unaffected parents. Thus, we anticipate that these mutated immune-related genes 
might have potential in causing immune system problems in those CP affected 
individuals. This is supported by a study of Trisomy 21 case or also known as Down 
Syndrome (DS). This disorder is categorized as a neurological disorder, which is the 
same disorder classification as CP. However, recently this T21 chromosome aberration 
was found to be causing the immune dysregulation which may lead to chronic 
autoinflammation (Sullivan et. al., 2017). Having said that, we anticipate that besides 
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DS, CP also has the possibility of being an immune dysregulation-related neurological 
disorder. 
 
4.4 Potentially Immune-related Genes Category 
The genes (ANKRD36, DNAH17 and TTC13) with ambiguous or unknown molecular 
function and/or have less reported studies were shown to be participating in some cases 
related to immune system. These genes are grouped as potentially immune-related 
genes to distinguish them from the confirmed nine immune-related genes (section 4.3) 
according to previous reported literature. Each of DNAH17 and TTC13 has one de novo 
mutation (n=1) whereas ANKRD36 (n=2) has one de novo mutation and one inherited 
mutation. The ANKRD36 at chromosome band 2q11.2 is the only gene that is implicated 
in our CP data with both types of sporadic and inherited variants of total three different 
mutations. For inherited, its mutations are exon14:c.1183_1184del:p.A395fs 
(frameshift deletion) and exon14:c.1186_1187insTT:p.V396fs (frameshift insertion) 
that are present in all subjects including affected CP subjects and unaffected parents, 
while its sporadic mutation is a stopgain of exon19:c.C1441T:p.Q481X that is present 
in diplegic B2- 2_S5 only.  
 
More than 20 years ago, this ANKRD36 was first obtained from the human cDNA and 
fetal brain and was termed as KIAA1641 (Nagase et. al., 2000). However, it is reported 
to be upregulating in the lymph node, making itself as a biomarker for the endometrical 
cancer (Sudo et. al., 2011). Generally, the ANKRD is well known as a large group 
domain to maintain the protein-protein interactions that are involved in cell signaling, 
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nucleic acid management, cell cycle regulation, skeletal muscle development and 
immune responses (Nagase et. al., 1996; Nagase et. al., 2000; Voronin et. al., 2008; Tee 
et. al., 2010). However specifically for ANKRD36, its function is unknown (Chen et. 
al., 2016). Regardless of unknown function, this gene is reported to be associated with 
Parkinson’s (Chew et. al., 2019), and Alzheimer’s (Swaminathan et. al., 2010) whereby 
both are autoimmune diseases. Besides not knowing its molecular function, this 
ANKRD of specific domain 36 has never been reported to be associated with CP. Of 
note, the domain 15 of the same protein group (ANKRD) that is expressed by ANKRD15 
at locus 9p24.3, with its 225 kb deletion was discovered to be the causative gene for a 
familial CP in a Jewish family in a case-control study (Lerer et. al., 2005). This is giving 
us a hint that the ANKRD group and/or ANKRD36 might have an impact on CP 
pathogenesis. 
  
DNAH17 was found in our CP data with a sporadic frameshift deletion of 
exon27:c.423delA:p.K1408fs at 17q25.3 that is present in two diplegic subjects (B2-
2_S5 and B5-1_S7). This variant has never been reported in LOVD. DNAH17 expresses 
its protein called heavy chain 17 that is associated with axonemal dynein motor protein 
(Milisav et. al., 1998), a motor protein that is involved in mediating cilia or flagella 
movement by sliding the microtubules along each other (Lindemann et. al., 2010). 
DNAH17 as potentially immune-related gene is expressedin adipocytes indicating its 
involvement in adipogenesis (Sohle et. al., 2012). Adipocytes via secreting factors play 
a role in mediating the physiology of immunology process (Lefterova et. al., 2009). 
There was a recent study that showed the loss of function in DNAH17 caused isolated 
male infertility due to asthenozoospermia and they described that DNAH17 was 
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responsible to encode for a sperm-specific axonemal outer dynein arm heavy chain 
(Whitfield et. al., 2019). No paper that describes DNAH17 mechanism in human body 
to be associated with CP pathology has been found, thus further DNAH17 pathogenesis 
study is suggested. Another suggested potential future analyses would be the DNAH17 
implication in immune system pathway. Next potentially immune-related gene is 
known to be encoding for tetratricopeptide repeat domain protein 13. This TTC13 of 
1q42.2 in our CP data is present with a sporadic frameshift deletion of 
exon12:c.1339delC:p.L447fs in B1-3_S4 (quadriplegia) and B2- 2_S5 (diplegia). For 
the purpose of knowing its pathogenesis potential and molecular function, we browsed 
through several reliable databases such as PubMed, Genecards, Uniprot and Google 
Scholar search engines. Unfortunately, unlike the other genes that are described before, 
this TTC13 entry is hardly found.  
 
Thus, we did not manage to collect information for this gene molecular function. We 
expect either this gene has not widely been studied or maybe its previous studies have 
not been published publicly. However, an in vivo study showed that TTC13 protein was 
highly expressed in kidney, liver and moderately expressed in the spleen, lymph node, 
T and B cells, which led to an assumption of this TTC13 may has a role in the immune 
system (Shannon, 2012, https://mospace.umsystem.edu/xmlui/handle/10355/43184). 
Based on these threegenes that are grouped under potentially immune-related genes, we 
suggested for more studies in order to confirm their role in immune system and their 




4.5 Other Gene Categories   
These categories in the current study database would certainly covers eight genes. There 
are five genes with one sporadic variant (n=1) which are ANO5, ASTE1, BEST3, DCHS2 
and GLYR1 and three genes with inherited variants are CTBP2 (n=1), CTDSP2 (n=2) 
and KRTAP19-6 (n=1). ANO5 found in our CP data with a stopgain mutation of 
exon20:c.C2295A:p.Y765X at 11p14.3 is present in two diplegic subjects (B1-1_S1 
and G5-2_S10). Via an animal study model, it is shown that this gene is expressed in 
skeletal muscle in the esophagus (Song et. al., 2014). As for its functional mechanism, 
it is reported to be involved in cellular structure and metabolism due to its active 
involvement in intracellular calcium activated chloride channel activity (Hartzell et. al., 
2009). This gene nor its variant has never been reported to be associated with CP. Apart 
from that, its recessive mutation was also reported to be the causative variant for 
proximal limb-girdle muscular dystrophy (LGMD2L) and distal non-dysferlin miyoshi 
myopathy (MMD3) (Bolduc et. al., 2010). 
 
Next is the ASTE1 which is also a cellular structure and metabolism gene. Its novel 
frameshift mutation of exon6:c.1894delA:p.R632fs of 3q22.1 has never been reported. 
A functional study was done for this gene that is expressed in using the drosophila 
model, whereby the finding showed that this gene is involved in epidermal growth 
factor (EGF) signaling (Kotarski et. al., 1998; Stelzer et. al., 2016). The EGF signaling 
is a pathway that controls various biologic responses such as cell proliferation, cell 
differentiation and cell motility signaling (Oda et. al., 2005). For the current record, this 
gene was found to cause plantar fibromatosis disease (Zaragoza et. al., 2017). Another 
cellular structure and metabolism gene is DCHS2 that encodes for a photocadherin 
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protein (Hong et. al., 2004). This gene with a stopgain mutation of 
exon5:c.C3293A:p.S1098X at 4q31.3 is present in two diplegic subjects (B1-1_S1 and 
B4-T1_S1). The cadherin family member gene (DCHS2) which is also known as 
PCDH-J is discovered to be expressing its protein in cerebral cortex (Hong et. al., 
2004). Despite its unknown biological function, its SNP variant is discovered to be 
potentially associated with amnestic mild cognitive impairment and Alzheimer's disease 
(Vieira et. al., 2016). As for CP case itself, the DCHS2 has never been reported, plus its 
stopgain variant in our study is a novel variant according to LOVD database screening. 
DCHS2 interacts with Fat3 (atypical cadherin family member) to regulate the network 
controlling cartilage differentiation and polarity during vertebrate craniofacial 
development (Le pabic et. al, 2014). 
 
Following that, the sporadic variant of frameshift mutation, exon7:c.773delT:p.L258fs 
at 12q15 of BEST3 was found in our CP data in B1-3_S4 (quadriplegia) and B4- T2_S2 
(hemiplegia) subjects. This cardiovascular system gene when its protein is observed to 
be expressed in vascular smooth muscle cells (VSMC) and was confirmed to be 
implicated in vitelliform macular dystrophy 2 disorder (Matchkov et. al., 2008). BEST3 
is responsible to regulate the membrane potential of cyclic guanosine monophosphate-
dependent Calcium-Activated Chloride (cGMP dependent Ca2+- activated Cl−) 
conductance in VSMC Cells by coupling intracellular calcium and nitric oxide 
(NO)/cGMP pathways (Matchkov et. al., 2004; Matchkov et. al., 2008). This novel 
variant of BEST3 had never been reported to be associated with CP before. The last 
gene with sporadic variant in our data is GLYR1 with a frameshift deletion, 
exon13:c.1140delG:p.G390fs at 16p13.3 that is found in B4-T1_S1 (diplegia) and G5- 
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2_S10 (diplegia). It has never been reported. This cellular structure and metabolism 
gene is characterized as a specific cofactor of the histone-lysine-specific demethylase, 
(LSD2/KDM1b) that stimulates histone demethylase activity by deriving the short 
peptides that can modulate LSD2/KDM1b’s enzymatic activity and biologicalfunction 
(Fang et. al., 2013). The LSD2 is well-known as an epigenetic regulator that is involved 
in many biological processes including oocytogenesis, gene transcription and gene 
activation (Ciccone et al., 2009; Van Essen et al., 2010), meanwhile the lysine (K)- 
specific demethylase (KDM) family members play important roles in biological 
processes such as gene expression, cell growth, differentiation, development, and 
disease pathogenesis (Egger et al., 2004; Bhaumik et al., 2007; Esteller, 2008; Nottke 
et al., 2009). As additional information, another disease that is related to GLYR1 is a 
microsatellite-unstable colorectal cancer (Alhopuro et. al., 2012). 
  
The CTBP2 with an inherited variant of exon5:c.2228_2259del:p.G743fs, the 
frameshift deletion of 32 nucleotide at 10q26.3 is another cellular structure and 
metabolism gene that is present in all affected and unaffected subjects of our CP data. 
According to Katsanis et. al., 1998, CTBP2 protein is highly expressed in heart, skeletal 
muscle and pancreas. CTBP2 encodes for two isoforms that are recognized as common 
isoform (48kD) and ribeye isoform (120kD). These isoforms enrich the CTBP2 
functions in cellular programs (Jung et. al., 2013) and transcriptional regulator 
(Chinnadurai, 2013) as available at https://www.ncbi.nlm.nih.gov/books/NBK6557/. An 
animal study showed that the CTBP2 defect causes embryonic lethal in mouse 
(Hilderbrand et. al., 2002), and it is also contributing to cancer (Deng et. al., 2010; Guan 
et. al., 2013). CTDSP2 is another cellular structure and metabolism gene. The variants 
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are two non-SNV variants (missense mutation) of exon4:c.C322A:p.L108I and 
exon4:c.G302C:p.R101T at 12q14.1, that are classified as uncertain significance due to 
insufficient criteria fulfilled according to ACMG guideline. It was found that this gene 
expression is in non-neuronal cells (Yeo et. al., 2005). It plays a role in the cell cycle 
arrest (Kashuba et. al., 2004; Zhu et. al., 2012) when its high expression decreases the 
number of cells in S phase (Kloet et. al., 2015). We hardly found any studies that show 
this gene is a causative gene, but it is proven that its involvement in the cell cycle arrest 
in hepatocellular carcinoma (Zhu et. al., 2012) and renal carcinoma (Kashuba et. al., 
2004) making itself a worth tumor suppressor gene. This gene also has never been 
reported to be implicated in CP and its specific variant found in our study also has never 
been reported in any disorders or diseases. KRTAP19-6 with an inherited variant of 
frameshift mutation of exon1:c.171delC:p.F57fs at 21q22.11. 
  
The KRTAP19-6 is described as one of the KRTAP family members (Rogers et. al., 
2002). It is present in the hair cortex, hair keratin intermediate filaments that are 
embedded in an interfilamentous matrix. KAP polymorphisms are believed to be 
influencing the difference in the hair fibre structure across the individuals and 
population (Kariya et. al., 2005; Rogers et. al., 2006; Shimomura et. al., 2005). The 
KRTAP19-6 has never been reported to be associated with CP cases before and its 
specific variant also has not been reported in any studies. Plus, its publication is also 





CHAPTER FIVE  
 
CONCLUSION 
5.1 Summary and Conclusion  
Literature has shown that CP cases with unknown causes are contributed by genetic 
factors since several genetic alterations have been discovered. Accordingly, this study 
explored the genomics of CP families that have multiple CP affected children with 
unknown causes. This has given new insights into CP genetics in selected CP families 
in Kelantan, Malaysia. Beginning with the clinical features, it is shown that CP 
phenotypes in this current study are clinically heterogenous for reasons such as siblings 
of the same parental line are classified with different phenotypes, and some CP 
subjects of the same CP phenotype also potray some differences in terms of clinical 
features, comorbidities and GMFCS. The clinical findings also proved that the CP 
condition is not their secondary medical condition but a possible result of genetic 
underlying factors since CP subjects show no dysmorphic features, no known genetic 
disorders, and they were born from uneventful pregnancies and uneventful deliveries.  
 
Boinformatics analysis produced a total of 37 variants from 29 genes that were 
classified for their pathogenicities according to ACMG standard guidelines. They are 
mostly new variants that have never been reported except for a variant in RBMX 
(c.905_906insCC:p.P 302fs) and HLA-DRB1 (c.118_119insT:p.P40fs). From this 
variant data, familial genetic CP is shown to be genetically heterogenous which both 
inherited and sporadic variants being implicated. We hypothesize that these genetic 
changes may contain important predictive information on this neurological disorder. 
Herein, exome sequencing identified a series of likely pathogenic null variants 
183 
implicating nervous and immune system genes in patients clinically diagnosed with 
familial CP. Interestingly, many mutated immune-related genes are found in CP 
affected subjects only which possibly indicates that the CP individuals may potentially 
have compromised immune system. Thus, CP could also be categorized as immune 
dysregulation-related neurological disorder. Identification of multiple new variants 
opens up for future studies to further understand the contribution of the related genes 




5.2 Study Limitations and Perspectives 
This current preliminary study is limited by the small sample size and the genetic 
alterations presented in our data need to be further validated using Sanger sequencing 
or any functional genomic assays. Future studies with larger sample size, more 
validation analysis and functional analysis are also suggested. Association of mutated 
immune-related genes with CP should also be studied to add new insights to the 
predictions of potential susceptibility to immune diseases as secondary medical 
condition and/or contribution of mutated immune-related genes towards CP 
susceptibility.   
 
Another limitation in this study is the lack of resources and proper facilities in 
conducting the NGS study in this campus which include a server for big data storage 
and bioinformatician with expertise in NGS data analysis. Thus, the NGS and 
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APPENDICES 
Appendix A: The Data Collection Format Sheet Sample 
 
 
Data Collection Sheet 
 
Patient ID:    




Inclusion Criteria (IC)  Exclusion Criteria (EC) 
 
1)  Fulfil clinical diagnostic 
criteria for Cerebral Palsy 
 
 1) Intra or post-partum events 
that may lead to hypoxia due 
to mechanical factor 
 
AND 
 2) Other  syndromic features 
with defined chromosomal 
abnormalities 
2) More than one family members 
(from the same parental lines) 
affected with similar clinical 







 4) Parental history of identifiable 




 5) Family history of identifiable 
genetic disorder related to 
Cerebral Palsy 
OR   
4) Parental age more than 40 years 




5) Syndromic features with 
coagulopathies, prematurity 





Criteria for inclusion: IC1 AND any of the IC2-5 




Physical Examination: Done/Not Done 
Developmental milestone: Normal/ Delayed 
If delayed, specify: 
 
Higher Mental Function 
 
Mental Retardation: Yes/No/Not Assessed 
If yes, specify: 
 
Specific Learning Disability: Yes/No/Not Assessed 
 
If yes, specify:    












Muscle Wasting: Yes/No 
Abnormal Movement: Yes/No 




Muscle Weakness: Yes/No 
If yes, specify: 
 
Cerebellar Dysfunction: Yes/No 
If yes, specify: 
 
Sensory abnormalities: Yes/No 
If yes, specify: 
 
Cranial Nerve Abnormalities: Yes/No 
If yes, specify: 
 











Appendix B: The DNA Extraction 
 
































D1_S3 79.11 1.933 2.325 77.71 1.916 2.247 78.15 1.935 2.345 76.31 1.929 2.194 78.323 
M1_S2 120.6 1.908 2.489 100.3 1.906 2.445 111.1 1.92 2.792 128.5 1.849 2.067 116.467 
B1-1_S1 101.1 1.921 2.279 102.5 1.91 2.149 97.64 1.944 2.315 122.9 1.92 2.273 108.833 
B1-3_S4 110.1 1.916 2.397 97.53 1.884 2.315 103.5 1.909 2.361 97.1 1.906 2.311 103.71 
Family 2 
D2_S7 137.9 1.909 2.322 132.6 1.931 2.414 265.2 1.9 2.331 202.5 1.908 2.312 157.667 
M2_S6 106.5 1.538 1.658 76.89 1.896 2.357 72.23 1.974 2.562 72.06 1.942 2.449 73.727 
G2-1_S8 68.77 1.962 2.753 84.48 1.662 1.892 67.62 1.959 2.602 68.52 1.921 2.444 73.54 
B2-2_S5 125.1 1.913 2.43 161.4 1.573 1.88 132.9 1.866 2.173 128.4 1.878 2.326 128.8 
Family 3 
D3_S9 85.91 1.84 2.296 138.7 1.887 2.448 95.18 1.86 2.326 90.07 1.894 2.362 90.387 
M3_S6 105.8 1.915 2.616 109.2 1.857 2.328 109.1 1.923 2.558 129 1.88 2.38 115.767 
G3- 3_S10 91.15 1.879 2.366 90.29 1.928 2.526 112.1 1.882 2.364 105.7 1.904 2.395 102.983 
 
 
































D4_S4 127.8 1.883 2.402 123.1 1.913 2.508 129.3 1.898 2.414 124.3 1.922 2.49 127.133 
M4_S3 76.21 1.847 1.932 75.47 1.881 1.923 78.28 1.904 1.959 84.07 1.763 1.793 76.653 
B4-T1_ S1 94.15 1.936 2.563 94.64 1.931 2.337 94.28 1.913 2.432 90.75 1.909 2.337 93.223 
B4-T2_ S2 55.08 1.90 2.403 56.03 1.931 2.422 60.66 1.901 2.409 65.05 1.923 2.342 60.58 
Family 5 
D5_S9 73.68 2.002 2.605 77.00 1.920 2.255 74.3 2.002 2.478 74.97 1.928 2.266 74.9875 
M5_S8 110.7 1.897 2.200 104.4 1.932 2.326 104 1.919 2.283 101.7 1.953 2.348 105.2 
B5-1_S7 252.8 1.922 2.366 238.7 1.886 2.219 199.2 1.869 2.153 163.2 1.911 2.27 213.475 
G5- 2_S10 228.7 1.926 2.357 148.3 1.909 2.249 133.6 1.897 2.198 120.1 1.929 2.279 157.675 
Family 6 
B6-2_S5 61.62 1.908 2.444 64.13 1.782 1.563 61.07 1.861 2.001 61.04 1.867 2.014 61.243 
 
 
Appendix C: DNA Library Preparation 
 
Table C1: The list of 20 samples with their assigned Illumina default Index sequences (PCR primer) of Index 5 [i5] and Index 7 [i7] 
that were determined using IEM software (refer Method section 2.9.1 and 2.9.4). 
 
Case Description [i7]_ID Index Sequence [i5]_ID Index Sequence Pool (PO1) or (PO2) 
Fam 1  
D1_S3 Normal father N703 AGGCAGAA E505 CTCCTTAC PO1 
M1_S2 Normal mother N702 CGTACTAG E505 CTCCTTAC PO1 
B1-1_S1 CP son N701 TAAGGCGA E505 CTCCTTAC PO1 
B1-3_S4 CP son N711 AAGAGGCA E505 CTCCTTAC PO1 
Fam 2  
D2_S7 Normal father N706 TAGGCATG E505 CTCCTTAC PO1 
M2_S6 Normal mother N705 GGACTCCT E505 CTCCTTAC PO1 
G2-1_S8 CP son N707 CTCTCTAC E506 TATGCAGT PO1 
B2-2_S5 CP son N704 TCCTGAGC E505 CTCCTTAC PO1 
Fam 3  
D3_S9 Normal father N706 TAGGCATG E506 TATGCAGT PO1 
M3_S6 Normal mother N705 GGACTCCT E506 TATGCAGT PO2 
G3-3_S10 CP daughter N712 GTAGAGGA E506 TATGCAGT PO1 
 
 
Table C1: Continued. 
 
 
Case Description [i7]_ID Index Sequence [i5]_ID Index Sequence Pool (PO1or PO2) 
Fam 4 
D4_S4 Normal father N709 GCTACGCT E505 CTCCTTAC PO2 
M4_S3 Normal mother N710 CGAGGCTG E505 CTCCTTAC PO2 
B4-T1_S1 CP son N707 CTCTCTAC E505 CTCCTTAC PO2 
B4-T2_S2 CP son N708 CAGAGAGG E505 CTCCTTAC PO2 
Fam 5 
D5_S9 CP father N710 CGAGGCTG E506 TATGCAGT PO2 
M5_S8 Normal mother N709 GCTACGCT E506 TATGCAGT PO2 
B5-1_S7 CP son N708 CAGAGAGG E506 TATGCAGT PO2 
G5-2_S10 CP daughter N711 AAGAGGCA E506 TATGCAGT PO2 
Fam 6 
B6-1_S5 CP son N712 GTAGAGGA E505 CTCCTTAC PO2 
 
Appendix D: The full scripted commands that had been executed successfully 
indicated by “done” echo for each execution step during Bioinformatics analyses. 
Appendix D.1 Raw Read Analyses for 2 arrays (array=batch 1 and array2=batch 2) 
 
D.1.1 First FastQC 
 
 





./fastqc/file directory for batch 1 raw/*.fastq.gz 
 
./fastqc/file directory for batch 2 raw/*.fastq.gz 
!/bin/bash 
 
array=(“B2-2_S5” “Undetermine(control)” “G2-1_S8” “B1-1_S1” “M2_S6” “G3- 




for i in {1..4}; do 
 
./trim_galore /file directory for batch 1/${element}_L00${i}_R1_001.fastq.gz /file 
directory for batch 1/${element}_L00${i}_R2_001.fastq.gz 
-a CTGTCTCTTATACACATCT--paired--path_to_cutadapt /file directory for adapter 
--length 100--clip_R1 17 --three_prime_clip_R1 5 –three_prime_clip_R2 5 \ 
 




echo “Completed for all arrays!” 
 

















array2=(“D4_S4” “M4_S3” “B4-T2_S2” “B4-T1_S1” “D5_S9” “G5-2_S10” “B5- 
1_S7” “M5_S8” “M3_S6” “B6-1_S5”) for element in ${array2 [@]} 
do 
for i in {1..4}; do 
 
./trim_galore /file directory for batch 2/${element}_L00${i}_R1_001.fastq.gz /file 
directory for batch 2/${element}_L00${i}_R2_001.fastq.gz 
-a CTGTCTCTTATACACATCT--paired--path_to_cutadapt /file directory for adapter -- 
length 100--clip_R1 17 --three_prime_clip_R1 5 –three_prime_clip_R2 5 \ 




echo “Completed for all arrays!” 
!/bin/bash 
 
./fastqc/file directory for clipped batch 1/*.fq.gz 
 
./fastqc/file directory for clipped batch 2/*.fq.gz 
 
Appendix D.2: Reference Mapping (Assembly) 
 
{element}.gz= refers to each sample ID in (“ ”) batch 1 and {element2}.gz= refers to 
each sample ID in (“ ”) in batch 2. 
D.2.1 Tools and software loading 
 
 





D.2.3 Transformed to unmapped BAM (uBAM) files 
 
!/bin/bash 
module load programming/jdk1.8 
module load bioinformatics/bwa-0.7.17 
module load bioinformatics/picard 
module load bioinformatics/samtools-1.5 
module load bioinformatics/GATK 
Generate dict file for indexing 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar 
CreateSequenceDictionary \ 
R=/file directory of hg19 database.fa \ 
O=/ file directory of hg19 database.dict 
array=( “B2-2_S5” “G2-1_S8” “B1-1_S1” “M2_S6” “G3-3_S10” “D2_S7” “D1_S3” 
“B1-3_S4” “D3_S9” “M1_S2”) 
array2=( “D4_S4” “M4_S3” “B4-T2_S2” “B4-T1_S1” “D5_S9” “G5-2_S10” “B5- 




for element in ${array[@]} 
do 
for i in {1..4}; do 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar FastqToSam \ 
FASTQ=/file directory for {element}_L00${i}_R1_001_val_1.fq.gz \ 
FASTQ2=/file directory for {element}_L00${i}_R2_001_val_2.fq.gz \ 






echo “Batch 1 unmapped BAM done” 
for element2 in ${array2[@]} 
do 
for i in {1..4}; do 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar FastqToSam \ 
FASTQ=/file directory for {element2}_L00${I}_R1_001_val_1.fq.gz \ 
FASTQ2=/ file directory for {element2}_L00${i}_R2_001_val_2.fq.gz \ 






echo “Batch 2 unmapped BAM done” 
 
D.2.4 Adapter Marking 
 
This will mark illumina adapters in the reads as XT 
 




for element in ${array[@]} 
do 
for i in {1..4}; do 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar MarkIlluminaAdapters 
\ 
INPUT=/file directory for {element}_L00${i}.bam \ 
OUTPUT=/file directory for {element}_L00${i}.bam \ 
METRICS=/file directory for {element}_L00${i}.metrics.txt 
done 
done 
echo “Batch 1 mark adapter done” 
for element in ${array[@]} 
do 
for i in {1..4}; do 
gzip/file directory for {element}_L00${i}.metrics.txt & 
done 
done 
echo “gzip batch 1 metrics done” 
 
D.2.4.2 For batch 2 {array2} 
 
 
D.2.4.3 Read Quality Changing 
 
1) Change read quality of XT reads to 2 
2) This will effectively mask the XT reads 
3) Shows up as ####### in the quality score 
4) Write as interleaved fastqc files 
for element2 in ${array2[@]} 
do 
for i in {1..4}; do 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar MarkIlluminaAdapters 
\ 
INPUT=/file directory for {element}_L00${i}.bam \ 
OUTPUT=/file directory for {element2}_L00${i}.bam \ 
METRICS=/file directory for {element2}_L00${i}.metrics.txt 
done 
done 
echo “Batch 2 mark adapter done” 
for element in ${array[@]} 
do 
for i in {1..4}; do 
gzip/file directory for {element2}_L00${i}.metrics.txt & 
done 
done 
echo “gzip batch 2 metrics done” 
echo “End: No Trim 17 Front 5 End” 
 
D.2.4.3 (a) For batch 1 read quality changing 
 
 
D.2.4.3 (b) For batch 2 read quality changing 
 
for element in ${array[@]} 
do 
for i in {1..4}; do 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar SamToFastq \ 
INPUT=/file directory for{element}_L00${i}.bam \ 
CLIPPING_ATTRIBUTE=XT CLIPPING_ACTION=2 INTERLEAVE=true 
NON_PF=true \ 
TMP_DIR=/file directory for {element}_L00${i}.fq.gz 
done 
done 
echo “Batch 1 done for change read quality” 
for element2 in ${array2[@]} 
do 
for I in {1..4}; do 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar SamToFastq \ 
INPUT=/file directory for {element2}_L00${i}.bam \ 
CLIPPING_ATTRIBUTE=XT CLIPPING_ACTION=2 INTERLEAVE=true 
NON_PF=true \ 
TMP_DIR=/file directory for {element2}_L00${i}.fq.gz 
done 
done 
echo “Batch 2 done for change read quality” 
 
D.2.5 Alignment mapping and merging with unmapped 
 
D.2.5.1 For batch 1 
for element in ${array[@]} 
do 
for i in {1..4}; do 
zcat /file directory for {element}_L00${i}.fq.gz | \ 
bwa mem –M –t 6 –p /file directory for hg19 database/hg19.sorted.fa – 2>/file 
directory for {element}_L00${i}.log | \ 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar MergeBamAlignment 
\ 
R=/file directory for hg19.sorted.fa \ 
UNMAPPED_BAM=/file directory for /${element}_L00${i}.bam 
ALIGNED_BAM=/dev/stdin \ 
O=/file directory for {element}_L00${i}_merged.bam \ 










D.2.5.2 For batch 2 
 
for element2 in ${array2[@]} 
do 
for I in {1..4}; do 
zcat /file directory for/${element2}_L00${i}.fq.gz | \ 
bwa mem –M –t 6 –p /file directory for hg19 database/hg19.sorted.fa – 2>/file 
location for /merged_BAM/Error_report/bwa_error_${element2}_L00${i}.log | \ 
java –Xmx20G –jar /opt/biotools/picard-tools-2.15.0/picard.jar MergeBamAlignment 
\ 
R=/file directory for hg19.sorted.fa \UNMAPPED_BAM=/file directory 
for/${element2}_L00${i}.bam \ 
ALIGNED_BAM=/dev/stdin \ 
O=/file directory for/${element2}_L00${i}_merged.bam \ 










echo “Batch 2 done for map and merge alignment with unmapped” 
 
Appendix D.3: Duplicate Marking 
 
D.3. 1 For batch 1 
 
for element in ${array[@]} 
do 
java -Xmx20G -jar /opt/biotools/picard-tools-2.15.0/picard.jar MarkDuplicates \ 
INPUT=/file directory for {element}_L001_merged.bam \ 
INPUT=/file directory for {element}_L002_merged.bam \ 
INPUT=/file directory for {element}_L003_merged.bam \ 
INPUT=/file directory for {element}_L004_merged.bam \ 
OUTPUT=/file directory for {element}_L1-4.bam \ 
METRICS_FILE=/file directory for {element}_L1-4.txt \ 
CREATE_INDEX=true \ 








java -Xmx20G -jar /opt/biotools/picard-tools-2.15.0/picard.jar MarkDuplicates \ 
INPUT=/file directory for {element2}_L001_merged.bam \ 
INPUT=/file directory for {element2}_L002_merged.bam \ 
INPUT=/file directory for {element2}_L003_merged.bam \ 
INPUT=/file directory for {element2}_L004_merged.bam \ 
OUTPUT=/file directory for {element2}_L1-4.bam \ 
METRICS_FILE=/file directory for {element2}_L1-4.txt \ 
CREATE_INDEX=true \ 




Appendix D.4: Base Recalibration (Run BQSR) 
 
D.4.1 Task 1: Analyze patterns of covariation in the sequence dataset 
 
for element in ${array[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T BaseRecalibrator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-I /file directory for {element}_L1-4.bam \ 
-L /file directory for /nexterarapidcapture_expandedexome_targetedregions.bed \ 
-knownSites /file directory for hg19 database/dbsnp_138.hg19.vcf \ 
-knownSites /file directory for hg19 
database/Mills_and_1000G_gold_standard.indels.hg19.sites.vcf \ 
-o / file directory for {element}_L1-4_recal_data.table 
done 
 
for element2 in ${array2[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T BaseRecalibrator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-I /file directory for {element2}_L1-4.bam \ 
-L /file directoryfor nexterarapidcapture_expandedexome_targetedregions.bed \ 
-knownSites /file directory for hg19 database/dbsnp_138.hg19.vcf \ 
-knownSites /file directory for hg19 
database/Mills_and_1000G_gold_standard.indels.hg19.sites.vcf \ 
-o / file directory for {element2}_L1-4_recal_data.table 
done 
 
D.4.2 Task 2: Do a second pass to analyze covariation remaining after recalibration 
 
for element in ${array[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \i 
-T BaseRecalibrator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-I file directory for {element}_L1-4.bam \ 
-L /file directory for nexterarapidcapture_expandedexome_targetedregions.bed \ 
-knownSites /file directory for hg19 database/dbsnp_138.hg19.vcf \ 
-knownSites /file directory for 
hg19database/Mills_and_1000G_gold_standard.indels.hg19.sites.vcf \ 
-BQSR /file directory for /expandedexome_targetedregions/${element}_L1- 
4_recal_data.table 
-o /file directory for {element}_L1-4_post_recal_data.table 
done 
 
for element2 in ${array2[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \i 
-T BaseRecalibrator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-I file directory for {element2}_L1-4.bam \ 
-L /file directory for nexterarapidcapture_expandedexome_targetedregions.bed \ 
-knownSites /file directory for hg19 database/dbsnp_138.hg19.vcf \ 
-knownSites /file directory for 
hg19database/Mills_and_1000G_gold_standard.indels.hg19.sites.vcf \ 
-BQSR /file directory for {element2}_L1-4_recal_data.table 
-o /file directory for {element2}_L1-4_post_recal_data.table 
done 
 
D.4.3 Task 3: Generate before/after plots 
 
for element in ${array[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T AnalyzeCovariates \ 
-R /file directoryfor hg19/hg19.sorted.fa \ 
-L /file directory for nexterarapidcapture_expandedexome_targetedregions.bed \ 
-before /file directory for {element}_L1-4_recal_data.table \ 
-after /file directory for {element}L1-4_post_recal_data.table \ 





for element2 in ${array2[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T AnalyzeCovariates \ 
-R /file directory for hg19/hg19.sorted.fa \ 
-L /filedirectoryfor nexterarapidcapture_expandedexome_targetedregions.bed \ 
-before /file directory for {element2}_L1-4_recal_data.table \ 
-after /file directory for {element2}L1-4_post_recal_data.table \ 
-plots /file directory for {element2}L1-4_recalibration_plots.pdf 
done 
 
D.4.4 Task 4: Generate before/after plots 
 
for element in ${array[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T PrintReads \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-I /file directory for {element}_L1-4.bam \ 
-L /file directory for nexterarapidcapture_expandedexome_targetedregions.bed \ 
-BQSR /file directory for {element}_L1-4_recal_data.table 
-o //file directory for {element}_L1-4_recal_reads.bam 
done 
 
for element2 in ${array2[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T PrintReads \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-I /file directory for {element2}_L1-4.bam \ 
-L /file location for nexterarapidcapture_expandedexome_targetedregions.bed \ 
-BQSR /file directory for {element2}_L1-4_recal_data.table 
-o //file directory for {element2}_L1-4_recal_reads.bam 
done 
 
Appendix D.5: Variant Calling and Joint Genotyping 
D.5.1: Variants Calling with HaplotypeCaller 
 
for element in ${array[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T HaplotypeCaller \ 
-R /file directory for hg/hg19database9.sorted.fa \ 
-I file directory {element}_L1-4_recal_reads.bam \ 
-L /file directory for nexterarapidcapture_expandedexome_targetedregions.bed \ 
--genotyping_mode DISCOVERY \ 
-stand_emit_conf 10 \ 
-stand_call_conf 30 \ 
-o file directory for {element}_L1-4_raw_snps_indels.g.vcf \ 
-ERC GVCF \ 




for element2 in ${array2[@]} 
do 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T HaplotypeCaller \ 
-R /file directory for hg/hg19database9.sorted.fa \ 
-I file directory for {element2}_L1-4_recal_reads.bam \ 
-L /file directory for nexterarapidcapture_expandedexome_targetedregions.bed \ 
--genotyping_mode DISCOVERY \ 
-stand_emit_conf 10 \ 
-stand_call_conf 30 \ 
-o file directory for {element2}_L1-4_raw_snps_indels.g.vcf \ 
-ERC GVCF \ 
-variant_index_type LINEAR -variant_index_parameter 128000 
done 
  
Appendix D.5.2: Join Genotyping 
 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T GenotypeGVCFs \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-stand_call_conf 4 -stand_emit_conf 4 \ 
-V /file directory for B2-2_S5_L1-4_raw_snps_indels.g.vcf \ 
-V /file directory for G2-1_S8_raw_snps_indels.g.vcf \ 
-V / file directory for B1-1_S1_L1-4_raw_snps_indels.g.vcf \ 
-V /file directory for M2_S6_L1-4_raw_snps_indels.g.vcf \ 
-V /file directory for G3-3_S10_L1-4_raw_snps_indels.g.vcf \ 
-V /file directory for D2_S7_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for D1_S3_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for B1-3_S4_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for D3_S9_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for M1_S2_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for D4_S4_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for M4_S3_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for B4-T2_S2_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for B4-T1_S1_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for D5_S9_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for G5-2_S10_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for B5-1_S7_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for M5_S8_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for M3_S6_L1-4_raw_snps_indels.g.vcf \ 
-V / file directory for B6-1_S5_L1-4_raw_snps_indels.g.vcf \ 
-o /file directory for CombinedBatch1_2AfterJoinGeno.vcf 
  
Appendix D.6: Variant Filtering 
 
D.6.1 Task 1: Build the SNP recalibration model 
 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T VariantRecalibrator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-input /file directory for CombinedBatch1_2AfterJoinGeno.vcf 
-resource:hapmap,known=false,training=true,truth=true,prior=15.0 /file directory for 
hg19database/hapmap_3.3.hg19.sites.vcf \ 
-resource:omni,known=false,training=true,truth=true,prior=12.0 / file directory for 
hg19database /1000G_omni2.5.hg19.sites.vcf \ 
-resource:1000G,known=false,training=true,truth=false,prior=10.0 / file directory for 
hg19database /Mills_and_1000G_gold_standard.indels.hg19.sites.vcf \ 
-resource:dbsnp,known=true,training=false,truth=false,prior=2.0 / file directory for 
hg19database /dbsnp_138.hg19.vcf \ 
-an DP \ 
-an QD \ 
-an FS \ 
-an SOR \ 
-an MQ \ 
-an MQRankSum \ 
-an ReadPosRankSum \ 
-an InbreedingCoeff \ 
-mode SNP \ 
-tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0 \ 
-recalFile /file directory for recalibrate_SNP.recal \ 
-tranchesFile /file directory for recalibrate_SNP.tranches \ 
-rscriptFile /file directory for recalibrate_SNP_plots.R 
  
D.6.2 Task 2: Apply the desired level of recalibration to the SNPs in the call set 
 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T ApplyRecalibration \ 
-R /file directory for crm_hg19/hg19.sorted.fa \ 
-input / file directory for CombinedBatch1_2AfterJoinGeno.vcf 
-mode SNP \ 
--ts_filter_level 99.0 \ 
-recalFile /filedirectoryfor recalibrate_SNP.recal \ 
-tranchesFile /file directory for recalibrate_SNP.tranches \ 
-o /file directory for recalibrated_snps_raw_indels.vcf 
  
D.6.3 Task 3: Build the Indel recalibration model 
 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T VariantRecalibrator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-input /file directory for recalibrated_snps_raw_indels.vcf \ 
-resource:mills,known=false,training=true,truth=true,prior=12.0 /file directory for hg19 
database/Mills_and_1000G_gold_standard.indels.hg19.sites.vcf \ 
-resource:dbsnp,known=true,training=false,truth=false,prior=2.0 file directory for 
crm_hg19/dbsnp_138.hg19.vcf \ 
-an QD \ 
-an DP \ 
-an FS \ 
-an SOR \ 
-an MQRankSum \ 
-an ReadPosRankSum \ 
-an InbreedingCoeff \ 
-mode INDEL \ 
-tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 90.0 \ 
--maxGaussians 4 \ 
-recalFile /file directory for recalibrate_INDEL.recal \ 
-tranchesFile /file directory for recalibrate_INDEL.tranches \ 
-rscriptFile /file directory for recalibrate_INDEL_plots.R 
  




Appendix D.7: Genotype Refinement 
 

















java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T ApplyRecalibration \ 
-R /filedirectoryfor hg19 database/hg19.sorted.fa \ 
-input /file directory for recalibrated_snps_raw_indels.vcf \ 
-mode INDEL \ 
--ts_filter_level 99.0 \ 
-recalFile /file directory for recalibrate_INDEL.recal \ 
-tranchesFile /file directory for recalibrate_INDEL.tranches \ 
-o /file directory for recalibrated_variants.vcf 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T CalculateGenotypePosteriors \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-V file directory for recalibrated_variants.vcf \ 
-supporting /file directory for hg19 database/1000G_phase3_v4_20130502.sites.vcf \ 
-ped /file directory for Pedigree_Trio.ped \ 
-o /file directory for recalibratedVariants.postCGP.vcf 
  





D.7.3 Task 3: Annotate possible de novo mutations 
 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T VariantFiltration \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-V /file directory for recalibratedVariants.postCGP.vcf \ 
-G_filter "GQ < 20.0" -G_filterName lowGQ \ 
-o /file directory for recalibratedVariants.postCGP.Gfiltered.vcf 
java -jar /opt/biotools/GenomeAnalysisTK.jar \ 
-T VariantAnnotator \ 
-R /file directory for hg19 database/hg19.sorted.fa \ 
-V /file directory for recalibratedVariants.postCGP.Gfiltered.vcf \ 
-A PossibleDeNovo -ped /filedirectoryfor Pedigree_Trio.ped \ 
-o /file directory for recalibratedVariants.postCGP.Gfiltered.deNovos.vcfdu 
  






-includeinfo - -allsample recalibratedVariants.postCGP.Gfiltered.deNovos.annovar 
comment 
perl /file directory for recalibratedVariants.postCGP.Gfiltered.deNovos.annovar 
 
perl /file directory for recalibratedVariants.postCGP.Gfiltered.deNovos.annovar /file 
directory for annovar/humandb/ -buildver hg19 -out CP_SNP_INDEL -remove -protocol 
cytoBand, 1000g2015aug_all, avsift, cg69, clinvar_20140929, clinvar_20170130, 
cosmic70, esp6500siv2_all, exac03, exac03nontcga, hrcr1, icgc21, kaviar_20150923, 
kgXref, nci60, snp137, snp138, ljb26_all, ensGene, knownGene, refGene –operation 
r,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,g,g,g -nastring . 
perl /file directory for annovar/convert2annovar.pl -format vcf4 /file directory for 
recalibratedVariants.postCGP.Gfiltered.deNovos.vcf -outfile /file 
for element in ${array[@]} 
do 
perl /file directory for annovar/table_annovar.pl /file directory for 
recalibratedVariants.postCGP.Gfiltered.deNovos.annovar.${element}.avinput /file 
directory for annovar/humandb/ -buildver hg19 -out CP_SNP_INDEL_${element} - 
remove -protocol cytoBand, 1000g2015aug_all, avsift, cg69, clinvar_20140929, 
clinvar_20170130, cosmic70, esp6500siv2_all, exac03, exac03nontcga, hrcr1, icgc21, 
kaviar_20150923, kgXref, nci60, snp137, snp138, ljb26_all, ensGene, knownGene, 





for element2 in ${array2[@]} 
do 
perl /file directory for 
geno_refinement/recalibratedVariants.postCGP.Gfiltered.deNovos.annovar.${element2} 
.avinput /file directory for annovar/humandb/ -buildver hg19 –out 
CP_SNP_INDEL_${element2} -remove -protocol cytoBand, 1000g2015aug_all, avsift, 
cg69, clinvar_20140929, clinvar_20170130, cosmic70, esp6500siv2_all, exac03, 
exac03nontcga, hrcr1, icgc21, kaviar_20150923, kgXref, nci60, snp137, snp138, 




perl /file directory for recalibrated_variants_withoutped.vcf -format vcf4old -includeinfo 
-outfile /file directory for recalibrated_variants_withoutped.annovar 
 
perl /file directory for recalibrated_variants_withoutped.annovar /file directory for 
annovar/humandb/ -buildver hg19 -out CP_SNP_INDEL -remove -protocol cytoBand, 
1000g2015aug_all, avsift, cg69, clinvar_20140929, clinvar_20170130, cosmic70, 
esp6500siv2_all, exac03, exac03nontcga, hrcr1, icgc21, kaviar_20150923, kgXref, 
nci60, snp137, snp138, ljb26_all, ensGene, knownGene, refGene -operation 
r,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,g,g,g –nastring . 
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